Document:

EX-10.15

 Exhibit 10.15 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

Patent Sublicense Agreement 

This Patent Sublicense Agreement (“Agreement”) is between mRNA RiboTherapeutics, Inc., a Wisconsin corporation having a place
of business at 726 Post Road, Madison, WI 53713, USA (“mRNA RiboTherapeutics”) and BioNTech AG, a German corporation having its principal place of business at An der Goldgrube 12, 55131 Mainz, Germany (“Company”).
This Agreement is effective as of July 14, 2017 (the “Effective Date“). Each of Company and mRNA RiboTherapeutics are referred to herein as a “Party” and collectively as the “Parties”. 

BACKGROUND 
 WHEREAS, The Trustees of the
University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”) owns certain intellectual property comprising patents, patent applications and technology relating to [***], and certain other intellectual property
comprising patents, patent applications and technology relating to [***], for all of which intellectual property mRNA RiboTherapeutics has a license from Penn pursuant to the Second Amended and Restated Patent License Agreement which became
effective as of December 20, 2016 (the “Penn License Agreement”), including the right to sublicense all or any part of said rights to other parties, and under which CELLSCRIPT, LLC (“Cellscript”) also has
rights pursuant to a patent sublicense agreement from mRNA RiboTherapeutics (the “Cellscript Sublicense Agreement”); and 

WHEREAS, Company desires a sublicense from mRNA RiboTherapeutics under Patents Rights (as defined below) for diagnostic and prognostic uses in
humans and non-human animals and for certain other uses pertaining thereto and mRNA RiboTherapeutics is willing to grant to Company a sublicense under Patents Rights for such uses under the terms and
conditions herein; 
 NOW, THEREFORE, in consideration of the mutual obligations contained in this Agreement, and intending to be legally
bound, the Parties agree as follows: 
  

	1.	 SUBLICENSE 

1.1 Sublicense Grant. mRNA RiboTherapeutics hereby grants to Company and Company hereby accepts from mRNA RiboTherapeutics a worldwide, non-exclusive sublicense under the Patent Rights during the Term to make, have made, import, use, offer for sale, sell and/or have sold Licensed Products according to the terms and conditions herein: (1) in
Field of Use B for all uses in the Diagnostic and Prognostic Field of Use that pertain to or are used in conjunction with products for therapeutic, prophylactic, cosmetic or other uses in or on humans or
non-human animals in the In Vivo Field of Use in Field of Use B; and (2) in Field of Use A for research and screening uses, including pre-clinical
research and screening comprising ex vivo uses in human or non-human animal cells or in vivo uses in animals, that pertain to and support research, development, manufacture, regulatory approval
and commercialization of diagnostic and prognostic products used in conjunction with therapeutic, prophylactic, cosmetic, veterinary or other products for the In Vivo Field of Use in Field of Use B, as said terms are defined in Sections 1.2
and 6.1 herein (the “Sublicense”). The Sublicense includes the right for Company to grant sublicenses to its affiliates and Third Parties for all or any part of the rights and fields of use granted to Company, under terms that are
consistent with this Agreement. No other rights or licenses are granted to Company hereunder by mRNA RiboTherapeutics; [***] 

 1.2 Related Definitions. 

Whenever the words or terms “comprising,” “containing,” “having,” “include,” includes,”
“including,” “such as,” “for example,” “an example,” “examples,” “e.g.,” “for further clarification” or the like are used in this Agreement, they shall be understood to be
followed by the words “without limitation” or “but without limitation”. The terms “a,” “an,” and “the” and the use of such terms or nouns in definitions in either the singular or the plural are to be
construed to cover both the singular and the plural unless otherwise noted. 
 “Licensed Products” means products that are
made, made for, used, imported, offered for sale or sold by Company or its Affiliates or Third Party sublicensees and that, in the absence of a license to Patent Rights, (i) would infringe (or, in the case of pending patent applications, upon
issuance, would infringe) at least one claim of the Patent Rights or (ii) use a process or machine covered by a claim of Patent Rights, whether the claim is issued or pending. For clarity, Licensed Products includes any method, procedure or
process, the use of which by Company or its Affiliates or Third Party sublicensees, in the absence of a license to Patent Rights by the user, would infringe, induce to infringe or contribute to infringing one or more claims of Patent Rights whether
the claim is issued or pending. 
 “Exhibit A-1 Patent Rights” means [***] 

“Exhibit A-2 Patent Rights” means [***] 

“Patent Rights” means Exhibit A-1 Patent Rights and/or Exhibit A-2 Patent Rights. 
 “Affiliate” means a legal entity that is controlling, controlled by
or under common control with Company and that has executed either this Agreement, a sublicense for at least a portion of the rights granted to Company under this Agreement, or a written joinder agreement agreeing to be bound by all of the terms and
conditions of this Agreement. The uncapitalized term “affiliate” means, with respect to a first legal entity, any other legal entity that is controlling, controlled by or under common control with said first legal entity. For
purposes of the definitions of “Affiliate” and “affiliate” herein, the word “control” means (x) the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of a legal
entity, (y) the right to receive fifty percent (50%) or more of the profits or earnings of a legal entity, or (z) the right to determine the policy decisions of a legal entity. 

“Field of Use A” means and is limited to internal laboratory research or screening [***]. For clarity, Field of Use A
includes laboratory research use in animals or human or animal cells, living or dead, from any source, including for pre-clinical laboratory research in laboratory animals or cultured human or non-human animal cells for the purpose of generating data and information prior to use in clinical trials for a use that requires approval by the FDA or another regulatory organization. For further clarity, a party
that has a sublicense in Field of Use A pertaining to sublicensed therapeutic or prophylactic or diagnostic or prognostic products in Field of Use B shall have the right under Patent Rights to perform
pre-clinical research in Field of Use A comprising in vivo uses in non-human animals or ex vivo uses in human or
non-human animal cells in order to obtain data and information to support pre-clinical development of such therapeutic or prophylactic or diagnostic or prognostic
products. 
 [***] 

 “Field of Use B” means the field other than Field of Use A and includes but
is not limited to therapeutic, prophylactic, diagnostic, prognostic and cosmetic uses in humans and agricultural, animal improvement and veterinary uses in animals. For clarity, Field of Use B includes any and all fields of use, including the In
Vivo Field of Use and Ex Vivo Field of Use, other than for Field of Use A. 
 “Fields of Use” means Field of Use
A and Field of Use B. 
 “Ex Vivo Field of Use” is a subfield of Field of Use A or Field of Use B wherein a
product or method that is covered by Patent Rights is used in cells, tissues or organs that are ex vivo or outside of a living human or animal body or organism, whether those cells, tissues or organs are subsequently used only ex vivo,
such as in culture, or are subsequently introduced into, used in or administered or applied to or on a living body or organism. [***] 

“In Vivo Field of Use” is a subfield of Field of Use A or Field of Use B wherein a product or method that is
covered by Patent Rights is used in vivo, [***] 
 “Diagnostic and Prognostic Field of Use” is a subfield of use
within Field of Use B wherein a product or service covered by Patent Rights is used for diagnosis, prognosis or testing of a human or non-human animal or a sample therefrom in order to detect, identify,
determine a cause, evaluate, analyze, understand, predict, rule in, or rule out a medical condition or disease or to predict an effect or response to treatment, and/or to monitor the effect of a treatment of such medical condition or disease. [***]

 “Veterinary Product” means a product that is covered by Patent Rights which is used for the care, treatment, breeding or
use of livestock or companion animals. 
 “Third Party” means any person, corporation, partnership, association, consortium
or business, legal or governmental entity other than Penn, mRNA RiboTherapeutics, Company or any of their respective affiliates. 
 1.3
Reservation of Rights by Penn. Penn reserves the right to use, and to permit other non-commercial entities to use, the Patent Rights for educational and
non-commercial research purposes. 
 1.4 U.S. Government Rights. The Parties acknowledge that
the United States government retains rights in intellectual property funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to,
any applicable requirement that products, which result from such intellectual property and are sold in the United States, must be substantially manufactured in the United States. To the extent any such U.S. manufacturing requirements apply, mRNA
RiboTherapeutics shall, upon request of Company, use commercially reasonable efforts to cause Penn to seek a waiver from the United States government for Company in respect of such U.S. manufacturing requirements. 

1.5 Sublicense Conditions. Company’s right to extend any or all of the rights granted to Company by mRNA RiboTherapeutics via a
sublicense to affiliates or Third Parties is subject to each of the following conditions:  

 1.5.1 Company will have the right to grant further sublicenses to its affiliates and to
Third Parties (“sub-sublicensees”) that permit multiple levels of sublicensing, including in Third Party sub-sublicenses that permit further levels of sublicensing (e.g., to “sub-sub-sublicensees”). In each further sub-sublicense agreement to an affiliate or Third Party, Company will require the sub-sublicensee to comply with terms and
conditions that are consistent with this Agreement, and in each agreement for further sublicensing (e.g., by a sub-sublicensee of Company to a sub-sub-sublicensee), the party granting the further sublicense
will require the party receiving the further sublicense to comply with terms and conditions that are consistent with its sub-sublicense agreement from Company. Except when used to clarify the meaning of the
different terms in this Section 1.5.1, the term sublicense in this Agreement includes any permitted sub-sublicense,
sub-sub-sublicense, etc. and the term sublicensee includes any permitted sub-sublicensee, sub-sub-sublicensee, etc. 

1.5.2 Within [***] days after Company enters into a sublicense agreement, Company will deliver to mRNA RiboTherapeutics a complete and accurate
copy of the entire sublicense agreement written in the English language, provided that Company will have the right to redact the terms and conditions of such sublicense agreement that are not necessary for mRNA RiboTherapeutics to confirm compliance
with all terms and conditions required under this Sublicense, including Section 1.5 hereof. mRNA RiboTherapeutics’ receipt of the sublicense agreement will not constitute a waiver of any right or obligation of mRNA RiboTherapeutics or of
Company under this Agreement. 
 1.5.3 In the event that Company causes or experiences a Trigger Event (as defined in Section 6.4), to
the extent permissible by law, all payments due to Company from its direct sublicensees pursuant to a sublicense to this Agreement that are payable by Company to Cellscript hereunder, including milestone payments and royalty payments, will, upon
notice from mRNA RiboTherapeutics to such sublicensees, become payable directly to mRNA RiboTherapeutics for the account of Company. Upon receipt of any such funds, mRNA RiboTherapeutics will remit to Penn the amounts owed to Penn and will remit to
Company the amount (if any) by which such payments from such sublicensees exceed the amounts owed by Company to mRNA RiboTherapeutics. Still further, in the event that mRNA RiboTherapeutics causes or experiences a trigger event according to the
terms of the Penn License Agreement, Company agrees that, upon notification from Penn, Company will remit to Penn all amounts payable by Company to mRNA RiboTherapeutics under this Agreement (including but not limited to all milestone payments and
royalty payments) for the account of mRNA RiboTherapeutics. 
 1.5.4 Company’s execution of a sublicense agreement will not relieve
Company of any of its obligations under this Agreement. Company is primarily liable to mRNA RiboTherapeutics for any act or omission of a sublicensee that would be a breach of this Agreement if performed or omitted by Company, and Company will be
deemed to be in breach of this Agreement as a result of such act or omission. Upon learning of any such breach of this Agreement due to an act or omission of a sublicensee of Company, Company will immediately take appropriate actions to stop such
act or omission, including termination of the sublicense by Company. Provided that Company takes such appropriate actions and stops such act or omission, a breach by said sublicensee shall not be considered a breach by Company that will be
considered a cause for termination of this Agreement under Section 6.3. 

 1.5.5 A sublicense granted by the Company or a further sublicensee thereof will not be
assignable or transferable by said sublicensee or further sublicensee thereof without the prior written consent of mRNA RiboTherapeutics, except to an affiliate of the sublicensee of Company or an affiliate of said further sublicensee thereof, or to
a Third Party company that:    (i) can demonstrate based on reliable financial information that it has all technical knowledge, capabilities and/or financial resources needed to perform in all respects in the place and stead of
said sublicensee or further sublicensee thereof; (ii) agrees to assume all duties and responsibilities under the sublicense; (iii) warrants that it will invest an amount of money that Company agrees is sufficient to develop and/or
commercialize the sublicensed Licensed Product(s); (iv) purchases more than fifty percent (50%) of all of the sublicensee’s or the further sublicensee’s shares or assets to which the sublicense pertains; and (v) agrees in writing to
be bound by all of the terms and conditions of the sublicense and a copy of such written undertaking is promptly provided to Company, which will provide a copy to mRNA RiboTherapeutics, which, in turn, will provide a copy to Penn as required in the
Penn License Agreement. 
 1.6 No License by Implication. Nothing in this Agreement confers by estoppel implication or otherwise, any
license or rights under any Penn patent other than rights under a patent included in the Patent Rights, regardless whether such patents are dominant or subordinate to the Patent Rights. 

1.7 Relation of this Agreement to the Sublicense Agreement from Cellscript. Concurrent with the execution of this Agreement,
Company is entering into a separate sublicense agreement with Cellscript (the “Sublicense Agreement from Cellscript”), pursuant to which Cellscript is granting Company a sublicense under Patent Rights with respect to certain fields
of use that are different from and are not included within the scope of the Sublicense granted to Company in this Agreement. 
  

	2	 DILIGENCE 

2.1 Development Plan and Sublicense Disclosure Report. By [***] and by [***] of every calendar year thereafter that encompasses the
Term, Company will deliver to mRNA RiboTherapeutics: (1) a copy of an annual development plan, including a projected timeline, for the Patent Rights and a summary of material development efforts for Licensed Products since the last development
plan (“Development Plan”); and [***], certified as correct by the accounting services manager or chief financial officer, that includes all additional information as listed on Exhibit B for the period since the last SDR. 

2.2 Company’s Efforts. Company will use commercially reasonable efforts to develop, commercialize, market and sell Licensed
Products in the sublicensed Fields of Use in a manner consistent with the Development Plan. In addition to Company’s own efforts to develop, commercialize, market and sell Licensed Products, the efforts of other parties, including Affiliates,
Third Party sublicensees, contractors, Third Parties funded by Company under a research or service agreement, and distributors, will also be deemed as efforts of Company. 

[Remainder of page left blank] 

	3	 FEES AND ROYALTIES 

3.1 Sublicense Grant Fees. In partial consideration for the Sublicense, Company will pay to mRNA RiboTherapeutics: (i) [***] and (ii)
[***] 
 3.2 Sublicense Maintenance Fees. In partial consideration of the Sublicense, Company will pay to mRNA RiboTherapeutics [***]
on each anniversary of the Effective Date until the date of first Sale of the first Licensed Product in Field of Use B, regardless of whether the Sale is achieved by Company, mRNA RiboTherapeutics, or an affiliate or sublicensee of any of the
foregoing. For clarity, the next annual sublicense maintenance fee under this Agreement is payable to mRNA RiboTherapeutics on July 1, 2018 if no Sale of a Licensed Product in Field of Use B occurs prior to July 1, 2018. 

3.3 Milestone Payments. In partial consideration of the Sublicense, Company will pay to mRNA RiboTherapeutics the applicable milestone
payment listed in Table D in this Section 3.3 the first time after achieving each milestone event for each Licensed Product in Field of Use B, regardless of whether the milestone is achieved by Company or an Affiliate or Third Party
sublicensee. Company will provide mRNA RiboTherapeutics with written notice within [***] days after each milestone is achieved by Company or a sublicensee and Company will pay to mRNA RiboTherapeutics all applicable milestone payments owed therefor
within [***] days of the end of the calendar quarter in which the milestone event is achieved. For clarity, each time a milestone is achieved with respect to a Licensed Product, then any other milestone payments with respect to earlier milestones
that have not yet been paid will be due and payable together with the milestone payment that is actually achieved. 
  

			
	 Section 3.3 Table D

MILESTONES for each Licensed Product that is

a Diagnostic, Prognostic or Other Medical Device Product

[***] 
 3.4 Earned
Royalties. In partial consideration of the Sublicense, Company will pay to mRNA RiboTherapeutics royalties on Net Sales of Licensed Products in the sublicensed Fields of Use as stated below. 

3.4.1 Earned Royalties on Licensed Products in Field of Use A. In partial consideration of the Sublicense, Company will pay to mRNA
RiboTherapeutics a [***] royalty on Net Sales of Licensed Products by Company or its Affiliates or Third Party sublicensees for use in [***]. For clarity, Company and its Affiliates or Third Party sublicensees shall only have the right to sell
Licensed Products for use in Field of Use A to Third Parties that have either a sublicense from or a contract with Company or an Affiliate or Third Party sublicensee to research, develop, test, evaluate, screen, manufacture and/or commercialize a
Licensed Product for diagnostic or prognostic use pertaining to a therapeutic, prophylactic or other product for humans or non-human animals in the In Vivo Field of Use in Field of Use B. 

 3.4.2 Earned Royalties on Licensed Products for the Diagnostic and Prognostic Use in
Field of Use B. In partial consideration of the Sublicense, Company will pay to mRNA RiboTherapeutics a [***] royalty on Net Sales of Licensed Products for [***] for the In Vivo Field of Use in Field of Use B during the Quarter. For the
avoidance of doubt, if Company or its Affiliates or Third Party sublicensees grant sublicenses to sell Licensed Products for such a diagnostic or prognostic use in Field of Use B, Company will pay to mRNA RiboTherapeutics [***] 

3.4.3 Royalty Reduction. If Company or an Affiliate or Third Party sublicensee of Company is obligated to pay Third Party Royalties
(defined below) for a Licensed Product in Field of Use B, then Company may deduct [***] of such Third Party Royalties from any royalties on Net Sales in Field of Use B due to mRNA RiboTherapeutics under Section 3.4.2 of this Agreement, provided
that: 
 (a) On an ongoing basis and prior to reduction of any royalty on Net Sales for a given calendar quarter, Company
first provides written evidence to mRNA RiboTherapeutics of Company’s or applicable sublicensee’s obligation to pay such Third Party Royalties; and 

(b) In no event shall royalties on Net Sales due to mRNA RiboTherapeutics in any reporting period be so reduced to less than
[***] for Licensed Products in Field of Use B. 
 “Third Party Royalties” means any royalty obligation [***] that Company
or its Affiliates or a Third Party sublicensee owes to one or more other parties pursuant to one or more licenses for patent rights comprising [***] and that are determined to be necessary to avoid infringement-related litigation with respect to the
manufacture, use or sale of any Licensed Product. 
 3.5 Related Definitions. 

3.5.1 The term “Sale” means any bona fide transaction for which consideration is received or expected by Company or its
Affiliates or Third Party sublicensees for the sale, use, lease, transfer or other disposition of a Licensed Product to a Third Party. A Sale is deemed completed at the time that Company or an Affiliate or Third Party sublicensee invoices, ships or
receives payment for a Licensed Product, whichever occurs first. 
 3.5.2 The term “Quarter” means each three-month period
beginning on the first day of January, April, July or October. 

 3.5.3 The term “Net Sales” means the consideration received or expected
from, or the fair market value attributable to, each Sale, less Qualifying Costs that are directly attributable to a Sale, specifically identified on an invoice or other documentation and actually borne by Company or its Affiliates or Third Party
sublicensees. For purposes of determining Net Sales, the words “fair market value” mean the cash consideration that Company or its Affiliates or Third Party sublicensees would realize from an unrelated buyer in an arm’s length sale of
an identical item sold in the same quantity and at the time and place of the transaction. 
 3.5.4 The term “Qualifying
Costs” means: (a) credits or refunds for claims or returns that do not exceed the original invoice amount; (b) prepaid outbound transportation expenses and transportation insurance premiums; and (c) sales and use taxes and
other fees imposed by and indefeasibly paid to a governmental agency. 
 3.6 Minimum Royalties. In partial consideration of the
Sublicense, [***], Company will pay to mRNA RiboTherapeutics the amount, if any, by which the applicable minimum royalties listed in the tables below exceed Company’s actual earned royalties under Section 3.4 for each Quarter after the
first Sale of a Licensed Product by Company or its Affiliates or Third Party sublicensees in the applicable Categories. The minimum royalties are divided into two Categories and outlined in the tables below and are tiered, cumulative and
individually payable after first Sale of Licensed Product in each of the two respective Categories. For clarity, the highest minimum royalty owed by Company to mRNA RiboTherapeutics under this Agreement would be [***]. For additional clarification,
Company is not obligated to pay minimum royalties to mRNA RiboTherapeutics on Category 1 Licensed Products until after the first Sale of a Licensed Product in Field of Use A by Company or its Affiliates or Third Party sublicensees, and Company is
not obligated to pay minimum royalties to mRNA RiboTherapeutics on a Category 3 Licensed Product until after the first Sale of Licensed Product in Field of Use B by Company or its Affiliates or Third Party sublicensees in the Diagnostic and
Prognostic Field of Use. 
 Category 1—Licensed Products in Field of Use A 

 

					
	 QUARTER:
	  	First Four
Quarters	 	All Subsequent
Quarters
	 MINIMUM:
	  	[***]	 	[***]

 Category 3—Licensed Products in Field of Use B 

That Are Diagnostic or Prognostic Products 
  

					
	 QUARTER:
	  	First Four
Quarters	 	All Subsequent
Quarters
	 MINIMUM:
	  	[***]	 	[***]

	4	 REPORTS AND PAYMENTS 

4.1 Royalty Reports. Within [***] days after the end of each Quarter following the first Sale, Company will deliver to mRNA
RiboTherapeutics a report, certified as accurate by the accounting services manager or chief financial officer of Company, detailing the calculation of all royalties, fees and other payments due to mRNA RiboTherapeutics for such Quarter. The report
will include, at a minimum, the following information for the Quarter, each listed by product, by country: [***]  
 4.2
Payments. Company will pay all royalties, fees and other payments due to mRNA RiboTherapeutics under Sections 3.3, 3.4 and 3.6 within [***] days after the end of the Quarter in which the royalties, fees or other payments accrued. mRNA
RiboTherapeutics agrees that it will pay to Penn all royalties, fees and other payments due to Penn according to and within the time periods required by the Penn License Agreement. For clarity, only one royalty will be due with respect to the Sale
of the same unit of Licensed Product. 
 4.3 Records. Company will maintain, and will cause its Affiliates and Third Party
sublicensees to maintain, complete and accurate books, records and related background information to verify Sales, Net Sales, and all of the royalties, fees, and other payments due or paid under this Agreement, as well as the various computations
reported under Section 4.1. The records for each Quarter will be maintained for at least [***] years after submission of the applicable report required for Section 4.1. 

4.4 Audit Rights. Upon reasonable prior written notice to Company, Company and its Affiliates and Third Party sublicensees will provide
Penn and its accountants (or mRNA RiboTherapeutics and its accountants in the event that mRNA RiboTherapeutics is Penn’s designated auditor) with access to all of the books, records, key personnel and related background information required by
Section 4.3 to conduct a review or audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. Access will be made available: (a) during normal business hours; (b) in a manner reasonably
designed to facilitate such accountant’s review or audit without unreasonable disruption to Company’s business; and (c) no more than once each calendar year during the Term (as defined below) and for a period of [***] years
thereafter. Company will promptly pay to mRNA RiboTherapeutics the amount of any underpayment determined by the review or audit, plus accrued interest. If the review or audit determines that Company has underpaid any payment by [***] or more, then
Company will also promptly pay the costs and expenses of the auditing party’s accountants in connection with the review or audit.    In addition, once annual Sales of Licensed Products exceed [***], Company will conduct, at
least once every [***] years at its own expense, an independent audit of Sales, Net Sales, and all of the royalties, fees, and other payments due or paid under this Agreement. Promptly after completion of the audit, Company will provide to mRNA
RiboTherapeutics a copy of the report of the independent auditors along with any underpayments and interest thereon. 
 4.5 Currency.
All dollar amounts referred to in this Agreement are expressed in United States dollars. All payments will be made in United States dollars. If Company receives payment from a sublicensee in a currency other than United States dollars for which a
royalty or fee is owed under this Agreement, then (a) the payment will be converted into United States dollars at the conversion rate for the foreign currency as published in the eastern edition of the Wall Street Journal as of the last
business day of the Quarter in which the payment was received by Company, and (b) the conversion computation will be documented by Company in the applicable report delivered to mRNA RiboTherapeutics under Section 4.1. 

 4.6 Place of Payment. All payments by Company to “mRNA RiboTherapeutics,
Inc.” and will be made to the following addresses: 
 [***] 

(Payment should include the

necessary amount to cover

Sender’s bank wire fees) 

4.7 Interest. All amounts that are not paid by Company when due will accrue interest from the date due until paid at a rate equal to
[***] (or the maximum allowed by law, if less). 
  

	5	 CONFIDENTIALITY AND USE OF NAMES 

5.1 Confidentiality. Each Party agrees that it will not, under this Agreement, provide to the other Party or its affiliates any
Confidential Information of such Party unless (i) such Party has first identified the general nature of such Confidential Information to such other Party in writing and such other Party has affirmatively agreed in writing to receive such
Confidential Information, or (ii) such other Party has specifically requested such Confidential Information in writing. For clarity, any such consent or request issued by email or other written electronic means shall satisfy the foregoing
“writing” requirements. Any Confidential Information disclosed by a Party to the other Party other than in accordance with this Section 5.1 will be deemed not to be Confidential Information of such Party. Notwithstanding the
foregoing, mRNA RiboTherapeutics is obligated to accept and treat as confidential any Confidential Information disclosed by Company in the reports or notices required by Sections 2.1, 2.3, 3.3, 3.4.3(a), 4.1, 4.4, 4.5, 4.6 and 6.6, which information
Company agrees mRNA RiboTherapeutics may disclose to Penn without the prior written consent of Company. 
 5.2 Confidential
Information. Each Party (“Disclosing Party”) may disclose to the other Party (“Receiving Party”), and Receiving Party may acquire during the course and conduct of activities under the Agreement, certain
proprietary or confidential information of Disclosing Party in connection with this Agreement. The term “Confidential Information” shall mean all ideas and information of any kind, whether in written, oral, graphical, machine-readable or
other form, whether or not marked as confidential or proprietary, which are transferred, disclosed or made available by Disclosing Party in accordance with Section 5.1. 

5.3 Restrictions. During the Term and for [***] years thereafter, Receiving Party shall keep all Disclosing Party’s
Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information. Receiving Party shall not use Disclosing Party’s Confidential Information except in connection with the
performance of its obligations and exercise of its rights under this Agreement. Receiving Party has the right to disclose Disclosing Party’s Confidential Information without Disclosing Party’s prior written consent, to the extent and only
to the extent reasonably necessary, to Receiving Party’s affiliates and their employees, subcontractors, consultants or agents who have a need to know such 

 
Confidential Information in order to perform Receiving Party’s obligations or exercise Receiving Party’s rights under this Agreement, provided said affiliates and their
employees, subcontractors, consultants or agents are required to comply with a written confidentiality agreement having restrictions on use and disclosure of Disclosing Party’s Confidential Information which are no less stringent than those in
this Section 5.3. Receiving Party assumes responsibility for compliance with such restrictions by its affiliates and their employees, subcontractors, consultants or agents. 

5.4 Exceptions. Receiving Party’s obligation of nondisclosure and the limitations upon the right to use the Disclosing Party’s
Confidential Information shall not apply to the extent that Receiving Party can demonstrate, as evidenced by contemporaneous written records, that the Disclosing Party’s information: (i) was known to Receiving Party or any of its
affiliates prior to the time of disclosure; (ii) is or becomes public knowledge through no fault or omission of Receiving Party or any of its affiliates; (iii) is obtained by Receiving Party or any of its affiliates from a Third Party
under no obligation of confidentiality to Disclosing Party; (iv) has been independently developed by employees, subcontractors, consultants or agents of Receiving Party or any of its affiliates without the aid, application or use of Disclosing
Party’s Confidential Information or (v) is not Confidential Information under Section 5.1. 
 5.5 Permitted
Disclosures. Receiving Party may disclose Disclosing Party’s Confidential Information to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

5.5.1 in order to comply with applicable law (including any securities law or regulation or the rules of a securities exchange) or with a legal
or administrative proceeding; 
 5.5.2 in connection with prosecuting or defending litigation, regulatory approvals and other regulatory
filings and communications, and filing, prosecuting and enforcing Patents in connection with Receiving Party’s rights and obligations pursuant to this Agreement; and 

5.5.3 in connection with exercising its rights hereunder, to its affiliates; to potential and future collaborators and sublicensees; permitted
acquirers or assignees; and investment bankers, investors and lenders, except that, mRNA RiboTherapeutics will obtain the prior written consent of Company before disclosing any information disclosed to mRNA RiboTherapeutics pursuant to Sections 2.1,
2.3, 3.3, 3.4.3(a), 4.1, 4.4, 4.6 and 6.6; 
 provided that (1) with respect to Sections 5.5.1 or 5.5.2, where reasonably
possible, Receiving Party shall notify Disclosing Party of Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it
may deem appropriate to protect the confidentiality of the information to be disclosed, and (2) with respect to Section 5.5.3, each of those named people and entities are required to comply with the restrictions on use and disclosure in
Section 5.3 (other than investment bankers, investors and lenders, which must be bound prior to disclosure by commercially reasonable obligations of confidentiality). 

5.6 Terms of this Agreement. The Parties agree that the terms of this Agreement shall be treated as Confidential Information of both
Parties, and thus may be disclosed only as permitted by Section 5.5. Each Party agrees not to issue any press release or public statement disclosing information relating to this Agreement or the terms hereof without the prior written consent of
the other Party not to be unreasonably withheld. 

 5.7 Relationship to the Confidentiality Agreement. This Agreement is in addition to a
certain “Confidentiality Agreement” between the Parties dated December 7, 2015, as amended and extended on December 1, 2016, and (a) all “Confidential Information” as defined therein that was disclosed or
received by the Parties prior to the Effective Date shall continue to be subject to the terms and conditions of the Confidentiality Agreement and (b) all Confidential Information disclosed or received by the Parties following the Effective Date
shall be subject to the terms and conditions of this Agreement. For the avoidance of doubt, all other confidentiality agreements concluded between mRNA RiboTherapeutics and Company prior to the Effective Date of this Agreement shall be superseded by
this Agreement. 
 5.8 Use of Penn’s, mRNA RiboTherapeutics’ or Company’s Name. Company and its Affiliates, Third Party
sublicensees, employees, and agents are not granted any rights hereunder to use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Penn or any Penn school, or their respective organizations, employees, students or
representatives, without the prior written consent of Penn. Except to the extent permitted pursuant to this Article 5, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or
any other trade name or trademark of the other Party for any Purpose, except as may be required by applicable law or regulation. 
  

	6	 TERM AND TERMINATION 

6.1 Term. This Agreement will commence on the Effective Date and terminate upon the expiration or abandonment of the last patent to
expire or become abandoned of the Patent Rights (the “Term”). 
 6.2 Early Termination by Company. Company may
terminate this Agreement at any time effective upon completion of each of the following conditions: (a) providing at least [***] days prior written notice to mRNA RiboTherapeutics of such intention to terminate; (b) ceasing to make, have made,
use, import, offer for sale and sell all Licensed Products; (c) providing documentation stating that all sublicenses granted by Company which are still in force at the date of termination can be assigned to mRNA RiboTherapeutics and working with
mRNA RiboTherapeutics to assign or terminate such sublicenses based on the specific circumstances related thereto; and (d) paying all amounts owed to mRNA RiboTherapeutics under this Agreement through the effective date of termination. For
clarity, Company may individually terminate either the Sublicense to Exhibit A-1 Patent Rights or the Sublicense to Exhibit A-2 Patent Rights provided that each of the
conditions stipulated in Section 6.2 is met with respect to the Patent Rights terminated from the Sublicense. [***] 
 6.3 Early
Termination by mRNA RiboTherapeutics. mRNA RiboTherapeutics may, to the extent permissible by law, terminate this Agreement if: (a) Company is more than [***] late in paying to mRNA RiboTherapeutics any amounts owed under this
Agreement and does not pay mRNA RiboTherapeutics in full, including accrued interest, within [***] days after receiving written notice of the breach from mRNA RiboTherapeutics (a “Payment Default”); or (b) other than a Payment
Default, Company materially breaches this Agreement and Company does not cure the breach [***] days after receiving written notice of the breach from mRNA RiboTherapeutics; or (c) Company causes or experiences a Trigger Event, or an Affiliate
or Third Party sublicensee of Company commences or causes a Patent Challenge (as defined Section in 6.4 below) and Company does not terminate the sublicense or cause the Patent Challenge to be terminated prior to or promptly upon learning of said
Patent Challenge. It is understood that, with respect to both of (a) and (b), Company is also responsible for its Affiliates and Third Parties sublicensees. 

 6.4 Trigger Event. The term “Trigger Event” means any of the
following: (a) Company (i) becomes insolvent, bankrupt or generally fails to pay its debts as such debts become due, (ii) is adjudicated insolvent or bankrupt, (iii) admits in writing its inability to pay its debts, (iv) suffers
the appointment of a custodian, receiver or trustee for its assets and, if appointed without its consent, not discharged [***], (v) makes an assignment of its assets for the benefit of creditors, or (vi) suffers proceedings being instituted
against it under any law related to bankruptcy, insolvency, dissolution, liquidation or the reorganization, readjustment or release of multiple debtors and, if contested by it, not dismissed or stayed within [***]; (b) the institution or
commencement by Company of any proceeding under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or release of multiple debtors; (c) the entering of any order for relief relating to any of the
proceedings described in Section 6.4(a) or (b) above; (d) the calling by Company of a meeting of multiple creditors with a view to arranging a composition of adjustment of its debts; (e) the act or failure to act by Company that
results in its consent to, approval of, or acquiescence in any of the proceedings described in Section 6.4(a)—(d) above; or (f) the commencement by Company or an Affiliate or Third Party sublicensee of Company of any action against
Penn to declare or render invalid or unenforceable the Patent Rights or any claim thereof, including but not limited to an action for declaratory judgment (a “Patent Challenge”). 

6.5 Effect of Termination. 

6.5.1 Effect of Termination Except under Section 6.2 Upon the termination of this Agreement prior to expiration of
the Term for any reason except pursuant to Section 6.2: (a) the Sublicense to the Patent Rights will terminate; (b) Company and all its Affiliates will cease all making, having made, using, importing, offering for sale and selling of all
Licensed Products with respect to Patent Rights under the Sublicense, except to the extent permitted by Section 6.5.1(f) and Section 6.6; (c) Company will pay to mRNA RiboTherapeutics all amounts, including accrued interest, owed to mRNA
RiboTherapeutics under this Agreement through the date of termination, including royalties on Licensed Products invoiced or shipped through the date of termination and any sell off period permitted by Section 6.6, whether or not payment is
received prior to termination or expiration of the sell off period permitted by Section 6.6; (d) Company will, at mRNA RiboTherapeutics’ request, return to mRNA RiboTherapeutics all Confidential Information of mRNA RiboTherapeutics (if
any) related to exploitation of Patent Rights and provide to mRNA RiboTherapeutics one summary of all work related thereto for Licensed Products generated by Company during the Term in order to facilitate the further development of the technology
licensed under this Agreement; (e) in the case of termination under Section 6.3, all duties of mRNA RiboTherapeutics and all rights (but not duties) of Company under this Agreement immediately terminate without further action required by
either mRNA RiboTherapeutics or Company; and (f) all outstanding Third Party sublicenses, to the extent each is not in default, will be assigned by Company to mRNA RiboTherapeutics, such assignment, will be accepted by mRNA RiboTherapeutics and
each Third Party sublicense agreement will remain in full force and effect with mRNA RiboTherapeutics as the sublicensor instead of Company, but the duties and obligations of mRNA RiboTherapeutics under the assigned sublicense agreements will not be
greater than the duties of mRNA RiboTherapeutics under this Agreement and the rights of mRNA RiboTherapeutics under the assigned sublicenses will not be less than those of mRNA RiboTherapeutics under this Agreement, including all financial
consideration and other rights of mRNA RiboTherapeutics and mRNA RiboTherapeutics may, at its sole discretion, amend such assigned agreements to contain terms and conditions found in this Agreement. [***] 

6.5.2 Effect of Termination under Section 6.2. Upon the termination of this Agreement under Section 6.2: (a) the
Sublicense to Company and all further sublicenses to Affiliates and Third Parties terminate (except to the extent that said Third Party sublicenses become direct sublicenses of mRNA RiboTherapeutics pursuant to Section 6.5.2(e)); (b) Company,
its Affiliates and Third Party sublicensees will cease all making, having made, using, importing, offering for sale and 

 
selling all Licensed Products under the Sublicense, except to the extent permitted pursuant to Section 6.5.2(e) and Section 6.6; (c) Company will pay to mRNA RiboTherapeutics all
amounts, including accrued interest, owed to mRNA RiboTherapeutics under this Agreement through the date of termination, including royalties on Licensed Products invoiced or shipped through the date of termination and any sell off period permitted
by Section 6.6, whether or not payment is received prior to termination or expiration of the sell off period permitted by Section 6.6, and (d) Company will, at mRNA RiboTherapeutics’ request, return to mRNA RiboTherapeutics all
confidential information of mRNA RiboTherapeutics; and (e) all outstanding sublicenses of Company to Third Parties and all outstanding sublicenses of Company’s Affiliates to Third Parties, to the extent each is not in default, will be
assigned by Company or its Affiliates to mRNA RiboTherapeutics (and Company will contractually obligate its Affiliates to make or cause such assignments), and each such assigned sublicense agreement will remain in full force and effect (including
for Exhibit A-1 Patent Rights and Exhibit A-2 Patent Rights) with mRNA RiboTherapeutics as the sublicensor instead of Company, but the duties and obligations of mRNA
RiboTherapeutics under the assigned sublicense agreements will not be greater than the duties and obligations of Company under this Agreement, and the rights of mRNA RiboTherapeutics under the assigned sublicense agreements will not be less than the
rights of Company under this Agreement, including all financial consideration and other rights of Company. mRNA RiboTherapeutics may, at its sole discretion, amend such assigned sublicense agreements to contain financial or other terms and
conditions found in this Agreement (excluding payment obligations which have already been satisfied by Company). 
 6.6
Inventory & Sell Off. Subject to the remainder of this Section 6.6, upon the termination of this Agreement for any reason, Company will: (1) cause physical inventories to be taken immediately of (a) all
completed Licensed Products on hand under the control of Company and its Affiliates and Third Party sublicensees and (b) such Licensed Products as are in the process of manufacture and any component parts on the date of termination of this
Agreement; (2) deliver promptly to mRNA RiboTherapeutics a copy of said written inventory, certified by an officer of Company; (3) promptly remove, efface or destroy or require or cause to be removed, effaced or destroyed all references to
Penn and mRNA RiboTherapeutics from any advertising, labels, web sites or other materials used in the promotion of the business of Company or its Affiliates or Third Party sublicensees; and (4) not represent in any manner that it has rights in
or to the Patent Rights or the Licensed Products under this Sublicense and cause its Affiliates and Third Party sublicensees not to represent that they have any rights in or to the Patent Rights or the Licensed Products. Subject to this
Section 6.6, Company and its Affiliates and Third Party sublicensees may sell off its inventory of Licensed Products existing on the date of termination for a period of [***] months and pay mRNA RiboTherapeutics royalties on Sales of such
inventory within [***] days following the expiration of such [***] month period. Notwithstanding the foregoing: (i) Company’s obligations under this Section 6.6 will not apply to the Sublicense or to Company’s sublicense
agreements if the Sublicense is assigned to Penn pursuant to Section 6.5.1; and (ii) the obligations of each of Company’s sublicensees pursuant to this Section 6.6 will not apply to Company’s or its Affiliates’ or Third
Party sublicensees’ sublicense agreements that are assigned to mRNA RiboTherapeutics pursuant to Sections 6.5.1(f) or 6.5.2(e). 
 6.7
Survival. Company’s obligation to pay all amounts, including accrued interest, owed to mRNA RiboTherapeutics under this Agreement will survive the termination of this Agreement for any reason. Articles 5, 6, 11, 12 and 13 and Sections
4.1 (until all Licensed Products which have been manufactured during the Term have been Sold), 4.2, 4.3 (for the time period set forth therein for all Sales of Licensed Products which have been manufactured during the Term), 4.4 (for the time period
set forth therein), 9.1.3 (for all amounts paid by Company to 

 
mRNA RiboTherapeutics that are payable to Penn following termination), and 4.5-4.7, 9.1.7 and 9.2.3 will survive the termination of this Agreement in
accordance with their respective terms. The Parties acknowledge and agree that the Sublicense is, for the purposes of section 365(n) of the U.S. Bankruptcy Code, a license to “intellectual property” as defined under Section 101 of the
U.S. Bankruptcy Code. The Parties intend that all payments under Article 3 of this Agreement constitute “royalties” within the meaning of section 365(n) of the U.S. Bankruptcy Code. 

 

	7	 PATENT PROSECUTION AND MAINTENANCE 

7.1 Patent Control. Penn and mRNA RiboTherapeutics control the preparation, prosecution and maintenance of the Patent Rights and the
selection of patent counsel, subject to the remainder of this Section 7.1. For purposes of this Article 7, the word “maintenance” includes any interference negotiations, claims, or proceedings, in any forum, brought by Penn, mRNA
RiboTherapeutics, a Third Party, or the United States Patent and Trademark Office or any foreign equivalent pertaining to Patent Rights, and any requests by Penn or mRNA RiboTherapeutics that the United States Patent and Trademark Office or any
foreign equivalent re-examine or reissue any patent in the Patent Rights. [***] 
  

	8	 INFRINGEMENT 

8.1 Control. As between Company and mRNA RiboTherapeutics, mRNA RiboTherapeutics shall have the exclusive right to initiate litigation
with respect to infringement of the Patent Rights, [***] Subject to the terms of [***], mRNA RiboTherapeutics will provide Company and its counsel with reasonable opportunities to consult with mRNA RiboTherapeutics regarding the enforcement of
Patent Rights. Subject to the foregoing, mRNA RiboTherapeutics will: (a) notify Company in writing prior to undertaking an enforcement action or initiating litigation with respect to infringement of any such Patent Rights; (b) provide
Company with copies of drafts of substantive communications (including legal briefs or filings) intended to be made by mRNA RiboTherapeutics or its representatives reasonably in advance to permit Company to review and comment on such drafts and
incorporate reasonable comments by Company thereon, (c) provide Company with copies of substantive communications made by the relevant infringer in connection with the infringement issue; and (d) take requests and comments made by Company
in relation to the infringement issue into account and not unreasonably reject such requests or comments. 
 8.2
Cooperation. Subject to mRNA RiboTherapeutics’ obligations pursuant to the terms and conditions of the Penn License Agreement, mRNA RiboTherapeutics will cooperate with Company on matters related to infringement in a
reasonable and prudent manner, preferably without litigation. In any litigation under this Article 8, each Party, at the reasonable request and sole expense of the other Party, will provide reasonable cooperation to such other Party. This
Article 8 will not be construed to require either Party to undertake any activities, including legal discovery, at the request of any Third Party, except as may be required by lawful process of a court of competent jurisdiction. 

 

	9	 REPRESENTATIONS, WARRANTIES, COVENANTS AND DISCLAIMER OF WARRANTIES 

9.1 Covenants of mRNA RiboTherapeutics. mRNA RiboTherapeutics covenants to Company that, during the Term: 

9.1.1 mRNA RiboTherapeutics will not breach, and to the extent within its power, will ensure that its sublicensed affiliates do not cause a
breach of, the Penn License Agreement in any manner that would result in Penn having the right to terminate the Penn License Agreement, and mRNA RiboTherapeutics will use diligent efforts to cure (or cause to be cured) any such breach of the Penn
License Agreement by mRNA RiboTherapeutics or its affiliates or Third Party sublicensees. 

 9.1.2 Upon mRNA RiboTherapeutics learning of any breach of a sublicense agreement by any of
its affiliate or Third Party sublicensees in any manner that would result in Penn having the right to terminate the Penn License Agreement, mRNA RiboTherapeutics will expeditiously take appropriate actions to stop such act or omission, up to and
including termination of the applicable sublicense pursuant to the terms of the Penn License Agreement. 
 9.1.3 mRNA RiboTherapeutics will
make all payments due under the Penn License Agreement, and make all required disclosures to Penn in connection therewith, in each case in a timely manner in accordance with the terms thereof. 

9.1.4 Promptly following mRNA RiboTherapeutics’ or any of its affiliates’ receipt of any material written notice or correspondence
about an issue pertaining to the Sublicense or to any matter that would reasonably be expected to adversely affect in any respect Company’s rights under this Agreement, mRNA RiboTherapeutics will, to the extent permissible, furnish a copy of
such notice or correspondence to Company, provided that mRNA RiboTherapeutics may redact portions of any such notice or correspondence that do not relate to or impact Company’s rights hereunder. 

9.1.5 mRNA RiboTherapeutics will promptly notify Company if mRNA RiboTherapeutics receives a notice from Penn of an intent to terminate the
Penn License Agreement. 
 9.1.6 mRNA will not amend the Penn License Agreement in any way that would negatively affect the rights or
obligations of Company under this Agreement. 
 9.1.7 mRNA RiboTherapeutics agrees that mRNA RiboTherapeutics and its affiliates will not
sue, bring an action against, or otherwise assert any claim against Company or its Affiliates or Third Party sublicensees or their successors in ownership (to which this Agreement or a sublicense under this Agreement is assigned according to terms
and conditions for assignment pursuant to Section 15.5 or Section 1.5.5 herein) for infringement of or misappropriation of any Patent Rights (as defined in Section 1.2) that are used by Company or its Affiliates or Third Party
sublicensees or their successors in ownership in the Sublicensed Fields of Use, as Fields of Use in the Sublicensed Fields of Use are defined in Section 1.2. [***] This covenant shall terminate with the termination of this Agreement unless the
termination is: (a) made under Section 6.3, and (b) within [***] days following Company’s receipt of notice of termination under Section 6.3, is either: (i) resolved by Company and mRNA RiboTherapeutics in writing, or
(ii) Company initiates a state or federal lawsuit contesting said termination (“Contested Termination”). In the event of a Contested Termination, this covenant shall continue to run during the [***] days, and if a lawsuit is
initiated, until said state or federal court enters a final decision from which no appeal has been or can be taken. 
 9.2 Covenants of
Company. Company covenants to mRNA RiboTherapeutics that, during the Term: 
 9.2.1 Upon Company learning of any breach of a sublicense
agreement by any of its Affiliates or Third Party sublicensees in any manner that would result in Penn having the right to terminate the Penn License Agreement, Company will use diligent efforts to cure (or cause to be cured) any such breach, up to
and including termination of the applicable sublicense, as stated in Section 1.5.4 of this Agreement. 

 9.2.2 Company will not breach this Agreement, and to the extent within its legal power, will
ensure that its Affiliates do not breach or cause breach of any sublicense under this Agreement in any manner that would result in Penn having the right to terminate the Penn License Agreement, and Company will use diligent efforts to cure (or cause
to be cured) any such breach of this Agreement by Company or any breach of any sublicense under this Agreement by its Affiliates or Third Party sublicensees. 

9.2.3 Company will pay to mRNA RiboTherapeutics all payments due under this Agreement pursuant to Article 3 and in accordance with the terms in
Articles 3 and Section 4.2 and will provide to mRNA RiboTherapeutics all information, reports and notices required in accordance with Sections 2.1, 2.3, 3.3, 3.4.3(a), 4.1, 4.4 and 6.6 and in the form of the sample report attached as Exhibit C,
in each case in accordance with the time periods set forth therein. 
 9.2.4 Promptly following Company’s or any of its Affiliates’
receipt of any material written notice or correspondence pertaining to the Sublicense or to any matter that could reasonably be expected to adversely affect in any respect mRNA RiboTherapeutics’ rights or obligations under this Agreement,
Company will, to the extent permissible, furnish a copy of such notice or correspondence to mRNA RiboTherapeutics, provided that Company may redact portions of any such letter that do not relate to or impact mRNA RiboTherapeutics’ rights
hereunder. 
 9.3 Representations and Warranties of mRNA RiboTherapeutics. As of the Effective Date, mRNA RiboTherapeutics, on behalf
of itself and its affiliates, hereby represents and warrants to Company that: 
 9.3.1 mRNA RiboTherapeutics has provided Company a true and
correct redacted copy of the Penn License Agreement (including all exhibits and amendments thereto), and there are no other agreements, written or verbal, between Penn and mRNA RiboTherapeutics. 

9.3.2 mRNA RiboTherapeutics has provided Company a true, correct redacted copy of the Cellscript Sublicense Agreement, and: (a) there are
no other agreements between mRNA RiboTherapeutics and Cellscript relating to the Penn License Agreement or the Patent Rights; (b) neither mRNA RiboTherapeutics nor Cellscript has granted any other sublicenses under the Patent Rights with
respect to Field of Use B; and (c) neither mRNA RiboTherapeutics nor Cellscript has made any agreements with any Third Party not to sue, or granted any liens or other rights or encumbrances in or to its rights in Patent Rights or the Penn
License Agreement. 
 9.3.3 Since the date of the Penn License Agreement, neither mRNA RiboTherapeutics nor any of its affiliates has
proposed to Penn, or received from Penn, any correspondence challenging the validity or enforceability of the Penn License Agreement or proposing to amend any provision of the Penn License Agreement. 

9.3.4 mRNA RiboTherapeutics has not (a) breached or defaulted under any provision of the Penn License Agreement in any material respect or
(b) received any written notice from Penn of any claims for indemnification pursuant to the Penn License Agreement. 
 9.3.5 To the
knowledge of mRNA RiboTherapeutics, (a) there are no facts that would preclude Penn from having clear title to the Patent Rights, (b) there are no pending or threatened litigations, interferences, reexaminations, oppositions or like
procedures involving any such Patent Rights and (c) all of the issued patents within the Patent Rights are valid and enforceable, are in full force and effect and have not lapsed, expired or otherwise terminated. 

 9.3.6 mRNA RiboTherapeutics believes the terms and conditions of this Agreement are fully
consistent with the terms and conditions of the Penn License Agreement. 
 9.3.7 mRNA RiboTherapeutics has not received, and to mRNA
RiboTherapeutics’ knowledge, Penn has not received, any written notice of any claim by any person or entity challenging the license rights of mRNA RiboTherapeutics, or the ownership of or rights of Penn in and to the Patent Rights, or the
validity or enforceability of the Patent Rights. 
 9.3.8 mRNA RiboTherapeutics does not own or have any licenses for any other patent rights
other than Patent Rights. 
 9.3.9 The Fields of Use sublicensed to Company in this Agreement are distinct from and do not overlap with the
fields of use granted to Company in the Sublicense Agreement from Cellscript, and any products researched, developed, manufactured and commercialized in fields of use granted under the Sublicense Agreement from Cellscript are subject only to the
payment and other obligations of the Sublicense Agreement from Cellscript, and not under this Agreement. 
 9.3.10 mRNA RiboTherapeutics
believes that the representations and warranties of mRNA RiboTherapeutics in this Agreement, do not, taken as a whole, (i) contain any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the
statements or facts contained therein, in light of the circumstances under which they were made, not misleading. mRNA RiboTherapeutics has not knowingly withheld any information with respect to the Penn License Agreement or the Patent Rights that
would reasonably be expected to be material to Company’s decision to enter into this Agreement. 
 9.4 Representations and Warranties
of Company. Company, on behalf of itself and its affiliates, hereby represents and warrants to mRNA RiboTherapeutics that, as of the Effective Date: 

9.4.1 Company is duly organized and validly existing under the laws of the jurisdiction of its incorporation and has full corporate power and
authority to enter into this Agreement. 
 9.4.2 Company is in good standing with all relevant governmental authorities. 

9.4.3 Company has taken all corporate actions necessary to authorize the execution and delivery of this Agreement and the performance of its
obligations under this Agreement. 
 9.4.4 The performance of the obligations of Company under this Agreement do not conflict with or
constitute a default under its charter documents, any contractual obligation of Company or any court order. 
 9.4.5 Company and its
attorneys and technical experts have reviewed the patents and patent applications comprising Patent Rights including both Exhibit A-1 Patent Rights and Exhibit A-2
Patent Rights that are listed in Exhibit A attached hereto. 
 9.4.6 Company has experience with and is familiar with the inventions covered
by Patent Rights and understands the use, purpose and benefits thereof. 
 9.4.7 Company believes that the representations and warranties of
Company in this Agreement, do not, taken as a whole, (i) contain any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under
which they were made, not misleading. Company has not knowingly withheld any information with respect to the any of Company’s above statements that would reasonably be expected to be material to mRNA RiboTherapeutics’ decision to enter
into this Agreement. 
 [Remainder of page left blank] 

 9.5 Disclaimer of Warranties. EXCEPT AS SPECIFICALLY SET FORTH IN THIS ARTICLE 9, NO
PARTY MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS OR SUFFICIENCY OF PATENT RIGHTS FOR A PARTICULAR PURPOSE, APPLICATION OR USE,
NON-INFRINGEMENT, OR ANY OTHER STATUTORY WARRANTY. 
  

	10	 ADDITIONAL TERMS REGARDING SUBLICENSING 

10.1 Purpose of this Article. This Article 10 sets forth terms and conditions for further sublicensing by Primary Sublicensors in the
Human In Vivo Therapeutics Field, wherein, for the purposes of this Article 10: 
  

	 	(a)	 “sublicensing” herein means any grant of a sublicense, covenant not to sue, or option for
current or future rights under Patent Rights, and the noun “sublicense” herein means a document that grants such sublicense, covenant not to sue, or option for current or future rights under Patent Rights; 

 

	 	(b)	 “Primary Sublicensors” herein means (i) mRNA RiboTherapeutics, (ii) Cellscript, and
(iii) any affiliate of (i) or (ii) that is granted a sublicense in the Human In Vivo Therapeutics Field; and 

  

	 	(c)	 “Human In Vivo Therapeutics Field” herein means any or all therapeutic
and prophylactic use(s) in humans in the In Vivo Field of Use in Field of Use B. 

 For clarity and the absence of
doubt, Article 10 shall not be interpreted in any way so as to limit, restrict or impose any terms or conditions on Primary Sublicensors’ rights to grant sublicenses under Patent Rights to any party at any time for any Field of Use other than
the Human In Vivo Therapeutics Field. 
 10.2 Human In Vivo Therapeutics Field Sublicenses.
Subject to the rights of the Primary Sublicensors and their respective owners under Section 10.4, mRNA RiboTherapeutics and Company agree that, from the Effective Date [***], mRNA RiboTherapeutics will not grant and will ensure that
other Primary Sublicensors will not grant Human In Vivo Therapeutics Field Sublicenses, including this Sublicense, to [***] 

“Human In Vivo Therapeutics Field Sublicense” means a sublicense to make, have made, use, import,
offer for sale, sell and/or have sold any number of products covered by Patent Rights comprising or incorporating modified RNA for the Human In Vivo Therapeutics Field, but excluding Product Sublicenses. 

 10.3 Product Sublicenses. Subject to the rights of the Primary Sublicensors and their
respective owners under Section 10.4, mRNA RiboTherapeutics and Company agree that, from the Effective Date until [***], mRNA RiboTherapeutics will (and will ensure that the other Primary Sublicensors will): 

(a) grant Product Sublicenses only to [***] 

wherein “Product Sublicenses” herein mean sublicenses under Patent Rights to research, develop, manufacture and/or
commercialize specific products [***], for a therapeutic or prophylactic use in humans in the In Vivo Field of Use, and 

wherein [***] 
 (b) only
grant Product Sublicenses for a total of [***] in the aggregate by all of the Primary Sublicensors across all such Product Sublicenses, [***] 

(c) except as set forth in Sections 10.2 and 10.3, not otherwise grant sublicenses under the Patent Rights to research, develop, manufacture
and/or commercialize products comprising or incorporating [***]. 
 10.4 Sale of a Primary Sublicensor. Company understands and
agrees that the owners of each of mRNA RiboTherapeutics and Cellscript shall have the right to sell all or any part of the outstanding stock or ownership interest or the business or the assets thereof, as applicable, of mRNA RiboTherapeutics and/or
Cellscript and/or any of their respective affiliates [***] at any time and without any conditions pursuant to this Agreement other than the requirements under Section 15.5, except that, as a condition to any such sale occurring prior to
April 1, 2020: 
 [Remainder of page left blank] 
  

 (a) the owners of each of mRNA RiboTherapeutics and Cellscript will sell mRNA
RiboTherapeutics or Cellscript to only one (1) Third Party purchaser, [***]; and 
 (b) without in any way negating or ceding or
giving up any of their current rights to sell all or any part of the stock, ownership interest, business or assets of mRNA RiboTherapeutics and/or Cellscript or to discuss any such sale with any potential purchaser at any time, including from the
Effective Date of this Agreement [***], the owners of mRNA RiboTherapeutics and Cellscript agree not to conduct Active Marketing of such sale of a Primary Sublicensor prior to [***], 

wherein “[***]” herein means [***]; and 

for the avoidance of doubt, Company agrees that this Section 10.4(a) shall not be interpreted so as to prohibit the owners of mRNA
RiboTherapeutics and/or Cellscript from proposing or discussing [***]; 
  

	 	(c)	 the purchaser of mRNA RiboTherapeutics or Cellscript, respectively, will pay [***];

 [Remainder of page left blank] 

	 	(d)	 on the effective date of any such sale of [***] and the purchaser and their assignees and successors in
ownership thereof shall have all the same rights as are held by Company under this Agreement to: 

  

	 	(i)	 grant Human In Vivo Therapeutics Field Sublicenses to affiliates and Third Parties without being subject
to any restrictions, limitations, or terms and conditions that apply to the Primary Sublicensors under Sections 10.2, and 

  

	 	(ii)	 grant Product Sublicenses to affiliates and any Third Parties to research, develop, manufacture and/or
commercialize any number of products comprising modified RNA covered by Patent Rights for any therapeutic or prophylactic use in humans in the In Vivo Field of Use without being subject to any of the restrictions, limitations or requirements
that the sublicensee is a Small Biotech Company as is required of the Primary Sublicensors in Section 10.3; and 

(e) on the effective date of any such sale of more than fifty percent (50%) of the outstanding stock or ownership interest or all of the
business or assets of mRNA RiboTherapeutics or Cellscript, all of the rights of the Primary Sublicensors to grant Product Sublicenses pursuant to Section 10.3 shall remain only with the Primary Sublicensors for which their stock, ownership
interest, business and assets were not sold. 
 [***]. 

10.5 From [***], Primary Sublicensors and any owners, assignees or successors in ownership thereof shall have the right to grant any
number of Human In Vivo Therapeutics Field Sublicense(s) to any parties without any conditions (other than those imposed by the Penn License Agreement or the Cellscript Sublicense Agreement) and to grant any number of Product
Sublicenses or any other sublicenses of any kind under Patent Rights to any parties without any limitations or restrictions or requirements whatsoever under this Article 10. 

[Remainder of page left blank] 

	11	 LIMITATION OF LIABILITY; DISCLAIMER. 

11.1 Limitation of Liability. PENN AND mRNA RIBOTHERAPEUTICS WILL NOT BE LIABLE TO COMPANY, ITS AFFILIATES, SUBLICENSEES, SUCCESSORS OR
ASSIGNS, OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM: ARISING FROM COMPANY’S USE OF THE PATENT RIGHTS, LICENSED PRODUCTS OR ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT; OR ARISING FROM THE COMPANY’S, COMPANY’S AFFILIATES’
OR COMPANY’S SUBLICENSEES’ DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NONE OF PENN, mRNA RIBOTHERAPEUTICS OR COMPANY WILL BE LIABLE TO THE OTHER OR ANY
THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY INDIRECT, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN IF SUCH PARTY HAS BEEN INFORMED OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED THAT THIS SECTION
11.1 WILL NOT APPLY: (a) TO A PARTY’S INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER ARTICLE 12 OR ARTICLE 13; (b) IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES; OR (c) WITH RESPECT TO A
PARTY’S LIABILITY FOR BREACH OF ARTICLE 5 or 10. 
 11.2 Disclaimer. THE PATENT RIGHTS, LICENSED PRODUCTS AND ANY OTHER
TECHNOLOGY LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NONE OF PENN, mRNA RIBOTHERAPEUTICS OR COMPANY MAKE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT, VALIDITY OR TITLE. 

 

	12	 PENN INDEMNIFICATION 

12.1 Indemnification. Company will defend, indemnify, and hold harmless each Penn Indemnified Party from and against any and all Penn
Liabilities with respect to an Indemnification Event. The term “Penn Indemnified Party” means each of Penn and its trustees, officers, faculty, students, employees, contractors, and agents. For clarity, mRNA RiboTherapeutics is not
a Penn Indemnified Party. The term “Penn Liabilities” means all damages, awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and
expenses (including, but not limited to, court costs, interest and reasonable fees of attorneys, accountants and other experts) that are incurred by a Penn Indemnified Party or awarded or otherwise required to be paid to Third Parties by a Penn
Indemnified Party. The term “Indemnification Event” means any Claim against one or more Penn Indemnified Parties arising out of or resulting from: [***] The term “Claim” in this Article 12 means any
charges, complaints, actions, suits, proceedings, hearings, investigations, claims or demands. 
 12.2 Reimbursement of Costs. Company
will pay directly all Penn Liabilities incurred for defense or negotiation of any Claim or will reimburse Penn for all documented Penn Liabilities incident to the defense or negotiation of any Claim within [***] days after Company’s
receipt of invoices for such fees, expenses and charges. 

 12.3 Control of Litigation. Company controls any litigation or potential litigation
involving the defense of any Claim, including the selection of counsel, with input from Penn. Penn reserves the right to protect its interest in defending against any Claim by selecting its own counsel, with any attorneys’ fees and litigation
expenses paid for by Company, pursuant to Sections 12.1 and 12.2. 
 12.4 Other Provisions. Company will not settle or compromise any
Claim giving rise to Penn Liabilities in any manner that imposes any restrictions or obligations on Penn or grants any rights to the Patent Rights or the Licensed Products without Penn’s prior written consent. If Company fails or declines to
assume the defense of any Claim within [***] days after notice of the Claim, or fails to reimburse a Penn Indemnified Party for any Penn Liabilities pursuant to Sections 12.1 and 12.2 within the [***] day time period set forth in
Section 12.2, then Penn may assume the defense of such Claim for the account and at the risk of Company, and any Penn Liabilities related to such Claim will be conclusively deemed a liability of Company. The indemnification rights of the Penn
Indemnified Parties under this Article 12 are in addition to all other rights that a Penn Indemnified Party may have at law, in equity or otherwise. 
  

	13	 OTHER INDEMNIFICATION 

13.1 Indemnification by Company. Company will indemnify, defend and hold harmless mRNA RiboTherapeutics and its affiliates, and its or
their respective directors, officers, employees and agents (“mRNA RiboTherapeutics Indemnified Parties”), from and against any and all liabilities, damages, losses, costs and expenses including the reasonable fees of
attorneys (collectively “Losses”) arising out of or resulting from any and all Third Party suits, claims, actions, proceedings, payment obligations or demands (“Claims” in this Article 13) to the extent based
upon: 
 13.1.1 the gross negligence or willful misconduct of Company, its Affiliates or Third Party sublicensees and its or their respective
directors, officers, employees and agents, in connection with Company’s performance of its obligations or exercise of its rights under this Agreement; 

13.1.2 any breach of any representation or warranty or express covenant made by Company under this Agreement; or 

 13.1.3 the development, testing, use, manufacture, commercialization, sale or other
disposition of Licensed Products by or on behalf of Company or its Affiliates or Third Party sublicensees, assignees or vendors or Third Parties, including, but not limited to, for (x) any product liability or other Claim of any kind related to
use by a Third Party of a Licensed Product, (y) any Claim by a Third Party that Company’s practice of any of the Patent Rights or the design, composition, manufacture, use, sale or other disposition of any Licensed Product infringes or
violates any patent, copyright, trade secret, trademark or other intellectual property right of such Third Party, and (z) any Claim by a Third Party relating to clinical trials or studies for Licensed Products; 

except, in each case above, to the extent such Claim arose out of or resulted from or is attributable to any acts or omissions of mRNA
RiboTherapeutics or its directors, officers, employees and agents, or other circumstances for which mRNA RiboTherapeutics has an indemnity obligation pursuant to Section 13.2 below. 

13.2 Indemnification by mRNA RiboTherapeutics. mRNA RiboTherapeutics will indemnify, defend and hold harmless Company and its
Affiliates, and its or their respective directors, officers, employees and agents (“Company Indemnified Parties”), from and against any and all Losses arising out of or resulting from any and all Claims to the extent based upon:

 13.2.1 the gross negligence or willful misconduct of mRNA RiboTherapeutics or its directors, officers, employees and agents, in connection
with mRNA RiboTherapeutics’ performance of its obligations or exercise of its rights under this Agreement; or 
 13.2.2 any breach of
any representation or warranty or express covenant made by mRNA RiboTherapeutics under this Agreement; 
 except, in each case above, to the
extent such Claim arose out of or resulted from or is attributable to any acts or omissions of Company or its Affiliates or Third Party sublicensees and its or their respective directors, officers, employees and agents or other circumstances for
which Company has an indemnity obligation pursuant to Section 13.1 above. 
 13.3 Procedure. If an Indemnified Party entitled to
indemnification under Sections 13.1 or 13.2 seeks such indemnification (wherein “Indemnified Party” in this Article 13 means a “Company Indemnified Party” and/or an “mRNA RiboTherapeutics Indemnified Party”),
such Indemnified Party will: 
 (i) inform the indemnifying Party in writing of a Claim as soon as reasonably practicable after such
Indemnified Party receives notice of such Claim; 
 (ii) permit the indemnifying Party to assume direction and control of the defense of the
Claim (including the sole right to settle such Claim at the sole discretion of the indemnifying Party, provided that (a) such settlement or compromise does not admit any fault or negligence on the part of the Indemnified Party, or impose
any obligation on, or otherwise materially adversely affect, the Indemnified Party or other Party and (b) the indemnifying Party first obtains the written consent of the Indemnified Party with respect to such settlement, which consent will not
be unreasonably withheld); 

 (iii) cooperate as reasonably requested (at the expense of the indemnifying Party) in the
defense of the Claim; and 
 (iv) undertake reasonable steps to mitigate any Losses with respect to the Claim. 

Notwithstanding anything in this Agreement to the contrary, the indemnifying Party will have no liability under Sections 13.1 or 13.2, as the
case may be, for Claims settled or compromised by the Indemnified Party without the indemnifying Party’s prior written consent. 
  

	14	 INSURANCE 

14.1 Coverages. Company will procure and maintain insurance or self-insurance that covers the following minimum liability amounts with
respect to personal injury, bodily injury and property damage arising out of Company’s performance under this Agreement: (a) during the Term, comprehensive general liability, including broad form and contractual liability, in a minimum
amount of [***] combined single limit per occurrence and in the aggregate; (b) prior to the commencement of clinical trials involving Licensed Products, clinical trials a minimum amount of [***] combined single limit per
occurrence and in the aggregate; and (c) prior to the Sale of the first Licensed Product, product liability a minimum amount of [***] combined single limit per occurrence and in the aggregate. Penn and mRNA RiboTherapeutics may
review periodically the adequacy of the minimum amounts of insurance or self-insurance for each liability coverage area required by this Section 14.1, and Penn and mRNA RiboTherapeutics reserve the right to request Company to adjust the limits
accordingly to the extent existing limits are not commercially reasonable. The required minimum amounts of insurance or self-insurance do not constitute a limitation on Company’s liability or indemnification obligations to Penn or mRNA
RiboTherapeutics under this Agreement. 
  

	15	 ADDITIONAL PROVISIONS 

15.1 Independent Contractors. The Parties are independent contractors. Nothing contained in this Agreement is intended to create an
agency, partnership or joint venture between the Parties. At no time will either Party make commitments or incur any charges or expenses for or on behalf of the other Party. 

15.2 No Discrimination. Company will not discriminate against any employee or applicant for employment because of race, color, sex,
sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status. 
 15.3 Compliance with Laws.
Company must comply with all prevailing laws, rules and regulations that apply to its activities or obligations under this Agreement. For example, Company will comply with applicable United States export laws and regulations. The transfer of certain
technical data and commodities may require a license from the applicable agency of the United States government and/or written assurances by Company that Company will not export data or commodities to certain foreign countries without prior approval
of the agency. Penn and mRNA RiboTherapeutics do not represent that no license is required, or that, if required, the license will issue. 

[Remainder of page left blank] 

 15.4 Modification, Waiver & Remedies. This Agreement may only
be modified by a written amendment that is executed by an authorized representative of each Party. Any waiver must be express and in writing. No waiver by either Party of a breach by the other Party will constitute a waiver of any different or
succeeding breach. Unless otherwise specified, all remedies are cumulative. 
 15.5 Assignment. This Agreement may not be assigned (by
operation of law or otherwise) by either Party without the prior written consent of the other Party (which consent will not be unreasonably withheld); except that, that either Party may assign this Agreement without such consent to an
affiliate or to a successor that purchases greater than fifty percent (>50%) of the outstanding stock or ownership interest or all or substantially all of such Party’s business or assets to which this Agreement relates, whether by sale of
shares or ownership interest, merger, consolidation, sale of assets or otherwise, provided that the assignee agrees in writing to be legally bound by this Agreement in the place and stead of the assignor and provides the non-assigning Party with a copy of said assignee’s written undertaking. Neither Party will grant a security interest in the Sublicense or this Agreement during the Term. Any prohibited assignment or security
interest in contravention of the foregoing will be null and void. The rights and obligations of the Parties under this Agreement will be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a
Party appearing herein will be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Section 15.5. 

15.6 Notices. Any notice or other required communication (each, a “Notice”) must be in writing, addressed to the
Party’s respective Notice Address listed on the signature page, and delivered: (a) personally, with signed receipt; (b) by certified mail, postage prepaid, return receipt requested; (c) by recognized overnight courier service,
charges prepaid; or (d) by facsimile. A Notice will be deemed received: if delivered personally, on the date of delivery; if mailed, [***] days after deposit in the United States mail; if sent via courier, [***] business day after
deposit with the courier service; or if sent via facsimile, upon receipt of confirmation of transmission provided that a confirming copy of such Notice is sent by certified mail, postage prepaid, return receipt requested. 

15.7 Severability & Reformation. If any provision of this Agreement is held to be invalid or unenforceable by a
court of competent jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable provision will be automatically revised to be a valid or enforceable provision that comes as close
as permitted by law to the Parties’ original intent. 
 15.8 Headings & Counterparts. The headings of the
articles and sections included in this Agreement are inserted for convenience only and are not intended to affect the meaning or interpretation of this Agreement. This Agreement may be executed in one or more counterparts, each of which when
executed and delivered by facsimile, electronic transmission, or by mail delivery, will be an original and all of which shall constitute one and the same instrument. 

15.9 Governing Law. This Agreement will be governed in accordance with the laws of the Commonwealth of Pennsylvania, without giving
effect to the conflict of law provisions of any jurisdiction. 

 15.10 Dispute Resolution. If a dispute arises between the Parties concerning any
right or duty under this Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute. If the Parties are unable to resolve the dispute amicably, then the Parties will submit to the exclusive jurisdiction of,
and venue in, the state and Federal courts located in the Eastern District of Pennsylvania with respect to all disputes arising under this Agreement. Notwithstanding anything herein to the contrary, in the event of an actual or threatened breach of
this Agreement, the aggrieved Party may seek provisional equitable relief (including restraining orders, specific performance or other injunctive relief) in any court of competent jurisdiction to protect the interests of such Party. 

15.11 Further Assurance. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments
and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry
out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

15.12 Interpretation. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the
singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or
limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein shall mean including, without limiting the generality of any description preceding such term. The
language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. The Parties acknowledge and agree that new products and uses for products
that are covered by Patent rights may be developed based on new advances in scientific knowledge. As such, the Parties’ agree that, if Company is of the opinion that such advances have resulted in changes which warrant interpretation of whether
such new products or uses are included within the Sublicensed Fields of Use granted to Company herein, the Parties agree to discuss and negotiate in good faith the need for an amendment or clarification of the meaning of the rights or Fields of Use
granted to Company in Section 1.1 of this Agreement in order to try to find a solution that is agreeable to the Parties. Then, if the Parties have not agreed on the necessity or the wording of such amendment within [***] days after
beginning good faith discussions, the Parties agree that, either both Parties will jointly agree on and appoint one independent Third Party, or each of the Parties will appoint one independent Third Party and those Third Parties will appoint one
additional independent Third Party (all of which Third Parties will be qualified and skilled in the scientific field and have knowledge of law related to patents and licenses) to decide whether such amendment is required to properly reflect this
intention. If the appointed independent Third Party or Third Parties decide(s) that said amendment is required, the Parties hereby agree to so amend this Agreement accordingly. If the appointed independent Third Party or Third Parties decide(s) that
said amendment is not required, there is no obligation on either Party to amend this Agreement. The costs of the appointed independent Third Party or Third Parties will be borne by the Party whose view has not been confirmed by such Third
Party(ies). 

 15.13 Integration. This Agreement with its Exhibits and the Confidentiality Agreement
contain the entire agreement between the Parties with respect to the Patent Rights and the Sublicense and supersede all other oral or written representations, statements, or agreements with respect to such subject matter. 

15.14 Condition Precedent to Execution of this Agreement. The Parties understand and agree that each Party’s willingness to enter
into this Agreement is conditioned upon the execution of both this Agreement and the Sublicense Agreement from Cellscript which grants certain other rights to Company under Patent Rights than the rights granted to Company in this Agreement. 

15.15 Entire Agreement. This Agreement and the separate Sublicense Agreement from Cellscript set forth the complete, final and only
agreements with respect to the subject matter hereof and supersede all other agreements and understandings between the Parties with respect to the subject matter hereof. The Parties acknowledge and agree that this Agreement and the Sublicense
Agreement from Cellscript are separate and distinct agreements and there will be no “cross default” with respect to this Agreement and the Sublicense Agreement from Cellscript. 

Each Party has caused this Agreement to be executed by its duly authorized representative. 

 

									
	mRNA RIBOTHERAPEUTICS, INC.	 		 	BioNTech AG

									
					
	By:	 	 [***]
	 		 	By:	 	 [***]

	Name:	 	[***]	 		 	Name:	 	[***]
	Title:	 	[***]	 		 	Title:	 	[***]

  

									
	Address: mRNA RIBOTHERAPEUTICS, INC.	 		 	    Address:	 	BioNTech AG
	        	 	726 Post Road	 		 		 	An der Goldgrube 12
		 	Madison, WI 53713	 		 		 	55131 Mainz
		 	USA	 		 		 	Germany

 EXHIBIT INDEX 

 

			
		
	Exhibit A	  	Patents and Patent Applications in Patent Rights
		
	Exhibit B	  	Sublicense Disclosure Report
		
	Exhibit C	  	Form of Royalty Report

 mRNA RiboTherapeutics, Inc. 

EXHIBIT A – Patents and Patent Applications in Patent Rights 

[***] 

 mRNA RiboTherapeutics, Inc. 

 Exhibit B 

Sublicense Disclosure Report 
 [***] 

 EXHIBIT C – Format of Royalty Report 

[***]EX-10.16

 Exhibit 10.16 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

LICENSE AND CO-DEVELOPMENT AGREEMENT 

THIS LICENSE AGREEMENT (“Agreement”) is made as of July 4, 2018 (“Effective Date”), by and
between BioNTech RNA Pharmaceuticals GmbH, a corporation organized and existing under the laws of Germany (“BioNTech”), having its principal place of business at An der Goldgrube 12, 55131 Mainz, Germany, and Genevant
Sciences GmbH, a corporation organized and existing under the laws of Switzerland (“Genevant”), having an address of Viaduktstrasse 8, 4051 Basel, Switzerland. BioNTech and Genevant are referred to individually as a
“Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, Genevant has an exclusive license to certain intellectual property rights relating to
RNA-based therapeutics enabled by lipid nanoparticle delivery technologies; 
 WHEREAS,
BioNTech is developing certain mRNA payloads for treatment in the field of oncology and infectious diseases and is also developing alone and in collaboration with third parties certain formulations useful for the delivery of mRNA payloads; 

WHEREAS, the Parties wish to jointly develop pharmaceutical products that combine the best mRNA payloads with the best lipid
nanoparticle technology in the fields of rare diseases and liver diseases, under the terms and conditions set forth herein; and 

WHEREAS, BioNTech wishes to obtain from Genevant a license to utilize the lipid nanoparticle delivery technologies in conjunction with
its development of mRNA payloads and delivery technologies in the oncology field, and Genevant is willing to grant such license to BioNTech, all under the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the receipt and sufficiency which
are hereby acknowledged, BioNTech and Genevant hereby agree as follows. 
 ARTICLE 1 

DEFINITIONS 
 Unless the
context otherwise requires, the terms in this Agreement with initial letters capitalized, shall have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement. 

1.1 “Accounting Standards” means internationally recognized accounting principles (including IFRS, US GAAP, and
the like), in each case, as then in effect and as consistently applied by the applicable Party or its Affiliate or Sublicensee. 

1.2 “Affiliate” means, (a) with respect to Genevant, any Person that, directly or indirectly through one or more
intermediaries is controlled by Genevant Sciences Ltd., but for only so long as such control exists; and (b) with respect to BioNTech, any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is
under common control with BioNTech, but for only so long as such control exists. For the purpose of this definition, “control” (including, with correlative meaning, the terms “controlled by” and “under common
control”) means (a) to possess, directly or indirectly, the power to direct the management 

  
 1 

 
or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise; or (b) direct or indirect beneficial
ownership of more than fifty percent (50%) of the voting share capital or other equity interest in such entity. Notwithstanding the above, for purposes of this Agreement, [***] and its Affiliates will not be deemed to be Affiliates of Genevant, and
AT Impf GmbH, having its place of business at Rosenheimer Platz 6, 81669 Munich, Germany, and any person or entity that, during the Term, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common
control with AT Impf GmbH (other than BioNTech AG or any person or entity that is directly or indirectly controlled by BioNTech AG) shall not be considered an Affiliate of BioNTech. 

1.3 “Alliance Manager” has the meaning set forth in Section 3.5 (Alliance Managers). 

1.4 “Allowable Expenses” has the meaning set forth in Exhibit F. 

1.5 “Applicable Laws” means the applicable provisions of any and all national, supranational, regional, state and
local laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits (including MAAs) of or from any court, arbitrator, Regulatory Authority or Governmental
Authority having jurisdiction over or related to the subject item. 
 1.6 [***] means [***]. 

1.7 “[***] Agreement” means the April 11, 2018, Cross License Agreement by and between Genevant Sciences Ltd. and
[***]. 
 1.8 “Auditor” has the meaning set forth in Section 8.8 (Audit Dispute). 

1.9 “BioNTech Development Milestone Plan” has the meaning set forth in Section 4.2. 

1.10 “BioNTech Field” means the treatment, prevention and diagnosis of illnesses in the field of oncology. 

1.11 “BioNTech Indemnitees” has the meaning set forth in Section 15.1 (Indemnification by Genevant). 

1.12 “BioNTech Joint Inventions” has the meaning set forth in Section 11.1(c) (Joint Patent Committee). 

1.13 “BioNTech Joint Patents” has the meaning set forth in Section 11.1(c) (Joint Patent Committee). 

1.14 “BioNTech Know-How” means all
Know-How that BioNTech Controls as of the Effective Date or during the Term that is necessary or reasonably useful for the Development, Manufacture or Commercialization of: (a) any BioNTech Product in the
BioNTech Field; and/or (b) any Co-Development Product in the Co-Development Field. BioNTech Know-How includes BioNTech Joint
Inventions, BioNTech Sole Inventions and BioNTech’s interest in Co-Owned Joint Inventions. 

  
 2 

 1.15 “BioNTech mRNA Payloads” means the five (5) mRNA payloads
created by BioNTech and the [***] identified in Exhibit A. The Parties agree that Exhibit A will include [***] mRNA payloads at the time of execution of this Agreement. Within twelve (12) months from execution of this Agreement, BioNTech may
propose [***] additional mRNA payloads to be included in the BioNTech mRNA Payloads and [***] the proposal made by BioNTech, [***]. Upon written agreement by the Parties to such final mRNA payload, Exhibit A will be updated to include such mRNA
payload. 
 1.16 “BioNTech Patents” means all Patents that BioNTech Controls as of the Effective Date or during the
Term that are necessary or reasonably useful for the Development, Manufacture or Commercialization of: (a) any BioNTech Product in the BioNTech Field; and/or (b) any Co-Development Product in the Co-Development Field. BioNTech Patents includes BioNTech Joint Patents BioNTech’s interest in Co-Owned Joint Patents. A list of BioNTech Patents existing as of the
Effective Date is attached as Exhibit H. While the Parties intend Exhibit H to be exhaustive, the failure to list a Patent on Exhibit H will not exclude it from the definition of BioNTech Patents if it otherwise meets the definition provided herein.

 1.17 “BioNTech Product” means any pharmaceutical product that contains a BioNTech mRNA Payload encapsulated
within a LNP (irrespective of whether such LNP is Contolled by Genevant or BioNTech). 
 1.18 “BioNTech Product
Infringement” has the meaning set forth in Section 11.4(a) (Notice). 
 1.19 “BioNTech Product Manufacturing Know-How” means Genevant Know-How that is necessary or reasonably useful to Manufacture any BioNTech Product in the BioNTech Field. 

1.20 “BioNTech Product Pharmacovigilance Agreement” has the meaning set forth in Section 5.4 (Pharmacovigilance).

 1.21 “BioNTech Product Supply Agreement” has the meaning set forth in Section 6.1 (Manufacture of BioNTech
Products). 
 1.22 “BioNTech Products Collaboration Plan” has the meaning set forth in Section 4.4 (Conduct of
Development Activities by Genevant). 
 1.23 “BioNTech Sole Inventions” means any Inventions made solely by
BioNTech’s or its Affiliates’ employees, agents or independent contractors. 
 1.24 “BioNTech Technology”
means the BioNTech Know-How and the BioNTech Patents. 
 1.25 “Blocker
Entity” has the meaning set forth in Section 16.5(b) (Taxes of Co-Entrepreneurship). 

1.26 “Board of Directors” has the meaning set forth in Section 1.49(a) (Competitor Change of Control). 

  
 3 

 1.27 “Business Day” means a day other than a Saturday, Sunday or a
bank or other public holiday in Mainz, Basel or New York. 
 1.28 “Calendar Quarter” means each respective period of
three (3) consecutive months ending on March 31, June 30, September 30, and December 31. 
 1.29
“Calendar Year” means each respective period of twelve (12) consecutive months ending on December 31. 
 1.30
“CFR” means the U.S. Code of Federal Regulations. 
 1.31 “Claims” means all Third Party demands,
claims, actions, proceedings and liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, legal costs and other expenses of any nature. 

1.32 “CMC” means chemistry, Manufacturing, and controls. 

1.33 “CMO” means contract Manufacturing organization. 

1.34 “Code” has the meaning set forth in Section 3.3 (JSC Decision-Making). 

1.35 “Co-Development Field” means the treatment, prevention and diagnosis of
liver diseases (as defined by the FDA and/or the EMA), excluding any oncology diseases. 
 1.36 “Co-Development Joint Inventions” has the meaning set forth in Section 11.1(c) (Joint Patent Committee). 

1.37 “Co-Development Joint Patents” has the meaning set forth in
Section 11.1(c) (Joint Patent Committee). 
 1.38 “Co-Development mRNA
Payloads” means the six (6) mRNA payloads to be created by BioNTech in the Co-Development Field and the [***] identified in Exhibit B of which five (5) will be selected for Development as
part of Co-Development Products. 
 1.39
Co-Development Product” means any pharmaceutical product that contains a Co-Development mRNA Payload encapsulated within a Genevant LNP and/or, if agreed
between the Parties in the JSC, within another LNP. 
 1.40 “Co-Development Product
Development Plan” has the meaning set forth in Section 9.2. 
 1.41
“Co-Development Product Commercialization Plan” has the meaning set forth in Section 10.2 (Commercialization Plan and Report). 

1.42 “Co-Development Product Infringement” has the meaning set forth in
Section 11.4(a) (Notice). 
 1.43 “Co-Development Product Pharmacovigilance
Agreement” has the meaning set forth in Section 9.10 (Co-Development Product Pharmacovigilance). 

  
 4 

 1.44 “Co-Development Product Supply
Agreement” has the meaning set forth in Section 9.11 (Manufacturing Responsibilities). 
 1.45 “Combination
Product” means any product containing (i) at least one Product and (ii) at least one additional active ingredient that is not a Product. 

1.46 “Commercialization” means the conduct of all activities undertaken before and after Regulatory Approval relating
to the promotion, marketing, sale and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling and delivering products to customers) of products, including: (a) sales force efforts,
detailing, advertising, medical education, planning, marketing, sales force training, and sales and distribution; and (b) scientific and medical affairs. For clarity, Commercialization does not include any Development activities, whether
conducted before or after Regulatory Approval. “Commercialize” and “Commercializing” have correlative meanings. 

1.47 “Commercially Reasonable Efforts” means, with respect to an entity’s obligations under this Agreement
relating to BioNTech Products or Co-Development Products, those efforts and resources that are consistent with the exercise of customary scientific and business practices as applied in the pharmaceutical
industry for a company of a similar stage and size as the entity and having similar resources (viewed in relation to such Party and all of its Affiliates plus, in the case of Genevant, [***] (applying that term to [***] mutatis mutandis as with
respect to Genevant)) for Development, regulatory, Manufacturing and Commercialization activities conducted with respect to products at a similar stage of Development or Commercialization and having similar commercial potential, taking into account
relative safety and efficacy, product profile, the regulatory environment, payors’ policies and regulations, competitiveness of the marketplace and the market potential of such products, the nature and extent of market exclusivity, including
patent coverage and regulatory data protection, price and reimbursement status, and all other relevant commercial, technical, legal, scientific, regulatory, or medical factors. 

1.48 “Competitor” means any of the competitive entities identified and separately agreed to in writing by the Parties
or their Affiliates (applying that term mutatis mutandis to such entity). 
 1.49 “Competitor Change of Control”
shall be deemed to have occurred if any of the following occurs after the Effective Date: 
 (a) any Competitor (i) becomes the
beneficial owner, directly or indirectly, of shares of capital stock or other interests (including partnership interests) of such Party then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the
election of the directors, managers or similar supervisory positions (“Voting Stock”) of such Party representing more than fifty percent (50%) of the total voting power of all outstanding classes of Voting Stock of such Party or
(ii) has the power, directly or indirectly, to appoint a majority of the Party’s managing directors or to elect a majority of the members of the Party’s board of directors, supervisory board or similar governing body (“Board
of Directors”); or 
 (b) such Party enters into a merger, consolidation or similar transaction with a Competitor (whether or not
such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction (i) the managing directors or the members of the Board of Directors of such Party immediately prior to such transaction constitute less
than a majority of the 

  
 5 

 
managing directors or the members of the Board of Directors of such Party or such surviving Person immediately following such transaction or (ii) the Persons that beneficially owned,
directly or indirectly, the shares of Voting Stock of such Party immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of such Party representing a majority of the total voting power of all
outstanding classes of Voting Stock of the surviving Person in substantially the same proportions as their ownership of Voting Stock of such Party immediately prior to such transaction; or 

(c) such Party sells or transfers to a Competitor, in one or more related transactions, properties or assets representing all or substantially
all of such Party’s consolidated total assets to which this Agreement relates. 
 Notwithstanding the foregoing, the occurrence of
neither of the following shall, by itself, be considered a Change in Control, the sale of capital stock of a Party in an initial public offering on an internationally recognized securities exchange, including the NYSE, NASDAQ, London Stock Exchange,
Frankfurt Stock Exchange, and Hong Kong Stock Exchange shall not constitute a Competitor Change of Control if entered into in the ordinary course of business and not for the purpose or effect of circumventing any other Party’s rights hereunder.

 1.50 “Confidential Information” of a Party means all Know-How,
unpublished patent applications and other information and data of a financial, commercial, business, operational or technical nature of such Party that is disclosed or made available by or on behalf of such Party or any of its Affiliates to the
other Party or any of its Affiliates, whether made available orally, in writing or in electronic or other form. The terms of this Agreement are the Confidential Information of both Parties. All Inventions made under this Agreement will constitute
the Confidential Information of the party that owns such Inventions as set forth in Section 11.1 (Ownership). All other data and results generated under this Agreement in relation to BioNTech Products shall constitute Confidential Information
of BioNTech, and all other data and results generated under this Agreement in relation to Co-Development Products shall constitute Confidential Information of both Parties. 

1.51 “Control” or “Controlled” means, with respect to any
Know-How, Patent or other intellectual property rights, that a Party has the legal authority or right (whether by ownership, license or otherwise, other than by virtue of any license granted to such Party by
the other Party pursuant to this Agreement) to grant a license, sublicense, access or other right (as applicable) under such Know-How, Patent, or other intellectual property rights to the other Party on the
terms and conditions set forth herein, in each case without breaching the terms of any agreement with a Third Party. 
 1.52
“Develop” or “Development” means to develop (including clinical, non-clinical and CMC development), analyze, test and conduct preclinical, clinical and all other regulatory
trials for a product, including all post-approval clinical trials, as well as all related regulatory activities and any and all activities pertaining to new indications, pharmacokinetic studies and all related activities including work on new
formulations, new methods of treatment, and CMC activities including new Manufacturing methods. “Developing” and “Development” have correlative meanings. 

  
 6 

  

 1.53 “Development Costs” means FTE Costs and Out-of-Pocket Costs incurred by the Parties and their Affiliates in Developing the Co-Development Products in the Co-Development Field, in each case to the extent incurred in accordance with this Agreement and the budget approved by the JSC as follows: 

(a) all Out-of-Pocket Costs and FTE Costs incurred for
activities specified in the Co-Development Product Development Plan including the FTE Costs of scientific, medical, technical and other personnel directly engaged in performing Development activities under the
Co-Development Product Development Plan, which costs shall be determined based on time actually spent performing the applicable activities, unless another basis is otherwise agreed in advance by the Parties in
writing; 
 (b) all Out-of-Pocket Costs and FTE Costs in
connection with any Manufacturing activities for pre-clinical or clinical supplies as set forth in the Co-Development Product Development Plan, including (i) the
Manufacturing Expenses for the Co-Development mRNA Payloads, Genevant LNPs, and Co-Development Products; (ii) costs and expenses incurred to purchase or package
Third Party comparator or Third Party combination drugs or devices; and (iii) costs and expenses of disposal of clinical samples; 

(c) all Out-of-Pocket Costs and FTE Costs incurred in
connection with Regulatory Filings with respect to Co-Development Products in the Co-Development Field; 

(d) all Out-of-Pocket Costs and FTE Costs associated with
[***] commitments mandated by Governmental Authorities, to the extent incurred with respect to Co-Development Products; 

(e) all Out-of-Pocket Costs and FTE Costs identifiable to
establishing, updating and maintaining a global safety database for Co-Development Products; 
 (f)
all Out-of-Pocket Costs and FTE Costs associated with companion and in vitro diagnostics, if applicable to the Development of a
Co-Development Product; and 
 (g) any other Out-of-Pocket Costs and FTE Costs incurred that are explicitly included in the budget under the Co-Development Product Development Plan approved by the JSC. 

Development Costs shall exclude all Allowable Expenses, capital expenditures not previously agreed to by the Parties as part of the Co-Development Product Development Plan, and any other cost not included in Development Costs, including by way of example, costs attributable to general corporate activities, executive management, investor
relations, treasury services, business development, corporate government relations, external financial reporting and other overhead unless otherwise agreed to in writing by the Parties. For the avoidance of doubt, Development Costs do not include Out-of-Pocket Costs, FTE Costs, or other amounts that are attributable and allocable to post-approval commercialization studies other than as specified in (d) above. 

1.54 “Development Reconciliation Procedures” has the meaning set forth in Section 9.12(b) (Development Costs
Reports). 
 1.55 “Direct Expenses” means, with respect to Co-Development
mRNA Payload, Genevant LNP, BioNTech Products or Co-Development Products, those material and services expenses captured in invoices and the like which are specifically attributable to Manufacture of the Co-Development mRNA Payload, Genevant LNP, BioNTech Product or Co-Development Product, including expenses of raw materials, Manufacturing supplies, solvents, containers,
container components, packaging, labels and other printed materials used in production. 

  
 7 

 1.56 “Disclosing Party” has the meaning set forth in
Section 12.1(a) (Duty of Confidence - subsection (a)). 
 1.57 “Dollar” means U.S. dollars, and “$”
shall be interpreted accordingly. 
 1.58 “EMA” means the European Medicines Agency or any successor entity thereto.

 1.59 “Excluded Claim” has the meaning set forth in Section 16.10(f) (Dispute Resolution - subsection (f)).

 1.60 “Executive Officers” has the meaning set forth in Section 3.3 (JSC Decision-Making). 

1.61 “FDA” means the United States Food and Drug Administration or any successor entity thereto. 

1.62 “First Commercial Sale” means, (a) with respect to any BioNTech Product in any country or jurisdiction in
the Territory, the first arm’s length sale of such BioNTech Product by BioNTech, its Affiliates or Sublicensees to a Third Party for distribution, use or consumption in such country or jurisdiction after Regulatory Approval has been obtained
for such BioNTech Product in such country or jurisdiction; and (b) with respect to any Co-Development Product in any country or jurisdiction in the Territory, the first arm’s length sale of such Co-Development Product by a Party, its Affiliates or Sublicensees to a Third Party for distribution, use or consumption in such country or jurisdiction after Regulatory Approval has been obtained for such Co-Development Product in such country or jurisdiction. 
 1.63 “FTE” means a full
day of work by one employee recorded in the conduct of the specified activities. 
 1.64 “FTE Costs” means the
product of: (a) that number of FTEs (proportionately, on a per-FTE basis) used by a Party or its Affiliates in directly performing activities assigned to such Party under and in accordance with the Co-Development Product Development Plan or the BioNTech Products Collaboration Plan, multiplied by (b) the applicable FTE Rate. 

1.65 “FTE Rate” means [***]. 

1.66 “Genevant Indemnitees” has the meaning set forth in Section 15.2 (Indemnification by BioNTech). 

1.67 “Genevant Joint Inventions” has the meaning set forth in Section 11.1(c) (Joint Patent Committee).

 1.68 “Genevant Joint Patents” has the meaning set forth in Section 11.1(c) (Joint Patent Committee). 

1.69 “Genevant Know-How” means all
Know-How that Genevant Controls as of the Effective Date or during the Term that is necessary or reasonably useful for the Development, 

  
 8 

 
Manufacture or Commercialization of: (a) any BioNTech Product in the BioNTech Field; or (b) any Co-Development Product in the Co-Development Field. Genevant Know-How includes Genevant Sole Inventions, Genevant Joint Inventions, and Genevant’s interest in
Co-Owned Joint Inventions. 
 1.70 “Genevant LNP” means the LNP delivery
platform Controlled by Genevant. The Parties will identify during Development of the BioNTech Products and/or Co-Development Products which part(s) of the Genevant LNP will be used in the BioNTech Products
and/or Co-Development Products in accordance with the terms of this Agreement. 
 1.71
“Genevant Patents” means all Patents in the Territory that Genevant Controls as of the Effective Date or during the Term that are necessary or reasonably useful for the Development, Manufacture or Commercialization of: (a) any
BioNTech Product in the BioNTech Field; or (b) any Co-Development Product in the Co-Development Field. Genevant Patents include Genevant Joint Patents, and
Genevant’s interest in Co-Owned Joint Patents. A list of Genevant Patents existing as of the Effective Date is attached as Exhibit G. While the Parties intend Exhibit G to be exhaustive, the failure to
list a Patent on Exhibit G will not exclude it from the definition of Genevant Patents if it otherwise meets the definition provided herein. 

1.72 “Genevant Sole Inventions” means any Inventions made solely by Genevant’s or its Affiliates’ employees,
agents or independent contractors. 
 1.73 “Genevant Technology” means the Genevant
Know-How and Genevant Patents. 
 1.74 “Government Authority” means any
federal, state, national, state, provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative,
police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body). 

1.75 “Incremental Withholding Taxes” has the meaning set forth in Section 16.5(b) (Tax Cooperation). 

1.76 “IND” means any investigational new drug application, clinical trial application, clinical trial exemption or
similar or equivalent application or submission for approval to conduct human clinical investigation filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 

1.77 “Indemnified Party” has the meaning set forth in Section 15.3 (Indemnification Procedure). 

1.78 “Indemnifying Party” has the meaning set forth in Section 15.3 (Indemnification Procedure). 

1.79 “Indirect Expenses” means, with respect to either a BioNTech Product or
Co-Development Product, labor expenses, including allocated FTE expenses for personnel directly involved in the Manufacturing the Co-Development mRNA Payload, Genevant
LNP, BioNTech Products or Co-Development Products in accordance with GMP requirements such as production, quality control, quality assurance, microbiology, and other similar departments as needed and to the
extent such personnel participate directly in the production of the Co-Development mRNA 

  
 9 

 
Payload, Genevant LNP, BioNTech Product or Co-Development Product and components thereof, and other indirect production expenses such as a reasonable
allocation of expenses associated with a either Party’s Manufacturing of Co-Development mRNA Payload, Genevant LNP, BioNTech Product or Co-Development Product,
including facility costs and personnel costs directly supporting the Manufacturing of the Co-Development mRNA Payload, Genevant LNP, BioNTech Product or Co-Development
Product in accordance with GMP requirements, including labor for and indirect expenses of quality control, quality assurance, raw material acquisition and acceptance, microbiology, document control, calibration/validation, and expenses for process
development and analytical methods development, but excluding, in each case, any Direct Expenses. 
 1.80
“Initiation” means, with respect to a clinical trial, the first dosing (whether with investigational drug, comparator drug or placebo) of the third subject in such clinical trial. 

1.81 “Initial BioNTech Product Manufacturing Know-How” has the meaning set
forth in Section 6.3(a) (BioNTech Product Initial Manufacturing Know-How). 
 1.82
“Invention” shall mean any process, method, composition of matter, article of Manufacture, discovery or finding, patentable or otherwise, that is made, generated, conceived or otherwise invented as a result of a Party exercising its
rights or carrying out its obligations under this Agreement, whether directly or via its Affiliates, agents or independent contractors, including all rights, title and interest in and to the intellectual property rights therein. 

1.83 “Joint Inventions” means any Inventions that are made jointly by one or more employees, agents or independent
contractors of one Party or its Affiliates and one or more employees, agents or independent contractors of the other Party or its Affiliates. 

1.84 “Joint Patent Committee” or “JPC” has the meaning set forth in Section 11.1(c) (Joint
Patent Committee). 
 1.85 “Joint Steering Committee” or “JSC” has the meaning set forth in
Section 3.1 (Joint Steering Committee). 
 1.86 “Know-How” means any
information, including discoveries, improvements, modifications, processes, methods, techniques, protocols, formulas, data, inventions, know-how, trade secrets and results, patentable or otherwise, including
physical, chemical, biological, toxicological, pharmacological, safety, and pre-clinical and clinical data, dosage regimens, control assays, and product specifications, but excluding any Patents. 

1.87 “Lead Commercialization Party” has the meaning set forth in Section 10.1. 

1.88 “LNP” means lipid nanoparticle. 

1.89 “Manufacture” or “Manufacturing” means performing all steps of the manufacturing of any BioNTech
mRNA Payload, Co-Development mRNA Payload, Genevant LNP, BioNTech Products or Co-Development Products, including: (a) acquisition, testing and release of raw
materials, excipients or active pharmaceutical ingredients and stability testing; (b) manufacturing and filling; (c) in-process quality control testing; (d) labeling and packaging;
(e) final quality release; and (f) storage prior to shipping and the related controls. 

  
 10 

 1.90 “Manufacturing Transfer” has the meaning set forth in
Section 6.4 (Manufacturing Transfer). 
 1.91 “MAA” or “Marketing Authorization Application”
means an application to the appropriate Regulatory Authority for approval to market a product (but excluding Pricing Approval) in any particular jurisdiction and all amendments and supplements thereto, including an NDA filed with the FDA in the U.S.

 1.92 “Manufacturing Expenses” means (a) with respect to a
Co-Development mRNA Payload, BioNTech Product or a Co-Development Product that is Manufactured by a Third Party [***] paid by either Party or its Affiliate to such Third
Party for such Co-Development mRNA Payload, Genevant LNP, BioNTech Product or Co-Development Product, and (b) with respect to a
Co-Development mRNA Payload, Genevant LNP, BioNTech Product or Co-Development Product that is Manufactured directly by either Party or its Affiliate the Direct Expenses
and Indirect Expenses incurred in connection with the Manufacture of the BioNTech Product or Co-Development Product [***]. Manufacturing Expenses shall not include any: (x) Manufacturing variances due to
idle plant capacity, (y) expenses allocable to other products, or (z) any profit related to intercompany transfer pricing. 

1.93 “mRNA Payload” means one or more mRNA constructs, each for the expression of a Protein of Interest, which are
contained in a BioNTech Product or in a Co-Development Product. 
 1.94
“NDA” means a New Drug Application (as more fully defined in 21 C.F.R. § 314.5 et seq. or successor regulation) and all amendments and supplements thereto filed with the FDA. 

1.95 “Net Sales” means, with respect to any Product, the gross amounts invoiced for sales or other dispositions of
such product by or on behalf of a Party, its Affiliates and Sublicensees to Third Parties, less the following deductions to the extent included in the gross invoiced sales price for such Product or otherwise paid or incurred by the Party or its
Affiliates or Sublicensees, as applicable, with respect to the sale or other disposition of such Product: 
 (a) normal and customary trade
and quantity discounts, allowances, and credits actually allowed and properly taken with respect to sales of such Product; 
 (b) credits or
allowances given or made for rejection or return of previously sold Products or for retroactive price reductions and billing errors; 
 (c)
discounts, rebates, reimbursements, and chargeback payments granted to managed health care organizations or other health care institutions (including hospitals), health care administrators, patient assistance or similar programs, pharmacy benefit
managers (or equivalents thereof), wholesalers and other distributors, pharmacies and other retailers, group purchasing organizations or other buying groups, health maintenance organizations, national, state/provincial, local, and other governments,
their agencies and purchasers and reimbursors (including Medicaid, Medicare and similar federal and state programs and other government programs), any other providers of health insurance coverage, or to trade customers related to such Product; 

  
 11 

 (d) costs of freight, insurance, and other transportation charges related to the
distribution of such Product (excluding any Taxes imposed on or with respect to net income, however denominated); 
 (e) import taxes,
export taxes, excise taxes sales taxes, VAT, consumption taxes, duties or other taxes levied on or measured by the billing amount with respect to sales of such Product (for avoidance of doubt, excluding any Taxes imposed on or with respect to net
income, however denominated); 
 (f) the portion of administrative fees paid during the relevant time period to group purchasing
organizations or pharmaceutical benefit managers relating to such Product; and 
 (g) that portion of the annual fee on prescription drug
Manufacturers imposed by the Patient Protection and Affordable Care Act, Pub. L. No. 111-148 (as amended) or any similar Applicable Law in any other jurisdiction that [***] allocates to sales of such
Product. 
 Such amounts shall be determined in accordance with the applicable Accounting Standards. Even if there is overlap between any of
the deductions described above, each individual item shall only be deducted once in the overall Net Sales calculation. To the extent that a Party, its Affiliates or Sublicensees receives any consideration other than monies for the sales of any
products, Net Sales shall include the fair market value of such consideration. 
 In the event that the Product is sold as a Combination
Product, Net Sales will be determined by multiplying Net Sales of such Combination Product by the fraction A/(A+B), where A is the invoice price of the Product, when sold separately, and B is the invoice price of any other active ingredient(s) in
the combination, when sold separately, in each case in the same country and similar class, purity and dosage as in the Combination Product. If, on a country-by-country
basis, the Product or the other active ingredient(s) in the Combination Product is/are not sold separately in such country, Net Sales shall be determined by multiplying actual Net Sales of such Combination Product by the fraction C/(C+D), where C is
the fair market value of the Product portion of such combination and D is the fair market value of the other active ingredient(s) (such fair market value is to be determined by mutual agreement of the Parties or, in the absence of such mutual
agreement, by a neutral Third Party). 
 1.96 “On-Going Clinical Study” has
the meaning set forth in Section 13.6(b)(iv) (Effect of Termination - subsection (iv)). 
 1.97 “Opt-Out” has the meaning set forth in Section 13.6(a) (Opt-out). 

1.98 “Opt-Out Party” has the meaning set forth in Section 13.6(a) (Opt-out). 
 1.99
“Out-of-Pocket Costs” means amounts paid to Third Party vendors or contractors, for services or materials provided by them directly in the performance
of activities under the Co-Development Product Development Plan or BioNTech Products Collaboration Plan to the extent such services or materials apply directly to the Development of any Co-Development Product or BioNTech Product (or such amounts paid to Third Parties for other activities not included in determination of Development Costs or Allowable Expenses, but for which sharing of Out-of-Pocket Costs is otherwise specified in this agreement). For clarity, Out-of-Pocket Costs
do not include payments for internal: salaries or benefits; facilities; utilities; general office or facility supplies; insurance; information technology, capital expenditures or the like unless such expenses were
pre-approved in writing by the Parties or agreed in the Co-Development Product Development Plan. 

  
 12 

 1.100 “Patent” means all patents and patent applications, including
all provisionals, substitutions, divisionals, reissues, reexaminations, renewals, continuations, continuations-in-part, substitute applications, priority applications
and inventors’ certificates, extensions and supplemental certificates and any and all foreign equivalents of the foregoing. 

1.101 “Person” means any individual, partnership, limited liability company, firm, corporation, association, trust,
unincorporated organization or other entity. 
 1.102 “Phase 1 Clinical Trial” means a human clinical trial that
would satisfy the requirements of 21 C.F.R. § 312.21(a) or any amended or successor regulations) or any equivalent regulations in other countries in the Territory, regardless of where such clinical trial is conducted. 

1.103 “Phase 2 Clinical Trial” means a human clinical trial that would satisfy the requirements for
a Phase 2 study as defined in 21 CFR § 312.21(b) (or any amended or successor regulations) or any equivalent regulations in other countries in the Territory, regardless of where such clinical trial is conducted. 

1.104 “Phase 3 Clinical Trial” means a human clinical trial that would satisfy the requirements for
a Phase 3 study as defined in 21 CFR § 312.21(c) (or any amended or successor regulations) or any equivalent regulations in other countries in the Territory, regardless of where such clinical trial is conducted. 

1.105 “PMDA” means Japan’s Pharmaceuticals and Medical Devices Agency or any successor entity thereto. 

1.106 “Pricing Approval” means such governmental approval, agreement, determination or decision establishing prices
for a BioNTech Product that can be charged and/or reimbursed in a regulatory jurisdiction where the applicable Governmental Authorities approve or determine the price and/or reimbursement of pharmaceutical products and where such approval or
determination is necessary for the commercial sale of such BioNTech Product in such jurisdiction. 
 1.107 “Product”
shall mean any BioNTech Product and/or any Co-Development Product, as applicable. 
 1.108
”Protein of Interest” means a protein as identified by a describing name and its amino acid sequence. For the avoidance of doubt, the term “Protein of Interest” comprises [***] protein, including but not limited to
[***] (for example: [***] of the Protein of Interest [***]), provided however that [***] possesses [***] the protein as identified by a describing name and its amino acid sequence. If the Protein of Interest is an antibody or another molecule
comprised of separated amino acid chains which might be delivered as separate mRNA constructs, such protein will be a single Protein of Interest for the purposes of this definition. 

1.109 “Receiving Party” has the meaning set forth in Section 12.1(a) (Duty of Confidence - subsection (a)). 

  
 13 

 1.110 “Regulatory Approval” means all approvals, including Pricing
Approvals and MAAs, that are necessary for the commercial sale of a product in a given country or regulatory jurisdiction. 
 1.111
“Regulatory Authority” means any applicable Government Authority responsible for granting Regulatory Approvals for products, including the FDA, the EMA, the PMDA, and any corresponding national or regional regulatory authorities.

 1.112 “Regulatory Exclusivity” means any exclusive marketing rights or data exclusivity rights conferred by any
Regulatory Authority with respect to a pharmaceutical product other than Patents, including orphan drug exclusivity, new chemical entity exclusivity, data exclusivity, or pediatric exclusivity. 

1.113 “Regulatory Filings” means, with respect to a BioNTech Product or
Co-Development Product, any submission to a Regulatory Authority of any appropriate regulatory application specific to BioNTech Product or Co-Development Product, and
shall include any submission to a regulatory advisory board and any supplement or amendment thereto. For the avoidance of doubt, Regulatory Filings shall include any IND, NDA, MAA or the corresponding application in any other country or
jurisdiction.  
 1.114 “Remedial Action” means any recall, corrective action or other regulatory action with
respect to BioNTech Product or Co-Development Product taken by virtue of Applicable Laws. 

1.115 “Royalty Term” has the meaning set forth in Section 8.3(b) (Royalty Term). 

1.116 “SEC” has the meaning set forth in Section 12.6(a) (Publicity/Use of Names - subsection (a)). 

1.117 “Sole Inventions” means any Inventions made solely by a Party’s or its Affiliates’ employees, agents
or independent contractors. 
 1.118 “Sublicense” means: (a) a license or sublicense to Develop, make, have
made, use, distribute, sell, offer for sale, have sold, import, export or otherwise Commercialize any BioNTech Product and (b) a license or sublicense to Develop, make, use, distribute, sell, offer for sale, have sold, import, export or
otherwise Commercialize any Co-Development Product. 
 1.119 “Sublicensee”
means a Third Party to whom BioNTech and/or Genevant has granted a Sublicense in accordance with the terms of this Agreement. 

1.120 “Tax” or “Taxes” means any (a) federal, provincial, territorial, state, municipal, local,
foreign or other taxes and other charges in the nature of a tax, including all income, excise, franchise, gains, capital, real property, goods and services, transfer, value added, gross receipts, windfall profits, severance, ad valorem, personal
property, production, sales, use, license, stamp, documentary stamp, estimated or withholding taxes, and all customs and import duties; (b) any liability for the payment of any amounts of the type described in clause (a) as a result of
being or having been a member of an affiliated, consolidated, combined or unitary group; and (c) any liability for the payment of any amounts as a result of being party to any tax sharing agreement or arrangement or as a result of any express
or implied obligation to indemnify any other person with respect to the payment of any amounts of the type described in clause (a) or (b). 

  
 14 

 1.121 “Tax Payment” has the meaning set forth in
Section 16.5(b) (Tax Cooperation). 
 1.122 “Term” has the meaning set forth in Section 13.1 (Term). 

1.123 “Territory” means worldwide. 

1.124 “Third Party” means any Person other than a Party or an Affiliate of a Party. 

1.125 “Third Party Products Liability Action” has the meaning set forth in Section 15.6(a) (Conduct of Product
Liability Claims - subsection (a)). 
 1.126 “Transfer Plan” has the meaning set forth in Section 2.4
(Initial Transfer of Know-How and Materials). 
 1.127 “Transfer Taxes” has
the meaning set forth in Section 16.5(e) (Value Added Tax). 
 1.128 “United States” or “U.S.”
means the United States of America including its territories and possessions. 
 1.129 “Valid Claim” means
(a) a claim of an issued and unexpired Patent that has not been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction that is not appealable or has not been
appealed within the time allowed for appeal, and that has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise, or
(b) a claim of a Patent application pending for no more than seven (7) years that has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken. 

1.130 “VAT” has the meaning set forth in Section 16.5(e) (Value Added Tax). 

1.131 “Voting Stock” has the meaning set forth in Section 1.49(a) (Competitor Change of Control - subsection
(a)). 
 1.132 “Withholding Taxes” has the meaning set forth in Section 16.5(b) (Tax Cooperation). 

1.133 Interpretation. In this Agreement, unless otherwise specified: 

(a) “includes” and “including” shall mean, respectively, includes without limitation and including without limitation;

 (b) words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders; 

(c) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the
particular provision in which such words appear; and 
 (d) the Exhibits and other attachments form part of the operative provision of this
Agreement and references to this Agreement shall include references to the Exhibits and attachments. 

  
 15 

 ARTICLE 2 

LICENSES 
 2.1 License
for BioNTech Products. 
 (a) License Grant. Subject to the terms and conditions of this Agreement, Genevant hereby grants to
BioNTech an exclusive (even as to Genevant, except as expressly set forth herein), royalty-bearing license (or, where applicable, sublicense), with the right to grant sublicenses in accordance with Section 2.1(b) (Sublicense Rights), under the
Genevant Technology to research, Develop, make, have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise Commercialize BioNTech Products solely in the BioNTech Field in the Territory. For the avoidance of doubt, the
above license to make and have made BioNTech Products shall only apply to the extent BioNTech is permitted to conclude a Manufacturing Transfer pursuant to Section 6.4 (Manufacturing Transfer). 

(b) Sublicense Rights. Subject to the terms of this Section 2.1(b) (Sublicense Rights), BioNTech may grant a sublicense of the
licenses granted in Section 2.1(a) (License Grant) to an Affiliate of BioNTech [***] without the prior written authorization of Genevant. BioNTech will provide Genevant with a copy of each fully executed Third Party sublicense agreement
promptly upon execution. To the extent reasonably necessary, BioNTech may redact financial and other sensitive terms to the extent not necessary to confirm BioNTech’s compliance with the terms of this Agreement. Each authorized sublicense, and
each Sublicensee’s rights, shall be in compliance with the following terms and conditions of this Agreement: Article 1 (Definitions), Article 2 (Licenses) (except Sections 2.2 (License for Co-Development
Products) and 2.4 (Initial Transfer of Know-How and Materials)), Articles 4-8, Article 11 (Intellectual Property Rights) (except Section 11.4(c)), Article 12
(Confidentiality; Publication), Article 13 (Term and Termination); (except Sections 13.4 (Effect of Termination by BioNTech), 13.5(b)(ii) (Effect of Termination by Genevant - subsection (b)(ii)), 
13.5(b)(iii) (Effect of Termination by Genevant -
subsection (b)(iii)), 13.5(d) (Effect of Termination by Genevant - subsection (d)), and 13.6 (Opt-Out in Relation to Co-Development Product Development)), Article 15
Indemnification; Liability) (except Section 15.6 (Conduct of Product Liability Claims)), and Article 16 (General Provisions). . BioNTech shall cause each Sublicensee to comply with the following terms and conditions of this Agreement as if such
Sublicensee were a Party to this Agreement: Article 1 (Definitions), Article 2 (Licenses) (except Sections 2.2 (License for Co-Development Products) and 2.4 (Initial Transfer of
Know-How and Materials)), Articles 4-8, Article 11 (Intellectual Property Rights) (except Section 11.4(c)), Article 12 (Confidentiality; Publication), Article 13
(Term and Termination); (except Sections 13.4 (Effect of Termination by BioNTech), ), 13.5(b)(ii) (Effect of Termination by Genevant - subsection (b)(ii)), 13.5(b)(iii) (Effect of Termination by Genevant - subsection (b)(iii)), 13.5(d) (Effect
of Termination by Genevant - subsection (d)), and 13.6 (Opt-Out in Relation to Co-Development Product Development)), Article 15 Indemnification; Liability) (except
Section 15.6 (Conduct of Product Liability Claims)), and Article 16 (General Provisions). No such permitted sublicense shall relieve BioNTech of any of its obligations or liabilities hereunder, for which obligations and liabilities BioNTech
shall remain fully responsible and liable. 
 2.2 License for Co-Development Products. 

(a) License Grant to BioNTech. Subject to the terms and conditions of this Agreement, Genevant hereby grants to BioNTech: a co-exclusive license (or, where applicable, sublicense) with Genevant, with the right to grant sublicenses including through multiple tiers in accordance with Section 2.2(c) (Sublicense Rights), under the
Genevant Technology to research, 

  
 16 

 
Develop, make, have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise Commercialize Co-Development Products solely in
the Co-Development Field in the Territory and solely as provided in the Co-Development Product Development Plan and
Co-Development Product Commercialization Plan. For the avoidance of doubt, (i) the above license to distribute, sell, offer for sale, have sold, import, export and otherwise Commercialize Co-Development Products shall only apply to BioNTech to the extent BioNTech is the Lead Commercialization Party for such Co-Development Product in accordance with the terms of
this Agreement; and (ii) the above license to make and have made Co-Development Products shall only apply to BioNTech to the extent the Parties agree in writing to modify Section 9.11 (Manufacturing
Responsibilities) to permit the manufacture of Co-Development Products by BioNTech. 
 (b)
License Grant to Genevant. Subject to the terms and conditions of this Agreement, BioNTech hereby grants to Genevant a co-exclusive license with BioNTech, with the right to grant sublicenses including
through multiple tiers in accordance with Section 2.2(c) (Sublicense Rights), under the BioNTech Technology to research, Develop, make, have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise Commercialize Co-Development Products solely in the Co-Development Field in the Territory and solely as provided in Co-Development Product
Development Plan and Co-Development Product Commercialization Plan. For the avoidance of doubt, the above license to distribute, sell, offer for sale, have sold, import, export and otherwise Commercialize Co-Development Products shall only apply to Genevant to the extent Genevant is the Lead Commercialization Party for such Co-Development Product in accordance with the terms of
this Agreement. 
 (c) Sublicense Rights. 

(i) Subject to the terms of this Section 2.2(c) (Sublicense Rights), each Party may grant a sublicense of the licenses granted in
Sections 2.2(a) (License Grant to BioNTech) and 2.2(b) (License Grant to Genevant) to an Affiliate of the Party without the prior written authorization of the other Party. 

(ii) [***] prior to the anticipated Regulatory Approval for any Co-Development Product in any
country in accordance with the then-current Co-Development Product Development Plan, neither Party may grant a sublicense of the licenses granted in Sections 2.2(a) (License Grant to BioNTech) and 2.2(b)
(License Grant to Genevant) in recognition of the fact that the Parties believe the unique nature of their contributions is necessary for the successful development of Co-Development Products. If any Party is
approached by a Third Party interested in a Sublicense for a Co-Development Product that has not yet received Regulatory Approval in any country or wishes to consider the possibility of offering a Sublicense
for a Co-Development Product that has not yet received Regulatory Approval in any country, that Party will raise such matter with the JSC which will consider it in good faith taking into account the best
interests of the Development of all the Co-Development Products and with the understanding that the Parties’ intention as expressed in this Agreement is not to grant such Sublicenses. 

(iii) [***] prior to the anticipated Regulatory Approval for any Co-Development Product in any
country in accordance with the then-current Co-Development Product Development Plan, the Lead Commercialization Party for such Co-Development Product may grant a
sublicense of the licenses granted in Sections 2.2(a) (License Grant to BioNTech) or 2.2(b) (License Grant to Genevant), as applicable, with respect to that Co-Development Product without the prior
written authorization of the Party only in accordance with the following procedure: 

  
 17 

 
Before granting any such sublicense, the Lead Commercialization Party will notify the other Party and give the other Party the opportunity to negotiate the terms of such a sublicense with the
Party before negotiating with any Third Party. If the Parties cannot reach agreement within [***] on the terms of a sublicense, then the Party may grant such a sublicense to a Third Party, provided that (i) the terms of such sublicense granted
to the Third Party are not more favorable than those offered to the other Party and (ii) prior to executing the sublicense with the Third Party such Party shall notify the other Party of the terms of the sublicense agreed with the Third Party
and [***] with such Third Party [***] If the other Party does not notify the Lead Commercialization Party that [***] upon its receipt of the above notice, the Lead Commercialization Party shall be free to execute the sublicense agreement with the
Third Party at the terms notified to the other Party. 
 (iv) The Party granting any Third Party sublicense hereunder will provide
the other Party with a copy of each fully executed Third Party sublicense agreement promptly upon execution. To the extent reasonably necessary, such Party may redact financial and other sensitive terms to the extent not necessary to confirm such
Party’s compliance with the terms of this Agreement. Each authorized sublicense shall be in compliance with the following terms and conditions of this Agreement Article 1 (Definitions), Article 2 (Licenses) (except Sections 2.1 (Licenses for
BioNTech) and 2.4 (Initial Transfer of Know-How and Materials)); Articles 9-10; Article 11 (Intellectual Property Rights) (except Section 11.4 (Infringement by
Third Parties) ); Article 12 (Confidentiality; Publication); Article 13 (Term and Termination) (except Sections 13.2(a) (Termination by BioNTech), 13.3 (Effect of Termination), 13.4 (Effect of Termination by BioNTech), and 13.5(c) (Effect of
Termination by Genevant - subsection (c)); Article 15 (Indemnification; Liability) (except Section 15.2(d) (Indemnification by BioNTech - subsection (d)) and Article 16 (General Provisions). BioNTech shall cause each Sublicensee to comply with
the following terms and conditions of this Agreement as if such Sublicensee were a Party to this Agreement: Article 1 (Definitions), Article 2 (Licenses) (except Sections 2.1 (Licenses for BioNTech)and 2.4 (Initial Transfer of Know-How and Materials)); Articles 9-10; Article 11 (Intellectual Property Rights) (except Section 11.4 (Infringement by Third Parties) ); Article 12 (Confidentiality;
Publication); Article 13 (Term and Termination) (except Sections 13.2(a) (Termination by BioNTech), 13.3 (Effect of Termination), 13.4 (Effect of Termination by BioNTech), and 13.5(c) (Effect of Termination by Genevant - subsection (c)); Article 15
(Indemnification; Liability) (except Section 15.2(d) (Indemnification by BioNTeech - subsection (d)) and Article 16 (General Provisions). No such permitted sublicense shall relieve such Party of any of its obligations or liabilities hereunder,
for which obligations and liabilities such Party shall remain fully responsible and liable. 
 2.3 Retained Rights. Genevant
retains the right under the Genevant Technology to exercise its rights and perform its obligations under this Agreement. In addition, Genevant retains, and hereby expressly reserves, the exclusive right to practice, and to grant licenses under, the
Genevant Technology (a) for any and all purposes outside the BioNTech Field and Co-Development Field; (b) in the BioNTech Field with any product that is not a BioNTech Product; and (c) in the Co-Development Field with any product that is not a Co-Development Product. BioNTech retains the right under the BioNTech Technology to exercise its rights and perform its
obligations under this Agreement. In addition, BioNTech retains, and hereby expressly reserves, the exclusive right to practice, and to grant licenses under, the BioNTech Technology (a) for any and all purposes outside the Co-Development Field and (b) in the Co-Development Field with any product that is not a Co-Development Product, subject to the
limitations of Section 2.6 (Exclusivity). 

  
 18 

 2.4 Initial Transfer of Know-How and
Materials. As of the Effective Date, the Parties have agreed on a plan for the transfer of Genevant Know-How (including the data therein) and certain tangible materials Controlled by Genevant as of the
Effective Date to BioNTech and the transfer of BioNTech Know-How (including the data therein) and certain tangible materials Controlled by BioNTech as of the Effective Date to Genevant which plan is attached
hereto as Exhibit D (the “Transfer Plan”). The Parties shall commence disclosing and making available to each other their respective Know-How and materials listed in the Transfer Plan
according to the timeline set forth in the Transfer Plan. The Parties shall cooperate with each other in good faith to enable a smooth transfer of their respective Know-How to each other. Upon reasonable
request by a Party, the other Party shall provide reasonable technical assistance of no more than two (2) FTEs working for three (3) months at the FTE Rate, including making appropriate employees available at reasonable times, places and
frequency, and upon reasonable prior notice, for the purpose of assisting the Party to understand and use the other Party’s Know-How in connection with the Party’s Development of BioNTech Products
and/or Co-Development Products. If a Party reasonably requests additional FTEs beyond that provided for in the preceding sentence, the Parties will negotiate for the provision of a reasonable amount of
additional FTEs. Nothing in this Section 2.4 (Initial Transfer of Know-How and Materials) will apply to the transfer of any Genevant Know-How relating to the
Manufacture of BioNTech Products. The transfer of any Genevant Know-How relating to the Manufacture of BioNTech Products is addressed in Article 6 (Manufacturing of BioNTech Products). 

2.5 No Implied Licenses; Negative Covenant. Except as set forth herein, neither Party shall acquire any license or other
intellectual property interest, by implication or otherwise, under any Know-How, Patents, trademarks or other intellectual property rights owned or controlled by the other Party. BioNTech hereby covenants not
to practice, and not to permit or cause any of its Affiliate or any Third Party to practice, any Genevant Technology for any purpose other than as expressly authorized in this Agreement, and Genevant hereby covenants not to practice, and not to
permit or cause any of its Affiliate or any Third Party to practice, any BioNTech Technology for any purpose other than as expressly authorized in this Agreement. Without limiting the generality of the foregoing, (a) BioNTech shall not,
directly or indirectly: (i) practice Genevant Technology to Develop, make, have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise Commercialize any BioNTech Product for use outside the BioNTech Field or any Co-Development Product for use outside the Co-Development Field; or (ii) permit or cause any of its Affiliates or any Third Party to engage in any of the activities
described in the preceding clause (i); and (b) Genevant shall not, directly or indirectly: (i) practice BioNTech Technology to Develop, make, have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise
Commercialize any Co-Development Product for use outside the Co-Development Field; or (ii) permit or cause any of its Affiliates or any Third Party to engage in any
of the activities described in the preceding clause (i). 
 2.6 Exclusivity. During the Term of this Agreement for the
relevant BioNTech Product or any Co-Development Product, BioNTech shall not conduct, itself or through an Affiliate or Third Party, and shall not enable a Third Party to conduct, any clinical Development,
promotion or Commercialization of any product involving the use of LNP with any BioNTech mRNA Payload or any Co-Development mRNA Payload contained in such BioNTech Product or
Co-Development Product other than in collaboration with Genevant pursuant to the terms of this Agreement. 

2.7 [***] Agreement. BioNTech understands and agrees that any sublicenses granted by Genevant hereunder to any Genevant
Technology owned by [***] is subject to the terms of the 

  
 19 

 
[***] Agreement. If the [***] Agreement is terminated, any such sublicenses will convert to a direct license from [***] provided that BioNTech: (a) is not then in breach of this Agreement;
(b) agrees in writing to be bound to [***] as a licensee under the terms and conditions of the [***] Agreement; and (c) agrees in writing that in no event shall [***] assume any obligations or liability, or be under any obligation or
requirement of performance that extends beyond [***] obligations and liabilities, as applicable, under the [***] Agreement. BioNTech further consents to Genevant providing a copy of this Agreement to [***]. 

ARTICLE 3 
 GOVERNANCE

 3.1 Joint Steering Committee. Within thirty (30) days after the Effective Date, the Parties shall establish a
Joint Steering Committee (the “Joint Steering Committee” or the “JSC”), composed of two (2) representatives of each Party, to guide the collaboration of the Parties under this Agreement and to oversee the
exchange of information between the Parties with respect to (a) the Development and Manufacturing of BioNTech Products (only to the extent it involves or affects Development or Manufacturing activities to be performed by Genevant under the
BioNTech Products Collaboration Plan or the Co-Development Product Development Plan) and (b) the Development, Manufacturing and Commercialization of Co-Development
Products. For the avoidance of doubt, all Development or Manufacturing activities for BioNTech Products which do not involve or affect Development or Manufacturing activities to be performed by Genevant under this Agreement as well as all
Commercialization activities relating to BioNTech Products shall not be subject to guidance or oversight by the JSC pursuant to this Section 3.1. Each JSC representative shall have appropriate knowledge and expertise and sufficient seniority
within the applicable Party to make decisions arising within the scope of the JSC’s responsibilities. The JSC shall in particular: 

(a) provide a forum for the discussion of and decision making regarding the Development of BioNTech Products (only to the extent it involves
or affects Development or Manufacturing activities to be performed by Genevant under the BioNTech Products Collaboration Plan or the Co-Development Product Development Plan); 

(b) provide a forum for BioNTech to keep Genevant informed regarding the Development of BioNTech Products in the BioNTech Field by BioNTech,
its Affiliates, and Sublicensees, including the status of any Regulatory Filings, Regulatory Approvals, or clinical trials; 
 (c) oversee
the transfer of Genevant Know-How and materials to BioNTech under Section 2.4 (Initial Transfer of Know-How and Materials); 

(d) oversee the transfer of BioNTech Know-How and materials to Genevant under Section 2.4
(Initial Transfer of Know-How and Materials); 
 (e) provide a forum for the discussion of and
decision making regarding the Development, Manufacturing and Commercialization of Co-Development Products by the Parties, their Affiliates, and Sublicensees; 

(f) review and discuss in good faith any updates to any Co-Development Product Development Plan, and
approve any updates to such Co-Development Product Development Plan; 

  
 20 

 (g) to the extent not set forth in any
Co-Development Product Development Plan, allocate responsibility for activities under any Co-Development Product Development Plan; 

(h) create and approve budgets for all activities under any Co-Development Product Development Plan;

 (i) discuss and agree on the Lead Commercialization Party for each Co-Development Product for the
Territory in accordance with Section 10.1 and allocate responsibility for Commercialization of such Co-Development Product in accordance with Section 10.2 (Commercialization Plan and Report); 

(j) to the extent not set forth in the Co-Development Commercialization Plan, allocate responsibility
for activities under the Co-Development Commercialization Development Plan; 
 (k) create and
approve budgets for all activities under the Co-Development Product Commercialization Plan; 
 (l)
create subcommittees to govern activities under the Agreement; 
 (m) discuss any proposed Sublicense that a Party wishes to grant for a Co-Development Product; and 
 (n) discuss and agree which technology developed by BioNTech outside of the
collaboration of this Agreement shall be included in the Co-Development Products. 
 The JSC shall have only such
powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement. The JSC, Executive Officers, Subcommittees, and Alliance Managers shall not have any right, power or authority:
(i) to determine any issue in a manner that would conflict with the express terms and conditions of this Agreement; or (ii) to modify or amend the terms and conditions of this Agreement. In addition, to the extent a Party grants any
Sublicenses in accordance with Section 2.1(b) (Sublicense Rights) or Section 2.2(c) (Sublicense Rights), the Party will be responsible for obtaining from its Sublicensees all information necessary to allow the Party to meet its obligations
to the JSC with respect to the subject matter of the Sublicense. 
 3.2 JSC Membership and Meetings. 

(a) Members. Genevant’s initial JSC representatives will be Peter Lutwyche and James Heyes and BioNTech’s initial JSC
representatives will be Andreas Kuhn and Katalin Kariko. BioNTech shall designate one of its JSC representatives to act as chairperson of the JSC. Each Party may replace its JSC representatives (and, for BioNTech, the chairperson) on written notice
to the other Party, but each Party shall strive to maintain continuity. The JSC members shall jointly prepare an agenda and shall direct the preparation of reasonably detailed minutes for each JSC meeting, which shall be circulated and approved
within thirty (30) days of such meeting. 
 (b) Meetings. The JSC shall hold meetings at such times as it elects to do so, but
in no event, shall such meetings be held less frequently than once per Calendar Quarter. Meetings may be held in person, or by audio or video teleconference; provided, that unless otherwise agreed by both Parties, at least one
(1) meeting per year shall be held in person, and all in-person JSC meetings shall be held at locations mutually agreed upon by the Parties. Each Party shall be responsible for all of its own expenses of
participating in JSC meetings. 

  
 21 

 (c) Non-Member Attendance. Each Party may
from time to time invite a reasonable number of participants, in addition to its representative, to attend JSC meetings in a non-voting capacity; provided, that if either Party intends to have any Third
Party (including any consultant) attend such a meeting, such Party shall provide at least three (3) days prior written notice to the other Party and obtain the other Party’s approval for such Third Party to attend such meeting, which
approval shall not be unreasonably withheld or delayed. Such Party shall ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement. 

3.3 JSC Decision-Making. All decisions of the JSC shall be made by unanimous vote, with each Party’s representatives
collectively having one (1) vote. If after reasonable discussion and good faith consideration of each Party’s view on a particular matter before the JSC, the representatives of the Parties cannot reach an agreement as to such matter within
[***] Business Days after such matter was brought to the JSC for resolution, such disagreement shall be referred to the Chief Executive Officer of BioNTech (or his or her designe e) and the Chief Executive Officer or Executive Chairman of Genevant
(or his or her designee) (collectively, the “Executive Officers”) for resolution, who shall use good faith efforts to resolve such matter within ten (10) Business Days after it is referred to them. If the Executive Officers are
unable to reach consensus on any such matter during such period, then: 
 (a) for any decision [***] BioNTech Products (except for decisions
primarily relating to the Manufacture of BioNTech Products prior to any Manufacturing Transfer); or the Co-Development mRNA Payloads; the Development of any
Co-Development Product for which BioNTech is the Lead Commercialization Party after completion of the first Phase 1 Clinical Trial for such Co-Development Product; or
Commercialization of any Co-Development Product for which BioNTech is the Lead Commercialization Partner, the Chief Executive Officer of BioNTech shall have the right to decide in good faith, provided that
(i) such decision is in compliance with the then-current Co-Development Products Development Plan and does not result in any additional efforts to be provided by Genevant and (ii) the Chief Executive
Officer of Genevant has not demonstrated on reasonable grounds before the expiry of the abovementioned period of [***] Business Days (1) that any such decision could reasonably be expected to have a material negative tax impact on Genevant, any
of its Affiliates, or any of its direct or indirect shareholders including by causing (A) Genevant or any of its Affiliates to be subject to net income taxation in any jurisdiction in which it does not have a taxable presence or nexus
immediately prior to the Effective Date or (B) Genevant, any of its Affiliates, or any of its direct and indirect shareholders to be treated as earning “passive income” for purposes of Section 1297 of the Internal Revenue Code of
1986, as amended (the “Code”) or “subpart F income” for purposes of Section 952 of the Code, in each case, as a result of or in connection with Commercialization activities and (2) that such material negative tax
impact prevails the Parties’ business interest, ignoring such tax impact, in the implementation of the relevant decision; and 
 (b)
for any decision [***] Genevant LNPs; the Manufacture of BioNTech Products prior to any Manufacturing Transfer; the Development of any Co-Development Product for which BioNTech is the Lead Commercialization
Party prior to completion of the first Phase 1 Clinical Trial for such Co-Development Product; or the Development or Commercialization of any Co-Development Product for
which Genevant is the Lead Commercialization Party, the Executive Officer of Genevant shall have the right to decide, provided that (i) such decision is in 

  
 22 

 
compliance with the then-current Co-Development Products Development Plan and does not result in any additional efforts to be provided by BioNTech and
(ii) the Chief Executive Officer of BioNTech has not demonstrated on reasonable grounds before the expiry of the abovementioned period of [***] that (1) any such decision could reasonably be expected to have a material negative tax impact
on BioNTech, any of its Affiliates, or any of its direct or indirect shareholders including by causing (A) BioNTech or any of its Affiliates to be subject to net income taxation in any jurisdiction in which it does not already have a taxable
presence or nexus immediately prior to the Effective Date or (B) Genevant, any of its Affiliates, or any of its direct and indirect shareholders to be treated as earning “passive income” for purposes of the Code or “subpart F
income” for purposes of Section 952 of the Code, in each case, as a result of or in connection with Commercialization activities and (2) that such material negative tax impact prevails the Parties’ business interest, ignoring
such tax impact, in the implementation of the relevant decision; and 
 (c) for all other decisions, no Party shall have any final
decision-making power. Notwithstanding anything to the contrary in (a) and (b) above, for any decision primarily related to the dosing of a Co-Development mRNA Payload or issues with the safety of a Co-Development mRNA Payload, no Party shall have any final decision-making power. 
 3.4
Subcommittees. Within two (2) weeks following the Effective Date, the JSC will form the following subcommittees to govern and monitor their collaboration with respect to Co-Development Products:
(i) a Joint Development Subcommittee, (ii) a Joint Manufacturing Subcommittee, (iii) a Joint Financial Subcommittee as well as any other subcommittee that the Parties deem appropriate. The related membership, meeting frequencies,
responsibilities will be agreed between the Parties prior to forming those subcommittees. Decisions of each subcommittee shall require unanimous consent. Issues that cannot be agreed on subcommittee level shall be escalated to the JSC. 

3.5 Alliance Managers. Promptly after the Effective Date, each Party shall appoint an individual to act as the alliance manager
for such Party (the “Alliance Manager”), which individual may also be a JSC member. Each Alliance Manager shall be responsible for alliance management between the Parties on a day-to-day basis throughout the Term. If not a member of the JSC, each Alliance Manager shall be permitted to attend meetings of the JSC as non-voting participants. The
Alliance Managers shall be the primary contact for the Parties regarding the activities contemplated by this Agreement and shall facilitate all such activities hereunder. Each Party may replace its Alliance Manager with an alternative representative
at any time upon written notice to the other Party. Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager upon written notice to the other Party. Each Alliance Manager shall be charged with
creating and maintaining a collaborative work environment within the JSC and between the Parties. 
 ARTICLE 4 

DEVELOPMENT OF BIONTECH PRODUCTS 

4.1 General. Subject to the terms and conditions of this Agreement, BioNTech shall be solely responsible for the Development of
BioNTech Products in the BioNTech Field in the Territory, including the performance of preclinical and clinical studies of any BioNTech Product in the BioNTech Field. 

4.2 BioNTech Products Development. BioNTech shall use Commercially Reasonable Efforts to conduct all Development of BioNTech
Products in the BioNTech Field in 

  
 23 

 
the Territory in accordance with a general development plan (as amended in accordance with this Agreement, the “BioNTech Development Milestone Plan”), the initial version of
which is set forth in Exhibit E. From time to time, but at least every [***], BioNTech will confirm whether the estimated timelines in the BioNTech Development Milestone Plan are still expected to be met or will update the BioNTech Development
Milestone Plan to reflect any changes. 
 4.3 Conduct of Development Activities by BioNTech. BioNTech shall Develop BioNTech
Products in the Field in the Territory in compliance with all Applicable Laws, including good scientific and clinical practices under the Applicable Laws of the country in which such activities are conducted. 

4.4 Conduct of Development Activities by Genevant. Notwithstanding the above, Genevant will assist BioNTech in the Development
and Manufacture of LNP formulations for use in BioNTech Products in accordance with a development plan to be agreed between the Parties (the “BioNTech Products Collaboration Plan”), the initial version of which is set forth in
Exhibit I. Within the framework of the BioNTech Products Collaboration Plan, Genevant will also assist in the identification of the final LNP to be used with each BioNTech Product to create BioNTech Products. As set forth in Article 6 (Manufacturing
of BioNTech Products), Genevant will also be responsible for Manufacture of the BioNTech Products. All activities of Genevant under this Section 4.4 shall be made in compliance with all Applicable Laws, including good scientific and clinical
practices under the Applicable Laws of the country in which such activities are conducted. 
 4.5 Records and Updates. Each
Party shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved by or on behalf of such Party in the
performance of Development or Manufacturing activities in relation to BioNTech Products pursuant to this Agreement. BioNTech shall keep the JSC regularly informed of the status of material Development activities conducted with respect to BioNTech
Products in the BioNTech Field in the Territory pursuant to this Agreement. Without limiting the foregoing, at least once every [***] months beginning with the third Calendar Quarter of the Calendar Year 2018, BioNTech shall provide the JSC or
Genevant with a summary report about its current and planned development activities for BioNTech Products in the BioNTech Field in the Territory, covering subject matter at a level of detail sufficient to enable Genevant to determine BioNTech’s
compliance with its diligence obligations under Section 4.6 (“Development Diligence”). BioNTech agrees that Genevant can provide such status reports and summaries to [***] to the extent required under the [***] Agreement. 

4.6 Development Diligence. BioNTech, directly and/or with or through Affiliates or Sublicensees, shall use Commercially
Reasonable Efforts to Develop, and to obtain Regulatory Approval for, the BioNTech Products in the BioNTech Field in the U.S., Germany, United Kingdom, France, Spain and Italy. It is understood and agreed by the Parties that BioNTech intends to seek
Regulatory Approval in the above listed countries first. Following Regulatory Approval in those countries of a BioNTech Product, if it is commercially reasonable to do so, BioNTech will also use Commercially Reasonable Efforts to seek Regulatory
Approval for such BioNTech Product in Asia and any other countries in Europe. 
 4.7 Development Costs. As between the
Parties, BioNTech shall be solely responsible for the cost for the Development of BioNTech Products in the BioNTech Field in the Territory. All assistance provided by Genevant pursuant to Section 4.4 (Conduct of Development Activities by
Genevant) shall [***] BioNTech, unless otherwise specified in Article 6 (Manufacturing of BioNTech Products). 

  
 24 

 4.8 Compliance. Each Party agrees that in performing its obligations under
this Agreement in relation to BioNTech Products: (a) it shall comply with all Applicable Laws; and (b) it will not employ or engage any Person who has been debarred or disqualified by any Regulatory Authority, or, to its knowledge, is the
subject of debarment or disqualification proceedings by a Regulatory Authority. 
 4.9 Subcontractor. BioNTech shall have the
right to engage subcontractors for the performance of its obligations under the Agreement in relation to BioNTech Products, and shall cause the subcontractor(s) engaged by it to be bound by written obligations of confidentiality and non-use of Genevant’s Confidential Information and invention assignment consistent with those contained herein, and BioNTech shall remain primarily responsible for the performance of such subcontractor(s). 

ARTICLE 5 
 REGULATORY
ACTIVITIES FOR BIONTECH PRODUCTS 
 5.1 Regulatory Responsibilities. BioNTech shall be responsible for all regulatory
activities necessary to obtain and maintain Regulatory Approval of BioNTech Products in the BioNTech Field in the Territory. BioNTech shall keep Genevant informed of regulatory developments related to BioNTech Products in the BioNTech Field in the
Territory both via the JSC and BioNTech’s reports pursuant to Section 4.5 (Records and Updates). 
 5.2 Regulatory
Filings. BioNTech shall prepare and submit all Regulatory Filings for BioNTech Products in the BioNTech Field in the Territory and shall own all Regulatory Filings and Regulatory Approvals for BioNTech Products in the BioNTech Field in the
Territory. Genevant will have the right to review and comment on any portions of Regulatory Filings relating to Genevant LNP or the manufacture of BioNTech Products other than the manufacture of the BioNTech mRNA Payloads prior to the submission of
such Regulatory Filings. [***], BioNTech agrees to provide to Genevant copies of any Regulatory Filings or data contained therein requested by Genevant for [***]. 

5.3 Remedial Actions. BioNTech will notify Genevant without undue delay (and in any event within timelines set by Applicable
Law), and promptly confirm such notice in writing, if it obtains information indicating that a BioNTech Product may be subject to any Remedial Action. The Parties will assist each other in gathering and evaluating such information as is necessary to
determine the necessity of conducting a Remedial Action. BioNTech shall, and shall ensure that its Affiliates and Sublicensees will, maintain adequate records to permit BioNTech to trace the Manufacture, distribution and use of the BioNTech
Products. BioNTech shall have the sole discretion with respect to any matters relating to any Remedial Action with respect to any BioNTech Product in the BioNTech Field in the Territory, including the decision to commence such Remedial Action and
the control over the conduct of such Remedial Action, provided that BioNTech shall notify Genevant prior to making any public disclosure of Remedial Action and shall keep Genevant regularly informed regarding any such Remedial Action. BioNTech shall
be solely responsible for the cost and expense of any such Remedial Action in the BioNTech Field, except [***] such Remedial Action [***]. 

  
 25 

 5.4 Pharmacovigilance. At least [***] prior to the filing of an IND for any
BioNTech Product, the Parties shall define and finalize the actions that the Parties shall employ with respect to such BioNTech Product to protect patients and promote their well-being in a written pharmacovigilance agreement (each a
“BioNTech Product Pharmacovigilance Agreement”), with BioNTech as the global safety database holder. These responsibilities shall include mutually acceptable guidelines and procedures for the receipt, investigation, recordation,
communication, and exchange (as between the Parties) of adverse event reports and any other information concerning the safety of the BioNTech Products. Such guidelines and procedures shall be in accordance with, and enable the Parties to fulfill,
local and national regulatory reporting obligations under applicable laws and regulations. Each Party hereby agrees to comply with its respective obligations under such Pharmacovigilance Agreement and to cause its Affiliates and Sublicensees to
comply with such obligations. BioNTech will maintain the global safety database pursuant to its own policy and as necessary to comply with Applicable Laws governing adverse experiences in the Territory. 

5.5 Development Disparity for BioNTech Products. In recognition of the fact that the Parties do not intend for the Development
of BioNTech Products to take precedence over the Co-Development Products and vice versa, the Parties agree to use Commercially Reasonable Efforts to ensure that the Development of both such products are
treated equally. 
 ARTICLE 6 

MANUFACTURING OF BIONTECH PRODUCTS 

6.1 Manufacture of BioNTech Products. Unless BioNTech requests a Manufacturing Transfer and such Manufacturing Transfer has been
fully completed in accordance with Section 6.4 (Manufacturing Transfer), Genevant shall be solely responsible for all preclinical, clinical and commercial Manufacture and supply of all BioNTech Products for all uses under this Agreement.
BioNTech will supply to Genevant all BioNTech mRNA Payloads for such Manufacture at BioNTech’s sole expense. Genevant may conduct such Manufacturing activities itself or through a Third Party CMO under Genevant’s control, subject to
Section 4.9 (Subcontractor). Within a reasonable time after the Effective Date (and no later than six (6) months following the Effective Date), the Parties will execute a supply agreement to govern the supply of BioNTech Products to
BioNTech from Genevant or the Third Party CMO selected and controlled by Genevant (“BioNTech Product Supply Agreement”). 

6.2 Payment for BioNTech Product Manufacture. BioNTech shall pay Genevant for supply of BioNTech Products at a price equal to
Genevant’s Manufacturing Expenses. The mechanism for invoicing, forecasting, and payment for such BioNTech Products will be set forth in the BioNTech Product Supply Agreement. 

6.3 Initial Transfer of BioNTech Product Manufacturing Know-How. 

(a) BioNTech Product Initial Manufacturing Know-How. During a mutually agreed time period prior
to any Regulatory Filing for BioNTech Products planned by BioNTech, Genevant shall make available and transfer to BioNTech, copies of the BioNTech Product Manufacturing Know-How that is listed in Exhibit L and
is necessary to enable BioNTech to prepare Regulatory Filings and clinical trials for the BioNTech Products. If a Regulatory Authority requests that BioNTech provide additional BioNTech Product Manufacturing
Know-How concerning the manufacture of the BioNTech Products beyond the information listed in Exhibit L, BioNTech will inform Genevant of such request and Genevant will provide such

  
 26 

 
information to BioNTech without any undue delay (and in any event reasonably in advance prior to any timelines set by the Regulatory Authority), provided that Genevant has such information in its
possession or control. If BioNTech believes any BioNTech Product Manufacturing Know-How related to the manufacture of the BioNTech Products other than that listed in Exhibit L is necessary to enable BioNTech
to prepare Regulatory Filings or clinical trials for the BioNTech Products, BioNTech may request such additional Know-How from Genevant. Provided BioNTech can demonstrate that such additional BioNTech Product
Manufacturing Know-How is reasonably necessary to enable BioNTech to prepare Regulatory Filings or clinical trials for the BioNTech Products, Genevant will produce such additional BioNTech Product
Manufacturing Know-How to BioNTech without any undue delay. All Genevant Manufacturing Know-How provided to BioNTech pursuant to this Section 6.3(a) (BioNTech
Product Initial Manufacturing Know-How) including the BioNTech Product Manufacturing Know-How listed on Exhibit L is herein after referred to as “BioNTech
Product Initial Manufacturing Know-How.” All services associated with transfer of any BioNTech Product Initial Manufacturing Know-How will be paid by BioNTech
in accordance with the FTE Rate. 
 (b) Use of BioNTech Product Initial Manufacturing
Know-How. BioNTech hereby covenants and agrees that BioNTech Product Initial Manufacturing Know-How will be used solely for purposes of the preparation of Regulatory
Filings and clinical trials and will not be used in the research and development of any products other than BioNTech Products. Only those employees with a need to know such information to prepare Regulatory Filings or clinical trials will be granted
access to the BioNTech Product Initial Manufacturing Know-How. Prior to granting access to the BioNTech Product Initial Manufacturing Know-How to any BioNTech employee,
BioNTech will identify such employee to Genevant in writing. In addition, prior to granting access to such employee, the employee will sign a nondisclosure agreement with BioNTech relating to the BioNTech Product Initial Manufacturing Know-How, which will include terms requiring the employee to maintain the BioNTech Product Initial Manufacturing Know-How in strict confidence and not to use the BioNTech
Product Initial Manufacturing Know-How in the research and development of any products or technology including or relating to LNP (other than BioNTech Products). 

(c) Batch Records. To the extent any batch records related to the manufacture of BioNTech Products by Genevant are required to be
reviewed in order for BioNTech to conduct any clinical trials, such batch records may only be made available to employees of BioNTech or its Affiliates who have signed a separate non-disclosure agreement
relating to the use of the batch records under which such employees will agree to only use such batch records for quality purposes relating to the relevant batches Manufactured by Genevant, to maintain the batch records in strict confidence and not
to use the batch records in the research and development of any products or technology including or relating to LNP (other than BioNTech Products). Such employees will not be involved in or have any responsibility or decision making authority for
the research and development of any products or technology including or relating to LNP (other than BioNTech Products). 
 6.4
Manufacturing Transfer. With respect to any BioNTech Product, and on a BioNTech Product-by-BioNTech Product basis, at a time following the completion of
the first Phase 1 Clinical Trial for such BioNTech Product, BioNTech may request from Genevant that (a) Genevant collaborate with BioNTech to transfer the Manufacturing of such BioNTech Product to BioNTech, a collaboration partner of BioNTech
in relation to such BioNTech Product or a CMO selected and controlled by BioNTech or such collaboration partner or (b) Genevant permit BioNTech or such collaboration partner to conclude a direct manufacturing and supply agreement

  
 27 

 
with the CMO selected by Genevant or such collaboration partner (“Manufacturing Transfer”). In the event of any request for Manufacturing Transfer, Genevant shall provide support
that is reasonably necessary or useful for BioNTech, the collaboration partner or the CMO to take over the Manufacturing of the relevant BioNTech Product within a reasonable period of time following such request. Further details of the Manufacturing
Transfer shall be reasonably agreed between the Parties in a Manufacturing Transfer plan. A Manufacturing Transfer shall be deemed completed, per BioNTech Product, upon both (i) completion of [***] successful batch Manufactured at the facility
to which the Manufacturing is transferred and (ii) approval of the change of Manufacturing facility by the Governmental Entity(ies) relevant for the Manufacturing or Commercialization of such BioNTech Product. All Manufacturing Transfer
services to be provided by Genevant under this Section 6.4 (Manufacturing Transfer) shall be paid by BioNTech in accordance with the FTE Rate. 

6.5 Pre-existing or Publicly Available Manufacturing
Know-how. For the avoidance of doubt, nothing in this Article 6 (Manufacturing of BioNTech Products) shall restrict BioNTech or its Affiliates or collaboration partners to use any Manufacturing Know-how that (i) was in the possession of BioNTech or such Affiliate or collaboration partner prior to disclosure of such Manufacturing Know-how by Genevant, as shown by
contemporaneous evidence, or (ii) is in the public domain by use and/or publication before its receipt from Genevant, or thereafter enters the public domain through no fault of, or breach of this Agreement by, BioNTech. 

ARTICLE 7 

COMMERCIALIZATION 

7.1 General. Subject to the terms and conditions of this Agreement, BioNTech shall be responsible for all aspects of the
Commercialization of the BioNTech Products in the BioNTech Field in the Territory, including: (a) developing and executing a commercial launch and pre-launch plan, (b) negotiating with applicable
governmental authorities regarding the price and reimbursement status of the BioNTech Products and obtaining and maintaining Pricing Approvals; (c) marketing, medical affairs, and promotion; (d) booking sales and distribution and
performance of related services; (e) handling all aspects of order processing, invoicing and collection, inventory and receivables; (f) providing customer support, including handling medical queries, and performing other related functions;
and (g) conforming its practices and procedures to Applicable Law relating to the marketing, detailing and promotion of BioNTech Products in the BioNTech Field in the Territory. As between the Parties, BioNTech shall be solely responsible for
the costs and expenses of Commercialization of the BioNTech Products in the BioNTech Field in the Territory. 
 7.2 Commercial
Diligence. BioNTech, directly and/or with or through Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to Commercialize BioNTech Products in the BioNTech Field in countries in the Territory in which a BioNTech Product has
received Regulatory Approval. 
 7.3 Commercialization Reports. BioNTech shall keep Genevant reasonably informed of
BioNTech’s, its Affiliates’ and Sublicensees’ Commercialization activities with respect to the BioNTech Products in the BioNTech Field in the Territory. Without limiting the foregoing, on [***] of each Calendar Year, beginning in the
Calendar Year of BioNTech’s first submission of an MAA for a BioNTech Product in the BioNTech Field in the Territory, BioNTech shall provide Genevant with a written report summarizing material Commercialization activities with respect to the
BioNTech Products in the BioNTech Field in the Territory performed in the [***] and material 

  
 28 

 
Commercialization activities with respect to the BioNTech Products in the BioNTech Field in the Territory planned for the [***]. BioNTech shall promptly respond to Genevant’s reasonable
questions or requests for additional information relating to the progress and results of its and its Affiliates’ and Sublicensees’ Commercialization activities under this Agreement. 

ARTICLE 8 
 BIONTECH
PRODUCT FINANCIAL PROVISIONS 
 8.1 [***] Milestone Payments. Within [***] after the first achievement of each
milestone event below for each BioNTech Product by or on behalf of BioNTech or any of its Affiliates or Sublicensees, BioNTech shall notify Genevant of the achievement of such milestone event and shall remit payment to Genevant within [***] of its
receipt of Genevant’s invoice for such payment. 
 [***] 

For clarity, (a) if a BioNTech Product undergoes [***] only one payment of [***] is due for such BioNTech Product; (b) [***] payments above are payable
on each BioNTech Product (for example, if BioNTech [***] for all five (5) BioNTech Products, BioNTech will make [***] and (c) each milestone payment is only due once per BioNTech Product. 

8.2 Commercial Milestones. 

(a) Within [***] after the end of the Calendar Quarter in which aggregate annual Net Sales of any BioNTech Product by or on behalf of BioNTech
or any of its Affiliates or Sublicensees in the BioNTech Field in the Territory first reach any threshold indicated in the milestone events listed below, BioNTech shall notify Genevant of the achievement of such milestone event and shall remit
payment to Genevant within [***] of its receipt of Genevant’s invoice for such payment. 
 [***] 

  
 29 

 For clarity, the commercial milestone payments above are payable only once per BioNTech Product on aggregate
annual Net Sales of such BioNTech Product. For example, if aggregate annual Net Sales for each of the five (5) BioNTech Products in a Calendar Year equal [***]. 

(b) If a commercial milestone event in Section 8.2(a) (Commercial Milestones - subsection(a)) is achieved for a BioNTech Product and
payment with respect to any previous milestone event has not been made for the same BioNTech Product, then such previous milestone event shall be deemed achieved for such BioNTech Product and BioNTech shall pay Genevant such unpaid previous
milestone payment(s) at the same time it pays the milestone payment for the commercial milestone event it achieved. 
 8.3 Royalty
Payments. 
 (a) Royalty Rate. During the Royalty Term, BioNTech shall pay to Genevant
non-refundable, non-creditable royalty of [***] on aggregate annual Net Sales of all BioNTech Products in the BioNTech Field in the Territory in each Calendar Year. 

(b) Royalty Term. Royalties under this Section 8.3 (Royalty Payments) shall be payable on a country-by-country and BioNTech Product-by-BioNTech Product basis from the First Commercial Sale of each BioNTech Product in a
country until the latest of: (i) expiration of the last-to-expire Valid Claim of the Genevant Patents that would, but for the licenses granted hereunder, be
infringed by the Manufacture, use or sale of such BioNTech Product in such country in the Territory; (ii) expiration of Regulatory Exclusivity for such BioNTech Product in such country (provided that during such Regulatory Exclusivity no
mRNA-based product directed to the same Protein of Interest and the same indication competitive to the relevant BioNTech Product comes on the market in the relevant country); and (iii) the [***] anniversary of the First Commercial Sale of such
BioNTech Product in such country (the “Royalty Term” for such BioNTech Product and country). 
 (c) Royalty Reports and
Payment. Within [***] Calendar Quarter, commencing with the Calendar Quarter during which the First Commercial Sale of any BioNTech Product is made anywhere in the Territory, BioNTech shall provide Genevant with a report that contains the
following information for such period, on a BioNTech Product-by-BioNTech Product and
country-by-country basis: (i) gross sales and Net Sales in the Territory; (ii) deductions from gross sales permitted pursuant to Section 1.95 (Net Sales)
in a reasonable level of detail (by each subsection set forth in the definition of Net Sales); (iii) a calculation of the royalty payment due on Net Sales in the Territory; and (iv) the exchange rates used. BioNTech will pay Genevant all
royalties owed with respect to Net Sales for such Calendar Quarter within thirty (30) days of its receipt of Genevant’s invoice for such royalties. 

8.4 Royalty Adjustment for Third Party License Payments. If BioNTech, its Affiliates or Sublicensees, in their reasonable
judgment, is required or determines it is reasonably necessary to make any payments to a Third Party for a license under any Patent to make, have 

  
 30 

 
made, use, offer for sale, sell and/or import BioNTech Products in the BioNTech Field in any country in the Territory, then the amount of royalties payable under Section 8.3(a) (Royalty
Rate) shall be reduced by [***] of the amount of any royalties paid to such Third Party on account of the sale of the BioNTech Products in such country in such Calendar Quarter; provided, however, that the royalties payable under
Section 8.3(a) (Royalty Rate) shall not be reduced by more than [***] of the amounts set forth in Section 8.3(a) (Royalty Rate) by reason of the adjustment provided for in this Section 8.4 (Royalty Adjustment for Third Party License
Payments). 
 8.5 Currency; Exchange Rate. All payments to be made by BioNTech to Genevant under this Agreement shall be made
in Dollars by bank wire transfer in immediately available funds to a bank account designated by written notice from Genevant. If any currency conversion shall be required in connection with any payment hereunder, such conversion shall be made by in
accordance with the currency conversion methodology generally applied by BioNTech in accordance with its group accounting practice provided such methodology is consistent with generally accepted accounting principles. 

8.6 Late Payments. Late payments shall be subject to an interest charge of [***], or the maximum rate permitted by law,
whichever is lower, which additional interest shall be compounded daily. 
 8.7 Financial Records and Audit. BioNTech shall
(and shall ensure that its Affiliates and Sublicensees will) maintain complete and accurate records in sufficient detail to permit Genevant to confirm the accuracy of any royalty payments and other amounts payable under this Agreement and to verify
the achievement of milestone events under this Agreement. Upon[***], such records shall be open for examination, during regular business hours, for a period of [***] from the end of the Calendar Year to which such records pertain, and not more often
than once each Calendar Year, by an independent certified public accountant selected by Genevant and reasonably acceptable to BioNTech, for the sole purpose of verifying for Genevant the accuracy of the financial reports furnished by BioNTech under
this Agreement or of any payments made, or required to be made, by BioNTech to Genevant pursuant to this Agreement. The independent certified public accountant shall disclose to Genevant only whether the audited reports are correct or incorrect and
the specific details concerning any discrepancies. No other information shall be provided to Genevant. Genevant shall bear the full cost of such audit unless such audit reveals an underpayment by BioNTech of more than [***] percent ([***]%) of the
amount actually due for any Calendar Year being audited, in which case BioNTech shall reimburse Genevant for the reasonable costs for such audit. BioNTech shall pay to Genevant any underpayment discovered by such audit within thirty (30) days
after the accountant’s report, plus interest (as set forth in Section 8.6 (Late Payments)) from the original due date. If the audit reveals an overpayment by BioNTech, then BioNTech may take a credit for such overpayment against any future
payments due to Genevant.  
 8.8 Audit Dispute. If BioNTech disputes the results of any audit conducted pursuant to
Section 8.7 (Financial Records and Audit), the Parties shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within thirty (30) days, the dispute shall
be submitted for resolution to a certified public accounting firm jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Auditor”). The decision of the
Auditor shall be final and the costs of such procedure as well as the initial audit shall be borne between the Parties in such manner as the Auditor shall determine. If the Auditor determines that there has been an underpayment by BioNTech, BioNTech
shall pay to Genevant the underpayment within thirty (30) 

  
 31 

 
days after the Auditor’s decision, plus interest (as set forth in Section 8.6 (Late Payments)) from the original due date. If the Auditor determines that there has been an overpayment
by BioNTech, then BioNTech may take a credit for such overpayment against any future payments due to Genevant. 
 ARTICLE 9 

DEVELOPMENT AND MANUFACTURING OF CO-DEVELOPMENT PRODUCTS 

9.1 General. Subject to the terms and conditions of this Agreement and as further set forth in the Co-Development Product Development Plan, BioNTech and Genevant shall be jointly responsible for the Development of the Co-Development Products in the Co-Development Field in the Territory. 
 9.2
Co-Development Product Development Plan. BioNTech and Genevant shall conduct all Development of Co-Development Products in the
Co-Development Field in the Territory in accordance with a comprehensive development plan (“Co-Development Product Development Plan”), the initial
version of which is set forth in Exhibit J. From time to time, but at least every [***], the Parties will update the Co-Development Product Development Plan to reflect any new planned Development activities
with respect to Co-Development Products. The updated Co-Development Product Development Plan will be submitted to the JSC for review, discussion and approval. If the
terms of the Co-Development Product Development Plan contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern. 

9.3 Conduct of Activities by Both Parties. To the extent such responsibility is allocated to it in the Co-Development Product Development Plan, each Party shall Develop Co-Development Products in the Co-Development Field in the Territory
in compliance with all Applicable Laws, including good scientific and clinical practices under the Applicable Laws of the country in which such activities are conducted. 

9.4 Records and Updates. The Parties shall maintain records, in sufficient detail and in good scientific manner appropriate for
patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved by or on behalf of each Party in the performance of Development activities pursuant to this Agreement. Each Party shall keep the JSC regularly
informed of the status of all material Development activities including regulatory activities conducted with respect to Co-Development Products in the Co-Development
Field in the Territory pursuant to this Agreement. Without limiting the foregoing, at least once every [***] beginning with [***] of the Calendar Year 2018 and at least every [***] thereafter, each Party shall provide the JSC or the other Party with
summaries in reasonable detail of all data and results generated or obtained in the course of such Party’s and its Affiliates’ or Sublicensees’ performance of activities with respect to
Co-Development Products in the Co-Development Field in the Territory, covering subject matter at a level of detail reasonably requested by the other Party and sufficient
to enable the other Party to determine the Party’s compliance with its diligence obligations under Section 9.6 (Development Diligence). 

9.5 Regulatory Filings. The Lead Commercialization Party will own all Regulatory Filings and Regulatory Approvals for Co-Development Products in the Co-Development Field in the Territory, unless otherwise agreed in writing by the JSC. 

  
 32 

 9.6 Development Diligence. Each Party, directly and/or with or through
Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to perform the activities allocated to it in the Co-Development Product Development Plan in order to Develop, and to obtain Regulatory
Approval for the Co-Development Products in the Co-Development Field in the Territory. 

9.7 Compliance. Each Party agrees that in performing its obligations under this Agreement: (a) it shall comply with all
Applicable Laws; and (b) it will not employ or engage any Person who has been debarred or disqualified by any Regulatory Authority, or, to its knowledge, is the subject of debarment or disqualification proceedings by a Regulatory Authority.

 9.8 Rights of Reference. Each Party will have the right to use and reference all Regulatory Filings (including data
contained therein) and Regulatory Approvals for the BioNTech Products as part of Development of the Co-Development Products. In addition, BioNTech will have the right to use and reference all Regulatory
Filings (including data contained therein) and Regulatory Approvals for Co-Development Products as part of Development of the BioNTech Products 

9.9 Remedial Actions. Each Party will notify the other Party without undue delay (and in any event within timelines set by
Applicable Law), and promptly confirm such notice in writing, if it obtains information indicating that a Co-Development Product may be subject to any Remedial Action. The Parties will assist each other in
gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. The Parties shall, and shall ensure that their Affiliates and Sublicensees will, maintain adequate records to permit the Parties to
trace the Manufacture, distribution and use of the Co-Development Products. The JSC will decide any matters relating to any Remedial Action with respect to any
Co-Development Product in the Co-Development Field in the Territory, including the decision to commence such Remedial Action and the control over the conduct of such
Remedial Action. To the extent a Remedial Action is caused by a Party’s failure to comply with the terms of this Agreement, such Party shall bear the costs of such Remedial Action. In all other event, the costs of the Remedial Action shall be
allocated in accordance with profit and loss sharing pursuant to Section 10.4 (Profit or Loss). 
 9.10 Co-Development Product Pharmacovigilance. At least sixty (60) days prior to the filing of an IND for any Co-Development Product, the Parties shall define and finalize
the actions that the Parties shall employ with respect to the Co-Development Products to protect patients and promote their well-being in a written pharmacovigilance agreement (the “Co-Development Product Pharmacovigilance Agreement”). The Lead Commercialization Party will be the global safety database holder for each Co-Development Product.
These responsibilities shall include mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication, and exchange (as between the Parties) of adverse event reports and any other information concerning the
safety of the Co-Development Products. Such guidelines and procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under applicable laws
and regulations. Each Party hereby agrees to comply with its respective obligations under such Co-Development Product Pharmacovigilance Agreement and to cause its Affiliates and Sublicensees to comply with
such obligations. The Party responsible for the global safety database will maintain the global safety database pursuant to its own policy and as necessary to comply with Applicable Laws governing adverse experiences in the Territory. 

9.11 Manufacturing Responsibilities. Unless otherwise determined by the JSC, Genevant shall be solely responsible for all
preclinical, clinical and commercial Manufacture and 

  
 33 

 
supply of all Co-Development Products for all uses under this Agreement. BioNTech will supply to Genevant all
Co-Development mRNA Payloads for such Manufacture. The Manufacturing Expenses for Co-Development mRNA Payloads Manufactured for preclinical or clinical use will be
included in Development Costs and the Manufacturing Expenses for Co-Development mRNA Payloads Manufactured for commercial use will be included in Allowable Expenses. Genevant may conduct such Manufacturing
activities itself or through a Third Party CMO under Genevant’s control, subject to Section 4.9 (Subcontractor). Within a reasonable time after the Effective Date, the Parties will execute one or more supply agreements to govern
(i) the Manufacturing and supply of Co-Development Products by Genevant or the Third Party CMO selected and controlled by Genevant (“Co-Development Product
Supply Agreement”) and (ii) the Manufacturing and supply of Co-Development mRNA Payloads by BioNTech. 

9.12 Costs of Joint Development. 

(a) Cost Sharing. Development Costs for Co-Development Products incurred during the Term by the
Parties shall be borne 50% by Genevant and 50% by BioNTech. For the avoidance of double-counting, the Parties acknowledge and agree that Development Costs shall not include Allowable Expenses for purposes of calculating Profit or Loss in accordance
with Section 10.4 (Profit or Loss) and, likewise, that any amounts included in Allowable Expenses shall not be included in Development Costs. 

(b) Development Costs Reports. Development Costs shall initially be borne by the Party incurring the cost or expense, subject to
reimbursement as provided in Section 9.12(c) (Reimbursement of Development Costs). Each Party shall calculate and maintain records of Development Costs incurred by it and its Affiliates, in coordination with the JSC, and the procedures for
monthly reporting of actual results, monthly review and discussion of potential discrepancies, quarterly reconciliation, reasonable cost forecasting, and other finance and accounting matters related to Development Costs will be determined by the JSC
(the “Development Reconciliation Procedures”). Such procedures will provide the ability to comply with financial reporting requirements of each Party. The Development Reconciliation Procedures shall provide that within fifteen
(15) days after the end of each Calendar Quarter, each Party shall submit to the Joint Financial Subcommittee of the JSC a report, in such reasonable detail and format as is established by the Joint Financial Subcommittee of all Development
Costs incurred by such Party during such Calendar Quarter. Within fourteen (14) days following the receipt of such report, each Party shall have the right to request reasonable additional information related to the other Party’s and its
Affiliates’ Development Costs during such Calendar Quarter in order to confirm that such other Party’s spending conforms with the approved budget. The Joint Financial Subcommittee shall establish reasonable procedures for the Parties to
share estimated Development Costs for each Calendar Quarter prior to the end of such Calendar Quarter, to enable each Party to appropriately accrue its share of Development Costs for financial reporting purposes, which shall include submission by
each Party to the Joint Financial Subcommittee of the JSC, [***], all Development Costs incurred by such Party [***] in such reasonable detail and format as is established by the Joint Financial Subcommittee. 

(c) Reimbursement of Development Costs. 

(i) The Party (with its Affiliates) that incurs more than its share of the total actual Development Costs for the Co-Development Products shall be paid by the other Party an amount of cash sufficient to reconcile to its agreed percentage of actual Development Costs in each Calendar Quarter. Notwithstanding the foregoing, on a
Calendar Year-to-date basis, the 

  
 34 

 
Parties shall not share any Development Costs in excess of the amounts allocated for such Calendar Year-to-date
period in the budget approved by the JSC; provided, however, that Development Costs in excess of the such budget shall be included in the calculation of Development Costs to be shared by the Parties if (i) the JSC approves such excess
Development Costs (either before or /after they are incurred), which approval shall not be unreasonably withheld to the extent the Development Costs in excess of the budget were not within the reasonable control of the Party (or Affiliate) incurring
such expense or (ii) to the extent such excess Development Costs do not exceed by more than 10% the total Development Costs allocated to be incurred by such Party and its Affiliates in the applicable Calendar Year-to-date period in accordance with the applicable budget for such Calendar Year. If any excess Development Costs are excluded from sharing by the Parties for a particular Calendar Year-to-date period pursuant to the foregoing sentence, such excess Development Costs shall be carried forward to the subsequent Calendar Quarters (provided that such Calendar
Quarters fall within the same Calendar Year) and, to the extent the total Development Costs incurred by such Party and its Affiliates for the Calendar Year-to-date as of
the end of such subsequent Calendar Quarter are less than 110% of the aggregate Development Costs allocated to such Party under the budget for such Calendar Year-to-date
period, such carried forward amounts shall be included in Development Costs to be shared by the Parties for such Calendar Year-to-date-period (i.e., so that the total
Development Costs incurred by such Party and its Affiliates that are shared pursuant to this Section 9.12 (Costs of Joint Development) during any Calendar Year do not exceed 110% of the Development Costs allocated to such Party under the budget
for such Calendar Year, unless otherwise approved by the JSC). 
 (ii) The Development Reconciliation Procedures shall provide for
the JSC to develop a written report setting forth in reasonable detail the calculation of any net amount owed by one Party to the other, as necessary to accomplish the sharing of Development Costs as well as any reimbursement payments that become
due from one Party to the other during such Calendar Quarter, and to prepare such reports promptly following delivery of the report described in Section 9.12(b) (Development Costs Reports) and in a reasonable time (to be defined in the
Development Reconciliation Procedures) in advance of payment. The net amount payable to accomplish the sharing of Development Costs as provided under this Agreement shall be paid by Genevant or BioNTech, as the case may be, within sixty
(60) days after the end of the applicable Calendar Quarter. 
 (iii) Sections 8.5 to 8.8 shall apply mutatis mutandis to the
payment or reimbursement of Development Costs pursuant to this Section 9.12 (Costs of Joint Development). 
 ARTICLE 10 

COMMERCIALIZATION; PROFIT/LOSS SHARING 

10.1 General. The Parties have defined in Exhibit B per Co-Development Product which
Party shall take the lead responsibility for the Commercialization of such Co-Development Product in the relevant Co-Development Field in the Territory (such Party the
“Lead Commercialization Party”). 
 10.2 Commercialization Plan and Report. Within a reasonable time (but no
later than [***] prior to the first anticipated Regulatory Approval of a Co-Development Product in each country in the Territory, the Parties shall prepare and provide to the JSC for approval a plan for the
Commercialization (including marketing, promotion, or joint co-promotion by the Parties, booking of revenues and pricing) of such Co-Development Products in the relevant
Co-Development Field in such country during the [***] after First Commercial Sale in such country, 

  
 35 

 
which plan shall be reasonable in scope and detail and may be amended by the Parties (the “Co-Development Product Commercialization Plan”
for such country). The Parties shall update each Commercialization Plan [***] (to cover the subsequent [***] period) and shall promptly provide each such update and any material amendments to each Commercialization Plan to the JSC. On an annual
basis commencing on the First Commercial Sale of any Co-Development Product anywhere in the Territory, the Parties shall provide the JSC with a report detailing their Commercialization activities with respect
to Co-Development Products in the previous [***] period, covering subject matter at a level of detail reasonably requested by the JSC. 

10.3 Commercialization Diligence. Each Party, directly and/or with or through Affiliates or Sublicensees, shall use Commercially
Reasonable Efforts to perform the activities allocated to it in the Co-Development Product Commercialization Plan and/or by the JSC in order to Commercialize the
Co-Development Products in the Co-Development Field in the Territory. 

10.4 Profit or Loss. The Parties shall share in the Profit or Loss for Co-Development
Products in the Territory as follows: BioNTech shall bear (and be entitled to) 50%, and Genevant shall bear (and be entitled to) 50%. The procedure for calculating Profit or Loss for Co-Development Products is
set forth in Exhibit F. The Joint Financial Subcommittee shall establish reasonable procedures to enable each Party to comply with its financial reporting requirements related to its share of Profit or Loss, which shall include submission by each
Party to the Joint Financial Subcommittee of the JSC a report, within fifteen (15) days after the end of each Calendar Quarter [***], commencing with the Calendar Quarter during which the First Commercial Sale of any Co-Development Product is made anywhere in the Territory, its Net Sales of Co-Development Products, any Other Income and the Allowable Expenses incurred during such period, in
each case in such reasonable detail and format as is established by the Joint Financial Subcommittee. To the extent any other matter relating to calculating Profit or Loss for Co-Development Products is not
explicitly addressed in Exhibit F it will be determined by the JSC. Sections 8.5 to 8.8 shall apply mutatis mutandis to the payment of profits or losses pursuant to this Section 10.4. 

ARTICLE 11 
 INTELLECTUAL
PROPERTY RIGHTS 
 11.1 Ownership. 

(a) Ownership of Sole Inventions. Ownership of all Sole Inventions shall be based on inventorship, as determined in accordance with the
rules of inventorship under United States patent laws. Genevant shall solely own any Genevant Sole Inventions and BioNTech shall solely own any BioNTech Sole Inventions. 

(b) Disclosure of Inventions. Genevant shall promptly disclose to BioNTech all Sole Inventions that are related to BioNTech Products.
In addition, each Party shall promptly disclose to the other Party (i) all Sole Inventions that are related to Co-Development Products and (ii) all Joint Inventions. For the avoidance of doubt, all
such Invention disclosure shall include any invention disclosures or other similar documents submitted by its respective employees, agents or independent contractors describing such Inventions, and shall promptly respond to reasonable requests from
the other Party for additional information relating to such Inventions. 
 (c) Joint Patent Committee. Within thirty (30) days
after the Effective Date, the Parties shall establish a Joint Patent Committee (the “Joint Patent Committee” or the “JPC”), composed of two (2) representatives of each Party. Any Invention that a Party believes
is a Joint 

  
 36 

 
Invention will be brought to the attention of the JPC. The JPC will first determine if the Invention is a Joint Invention and, if so, whether patent protection should be filed for such Joint
Invention. If the JPC determines that the Invention is a Sole Invention, then ownership of the Invention will be as set forth in Section 11.1(a) (Ownership of Sole Inventions). If the JPC determines that the Invention is a Joint Invention, then
the JPC will determine whether the Joint Invention shall be solely owned by BioNTech (“BioNTech Joint Inventions”), solely owned by Genevant (“Genevant Joint Inventions”), or jointly owned by both Parties (“Co-Owned Joint Inventions”). Such determination will be made based on the Parties relative contributions to the Joint Invention and the degree to which the Joint Invention is an improvement on any pre-exisiting BioNTech Technology or Genevant Technology. All Patents claiming BioNTech Joint Inventions shall be referred to herein as “BioNTech Joint Patents.” All Patents claiming Genevant Joint
Inventions shall be referred to herein as “Genevant Joint Patents.” All Patents claiming Co-Owned Joint Inventions shall be referred to herein as
“Co-Owned Joint Patents.” Genevant agrees to assign, and hereby assigns, to BioNTech its entire right, title, and interest in and to all BioNTech Joint Inventions and BioNTech Joint Patents.
BioNTech agrees to assign, and hereby assigns, to Genevant its entire right, title, and interest in and to all Genevant Joint Inventions and Genevant Joint Patents. The JPC may also be used by the Parties to coordinate any other activities of the
Parties under this Article 11 (Intellectual Property Rights). If the JPC is unable to agree on any matter in this Section 11.1(c) (Joint Patent Committee), then any such disagreement shall be referred to the Executive Officers for resolution,
who shall use good faith efforts to resolve such matter within [***] after it is referred to them. 
 (d) Use of Joint Inventions.
Subject to the exclusive licenses granted in Article 2 (Licenses) above, each Party shall be entitled to use and commercialize (including granting licenses to Third Parties) itself any BioNTech Joint Inventions, Genevant Joint Inventions, Co-Owned Joint Inventions, BioNTech Joint Patents, Genevant Joint Patents, and Co-Owned Joint Patents in any field in any country without any payment obligation to the other
Party. Notwithstanding the above, either Party may only grant a license to a Third Party under any BioNTech Joint Inventions, Genevant Joint Inventions, Co-Owned Joint Inventions, BioNTech Joint Patents,
Genevant Joint Patents, or Co-Owned Joint Patents with the prior written consent of the other Party, such consent not to be unreasonably withheld. In the event one Party desires to grant a license under any
BioNTech Joint Inventions, Genevant Joint Inventions, Co-Owned Joint Inventions, BioNTech Joint Patents, Genevant Joint Patents, or Co-Owned Joint Patents to any Third
Party, such Party shall inform the other Party thereof by disclosing to other Party the relevant licensee as well as the licensed field. BioNTech hereby expressly consents to the grant by Genevant to [***] of a license under Genevant’s shares
in the BioNTech Joint Inventions, Genevant Joint Inventions, Co-Owned Joint Inventions, BioNTech Joint Patents, Genevant Joint Patents, or Co-Owned Joint Patents
consistent with Genevant’s obligations under the [***] Agreement. 
 11.2 Patent Prosecution and Maintenance. 

(a) BioNTech Patents and Genevant Patents. BioNTech shall have the sole right, but not the obligation, to control the preparation,
filing, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of all BioNTech Patents (excluding Co-Owned Joint Patents) worldwide, at its sole cost and expense and
by counsel of its own choice. Genevant shall have the sole right, but not the obligation, to control the preparation, filing, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of all Genevant Patents
(excluding Co-Owned Joint Patents) worldwide, at its sole cost and expense and by counsel of its own choice. 

  
 37 

 (b) Co-Owned Joint Patents.  

(i) Genevant shall have the first right, but not the obligation, to control the preparation, filing, prosecution (including any
interferences, reissue proceedings and reexaminations) and maintenance of all Co-Owned Joint Patents (except Co-Owned Joint Patents that relate primarily to BioNTech
Products), at its sole cost and expense and by counsel selected by Genevant and reasonably acceptable to BioNTech. Genevant shall consult with BioNTech and keep BioNTech reasonably informed of the status of such Patents and shall promptly provide
BioNTech with all material correspondence received from any patent authority in connection therewith. In addition, Genevant shall promptly provide BioNTech with drafts of all proposed material filings and correspondence to any patent authority with
respect to such Patents for BioNTech’s review and comment prior to the submission of such proposed filings and correspondence. Genevant shall confer with BioNTech and consider in good faith BioNTech’s comments prior to submitting such
filings and correspondence, provided that BioNTech provides such comments within fourteen (14) days (or a shorter period reasonably designated by Genevant if fourteen (14) days is not practicable given the filing deadline) of receiving the
draft filings and correspondence from Genevant. In the event that Genevant desires to abandon or cease prosecution or maintenance of any such Patent in any country or jurisdiction, Genevant shall provide reasonable prior written notice to BioNTech
of such intention to abandon (which notice shall, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Patent in the relevant patent office). In such case, upon
BioNTech’s written election provided no later than [***] after such notice from Genevant, BioNTech shall have the right to assume prosecution and maintenance of such Patent at BioNTech’s expense. If BioNTech does not provide such election
within [***] after such notice from Genevant, Genevant may, in its sole discretion, continue prosecution and maintenance of such Patent or discontinue prosecution and maintenance of such Patent. 

(ii) BioNTech shall have the first right, but not the obligation, to control the preparation, filing, prosecution (including any
interferences, reissue proceedings and reexaminations) and maintenance of Co-Owned Joint Patents that relate primarily to BioNTech Products, at its sole cost and expense and by counsel selected by BioNTech and
reasonably acceptable to Genevant. BioNTech shall consult with Genevant and keep Genevant reasonably informed of the status of such Patents and shall promptly provide Genevant with all material correspondence received from any patent authority in
connection therewith. In addition, BioNTech shall promptly provide Genevant with drafts of all proposed material filings and correspondence to any patent authority with respect to such Patents for Genevant’s review and comment prior to the
submission of such proposed filings and correspondence. BioNTech shall confer with Genevant and consider in good faith Genevant’s comments prior to submitting such filings and correspondence, provided that Genevant provides such comments within
fourteen (14) days (or a shorter period reasonably designated by BioNTech if fourteen (14) days is not practicable given the filing deadline) of receiving the draft filings and correspondence from BioNTech. In the event that BioNTech
desires to abandon or cease prosecution or maintenance of any such Patent in any country or jurisdiction, BioNTech shall provide reasonable prior written notice to Genevant of such intention to abandon (which notice shall, to the extent possible, be
given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Patent in the relevant patent office). In such case, upon Genevant’s written election provided no later than [***] after such notice
from BioNTech, Genevant shall have the right to assume prosecution and maintenance of such Patent at Genevant’s expense. If Genevant does not provide such election within [***] after such notice from BioNTech, BioNTech may, in its sole
discretion, continue prosecution and maintenance of such Patent or discontinue prosecution and maintenance of such Patent. 

  
 38 

 11.3 Cooperation of the Parties. Each Party agrees to cooperate fully in the
preparation, filing, prosecution and maintenance of Patents under Section 11.2 (Patent Prosecution and Maintenance), at its own cost. Such cooperation includes: (a) executing all papers and instruments, or requiring its employees or
contractors, to execute such papers and instruments, so as enable the other Party to apply for and to prosecute patent applications in any country as permitted by Section 11.2 (Patent Prosecution and Maintenance); and (b) promptly
informing the other Party of any matters coming to such Party’s attention that may affect the preparation, filing, prosecution or maintenance of any such patent applications. 

11.4 Infringement by Third Parties. 

(a) Notice. In the event that either Genevant or BioNTech becomes aware of (i) any infringement or threatened infringement by a
Third Party of any Genevant Patent, BioNTech Patent, Genevant Joint Patent, BioNTech Joint Patent, or Co-Owned Joint Patent in the Territory, which infringing activity involves the using, making, importing,
offering for sale or selling of a product competing with a BioNTech Product or Co-Development Product (regardless of whether or not a Party is currently Developing using, making, importing, offering for sale,
selling, or otherwise Commercializing the same BioNTech Product or Co-Development Product), or the submission to a Party or a Regulatory Authority in the Territory of an application for a product referencing a
BioNTech Product or Co-Development Product, or any declaratory judgment or equivalent action (including an action before the U.S. Patent and Trademark Office such as an inter partes review) challenging any
Genevant Patent, BioNTech Patent, Genevant Joint Patent, BioNTech Joint Patent, or Co-Owned Joint Patent in connection with any such infringement (each, a “BioNTech Product Infringement” or a
“Co-Development Product Infringement,” as applicable), or (ii) any infringement or threatened infringement by a Third Party of any Co-Owned Joint
Patent, which infringing activity is unrelated to a BioNTech Product or a Co-Development Product, it will promptly notify the other Party in writing to that effect. Any such notice shall include evidence to
support an allegation of infringement or threatened infringement, or declaratory judgment or equivalent action, by such Third Party. 
 (b)
Enforcement of Patents against BioNTech Product Infringements. 
 (i) BioNTech Patents and
Co-Owned Joint Patents. BioNTech shall have the sole right, as between Genevant and BioNTech, but not the obligation, to bring an appropriate suit or take other action against any Person or entity engaged
in, or to defend against, a BioNTech Product Infringement of any BioNTech Patent or Co-Owned Joint Patent at its own expense and by counsel of its own choice. Notwithstanding the above, if in the event of the
filing of any declaratory judgment or equivalent action (including an action before the U.S. Patent and Trademark Office such as an inter partes review) challenging any Co-Owned Joint Patent, BioNTech does not
inform Genevant of an intent to defend such action with respect to such Co-Owned Joint Patent within (A) [***] days following the notice of such action or (B) [***] days before the time limit, if any, set
forth in the appropriate laws and regulations for responding to such action, whichever comes first, Genevant shall have the right, but not the obligation, to bring and control the defense of any such action at its own expense and by counsel of its
own choice, and BioNTech shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If such declaratory judgment or action challenging an Co-Owned Joint Patent
was brought in response to BioNTech initiating a suit or other action or otherwise making 

  
 39 

 
a claim for a BioNTech Product Infringement or if BioNTech initiates a suit or other action for a BioNTech Product Infringement in response to such challenge to an
Co-Owned Joint Patent, then BioNTech will reimburse Genevant for all costs, expenses, and fees (including attorney’s fees) spent defending such action. 

(ii) Genevant Patents. Genevant shall have the first right, as between Genevant and BioNTech, but not the obligation, to bring
an appropriate suit or take other action against any Person or entity engaged in, or to defend against, a BioNTech Product Infringement of any Genevant Patent at its own expense and by counsel of its own choice. BioNTech shall have the right, at its
own expense, to be represented in any such action by counsel of its own choice, and Genevant and its counsel will reasonably cooperate with BioNTech and its counsel in strategizing, preparing and prosecuting any such action or proceeding. If
Genevant fails to bring an action or proceeding with respect to such BioNTech Product Infringement of any Genevant Patent within (A) [***] days following the notice of alleged infringement or declaratory judgment or (B) [***] days before
the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, BioNTech shall have the right, but not the obligation, to bring and control any such action at its own expense and by
counsel of its own choice, and Genevant shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

(iii) Recovery. Except as otherwise agreed by the Parties as part of a cost-sharing arrangement, any recovery or damages
realized as a result of any action or proceeding with respect to any BioNTech Product Infringement shall be used first to reimburse the Parties’ documented
out-of-pocket legal expenses relating to the action or proceeding, and any remaining damages relating to BioNTech Product Infringement (including lost sales or lost
profits) shall be retained by the Party responsible for the action or proceeding except that any remaining damages retained by BioNTech shall be deemed to be Net Sales subject to royalty payments to Genevant in accordance with the royalty provisions
of Section 8.3 (Royalty Payments). 
 (c) Enforcement of Patents against Co-Development
Product Infringements. 
 (i) Genevant shall have the first right, as between Genevant and BioNTech, but not the obligation, to
bring an appropriate suit or take other action against any Person or entity engaged in, or to defend against, a Co-Development Product Infringement of any Genevant Patent or
Co-Owned Joint Patent at its own expense and by counsel of its own choice. BioNTech shall have the right, at its own expense, to be represented in any such action by counsel of its own choice, and Genevant and
its counsel will reasonably cooperate with BioNTech and its counsel in strategizing, preparing and prosecuting any such action or proceeding. If Genevant fails to bring an action or proceeding with respect to such
Co-Development Product Infringement of any Genevant Patent or Co-Owned Joint Patent within (A) [***] days following the notice of alleged infringement or
declaratory judgment or (B) [***] days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, BioNTech shall have the right, but not the obligation, to bring and
control any such action at its own expense and by counsel of its own choice, and Genevant shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. Except as otherwise agreed by the Parties as part
of a cost-sharing arrangement, any recovery or damages realized as a result of such action or proceeding with respect to such Co-Development Product Infringement of any Genevant Patent or Co-Owned Joint Patent shall be used first to reimburse the Parties’ documented out-of-pocket legal expenses relating to the action
or proceeding, and any remaining 

  
 40 

 
compensatory and punitive damages relating to such Co-Development Product Infringement of a Genevant Patent or
Co-Owned Joint Patent (including lost sales or lost profits) shall be deemed to be Net Sales subject to the sharing of profits in accordance with the provisions of Section 10.4 (Profit or Loss). 

(ii) BioNTech shall have the first right, as between Genevant and BioNTech, but not the obligation, to bring an appropriate suit or
take other action against any Person or entity engaged in, or to defend against, a Co-Development Product Infringement of any BioNTech Patent at its own expense and by counsel of its own choice. Genevant shall
have the right, at its own expense, to be represented in any such action by counsel of its own choice, and BioNTech and its counsel will reasonably cooperate with Genevant and its counsel in strategizing, preparing and prosecuting any such action or
proceeding. If BioNTech fails to bring an action or proceeding with respect to such Co-Development Product Infringement of any BioNTech Patent within (A) [***] days following the notice of alleged
infringement or declaratory judgment or (B) [***] days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, Genevant shall have the right, but not the
obligation, to bring and control any such action at its own expense and by counsel of its own choice, and BioNTech shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. Except as otherwise
agreed by the Parties as part of a cost-sharing arrangement, any recovery or damages realized as a result of such action or proceeding with respect to such Co-Development Product Infringement of any BioNTech
Patent shall be used first to reimburse the Parties’ documented out-of-pocket legal expenses relating to the action or proceeding, and any remaining damages
relating to such Co-Development Product Infringement of a BioNTech Patent (including lost sales or lost profits) shall be deemed to be Net Sales subject to the sharing of profits in accordance with the
provisions of Section 10.4 (Profit or Loss). 
 (d) Enforcement of Co-Owned Joint Patents
against Infringements unrelated to BioNTech Products or Co-Development Products 
 (i)
Genevant shall have the first right, as between Genevant and BioNTech, but not the obligation, to bring an appropriate suit or take other action against any Person or entity engaged in, or to defend against, an infringement of any Co-Owned Joint Patent, if such infringing activity is unrelated to a BioNTech Product or a Co-Development Product and occurs in any field other than the BioNTech Field, at its
own expense and by counsel of its own choice. BioNTech shall have the right, at its own expense, to be represented in any such action by counsel of its own choice, and Genevant and its counsel will reasonably cooperate with BioNTech and its counsel
in strategizing, preparing and prosecuting any such action or proceeding. If Genevant fails to bring an action or proceeding with respect to such infringement within (A) [***] days following the notice of alleged infringement or declaratory
judgment or (B) [***] days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, BioNTech shall have the right, but not the obligation, to bring and control any
such action at its own expense and by counsel of its own choice, and Genevant shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

(ii) BioNTech shall have the first right, as between Genevant and BioNTech, but not the obligation, to bring an appropriate suit or
take other action against any Person or entity engaged in, or to defend against, an infringement of any Co-Owned Joint Patent, if such infringing activity is unrelated to a BioNTech Product or a Co-Development Product and occurs in the BioNTech Field, at its own expense and by counsel of its own choice. Genevant shall have the right, at its own expense, to be represented in any such action by counsel of its
own 

  
 41 

 
choice, and BioNTech and its counsel will reasonably cooperate with Genevant and its counsel in strategizing, preparing and prosecuting any such action or proceeding. If BioNTech fails to bring
an action or proceeding with respect to such infringement within (A) [***] days following the notice of alleged infringement or declaratory judgment or (B) [***] days before the time limit, if any, set forth in the appropriate laws and
regulations for the filing of such actions, whichever comes first, Genevant shall have the right, but not the obligation, to bring and control any such action at its own expense and by counsel of its own choice, and Genevant shall have the right, at
its own expense, to be represented in any such action by counsel of its own choice. 
 (e) Cooperation. In the event a Party brings
an action in accordance with this Section 11.4, the other Party shall cooperate fully, including, if required to bring such action, the furnishing of a power of attorney or being named as a party to such action. 

11.5 Infringement of Third Party Rights. 

(a) Each Party shall promptly notify the other in writing of any allegation by a Third Party that the Manufacture, Development, importation,
use, marketing, offer for sale, or sale of any BioNTech Product or Co-Development Product in the Territory infringes or may infringe the intellectual property rights of a Third Party. 

(b) If a Third Party asserts that any of its Patents or other rights are infringed by the Manufacture, Commercialization or Development by
BioNTech or its Affiliates of any BioNTech Product in the Territory, BioNTech shall have the sole right but not the obligation to defend against any such assertions at its sole cost and expense. Genevant shall cooperate fully and shall provide full
access to documents, information and witnesses as reasonably requested by BioNTech in connection with such defense. BioNTech will reimburse to Genevant all Third Party costs incurred in connection with such requested cooperation. 

(c) If a Third Party asserts that any of its Patents or other rights are infringed by the Manufacture, Commercialization or Development by
either Party or its Affiliates of any Co-Development Product in the Territory, the Parties shall jointly defend against any such assertions and share equally the costs and expenses of such defense. 

11.6 Consent for Settlement. Neither Party shall unilaterally enter into any settlement or compromise of any action or
proceeding under this Article 11 (Intellectual Property Rights) that would in any manner alter, diminish, or be in derogation of the other Party’s rights under this Agreement without the prior written consent of such other Party, which shall
not be unreasonably withheld. 
 11.7 Patent Extensions. The JSC will make all decisions concerning patent term restoration,
supplemental protection certificates or their equivalents, and patent term extensions with respect to the BioNTech Patents, Genevant Patents, and Co-Owned Joint Patents in any country in the Territory where
applicable with respect to Co-Development Products. 
 11.8 Trademarks. The JSC will
determine who shall own and be responsible for all trademarks, trade names, branding or logos related to Co-Development Products in the Co-Development Field in the
Territory. 

  
 42 

 11.9 Delegation to [***] BioNTech understand and agrees that, to the
extent required by the [***] Agreement, Genevant may permit [***] to exercise any of Genevant’s rights under this Article 11 (Intellectual Property Rights) with respect to the Genevant Patents. 

ARTICLE 12 

CONFIDENTIALITY; PUBLICATION 

12.1 Duty of Confidence. Subject to the other provisions of this Article 12 (Confidentiality; Publication): 

(a) all Confidential Information disclosed by a Party (the “Disclosing Party”) or its Affiliates under this Agreement will be
maintained in confidence and otherwise safeguarded by the recipient Party (the “Receiving Party”) and its Affiliates using at least the same standard of care as the Receiving Party uses to protect its own proprietary or Confidential
Information (but in no event less than reasonable care); 
 (b) the Receiving Party may only use any such Confidential Information for the
purposes of performing its obligations or exercising its rights under this Agreement; and 
 (c) the Receiving Party may disclose
Confidential Information of the Disclosing Party only to: (i) the Receiving Party’s Affiliates; and (ii) employees, directors, agents, contractors, consultants and advisers of the Receiving Party and its Affiliates, in each case to
the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement; provided, that such Persons are bound to maintain the confidentiality, and not to make any unauthorized use, of the
Confidential Information in a manner consistent with this Article 12 (Confidentiality; Publication). 
 12.2 Exceptions. The
foregoing obligations as to particular Confidential Information of a Disclosing Party shall not apply to the extent that the Receiving Party can demonstrate by competent evidence that such Confidential Information: 

(a) is known by the Receiving Party at the time of its receipt, and not through a prior disclosure by the Disclosing Party, as shown by
contemporaneous written documents of the Receiving Party; 
 (b) is in the public domain by use and/or publication before its receipt from
the Disclosing Party, or thereafter enters the public domain through no fault of, or breach of this Agreement by, the Receiving Party; 

(c) is subsequently disclosed to the Receiving Party on a non-confidential basis by a Third Party who
may lawfully do so and is not under an obligation of confidentiality to the Disclosing Party; or 
 (d) is developed by the Receiving Party
independently and without use of or reference to any Confidential Information disclosed to it by or on behalf of the Disclosing Party, as shown by contemporaneous written documents of the Receiving Party. 

  
 43 

 12.3 Authorized Disclosures. Notwithstanding the obligations set forth in
Section 12.1 (Duty of Confidence), the Receiving Party may disclose Confidential Information of the Disclosing Party and the terms of this Agreement to the extent such disclosure is reasonably necessary in the following instances: 

(a) filing or prosecuting of Patents as permitted by this Agreement; 

(b) enforcing the Receiving Party’s rights under this Agreement or performing the Receiving Party’s obligations under this
Agreement; 
 (c) in Regulatory Filings that such Party has the right to file under this Agreement; 

(d) prosecuting or defending litigation as permitted by this Agreement; 

(e) to the Receiving Party’s directors, Affiliates, actual or potential Sublicensees, commercial partners, independent contractors,
consultants, attorneys, independent accountants or financial advisors who, in each case, have a need to know such Confidential Information in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement,
provided, in each case, that any such Person agrees to be bound by terms of confidentiality and non-use (or, in the case of the Receiving Party’s attorneys and independent accountants, such Person
is obligated by applicable professional or ethical obligations) at least as restrictive as those set forth in this Article 12 (Confidentiality; Publication); 

(f) to actual or potential investors, investment bankers, lenders, other financing sources or acquirors (and attorneys and independent
accountants thereof) in connection with potential investment, acquisition, collaboration, merger, public offering, due diligence or similar investigations by such Third Parties or in confidential financing documents, provided, in each case,
that any such Third Party agrees to be bound by terms of confidentiality and non-use (or, in the case of the Receiving Party’s attorneys and independent accountants, such Third Party is obligated by
applicable professional or ethical obligations) that are no less stringent than those contained in this Agreement (except to the extent that a shorter confidentiality period is customary in the industry); and 

(g) such disclosure is required by court order, judicial or administrative process or Applicable Law, provided that in such event the
Receiving Party shall promptly inform the Disclosing Party of such required disclosure and provide the Disclosing Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed as required by court
order, judicial or administrative process or Applicable Law shall remain otherwise subject to the confidentiality and non-use provisions of this Article 12 (Confidentiality; Publication), and the Receiving
Party shall take all steps reasonably necessary, including seeking of confidential treatment or a protective order, to ensure the continued confidential treatment of such Confidential Information. 

12.4 Publication in relation to BioNTech Products. Genevant shall not publish nor otherwise publicly disclose any data or
results regarding any BioNTech Product without the prior written consent of BioNTech. Prior to publishing the results of any studies carried out by Genevant in relation to BioNTech Products under this Agreement, BioNTech shall provide Genevant with
the opportunity to review and comment on the proposed publication at least thirty (30) days prior to its intended submission for publication. BioNTech shall: (i) consider in good faith any comments thereto provided by Genevant within such
thirty (30) day period; and (ii) remove any Confidential Information of Genevant identified by Genevant as part of its review. 

  
 44 

 12.5 Publication in relation to
Co-Development Products. Neither Party shall publish or otherwise publicly disclose any data or results regarding any Co-Development Products without the prior
written consent of the other Party. 
 12.6 Publicity/Use of Names. No disclosure of the existence, or the terms, of this
Agreement may be made by either Party or its Affiliates, and neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure
relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by law. Notwithstanding the above, each Party and its Affiliates may disclose on its website and in its
promotional materials that the other Party is a development partner of such Party for the BioNTech Products and may use the other Party’s name and logo in conjunction with such disclosure. 

(a) A Party may disclose this Agreement and its terms, and material developments or material information generated under this Agreement, in
securities filings with the U.S. Securities and Exchange Commission (“SEC”) (or equivalent foreign agency) to the extent required by law after complying with the procedure set forth in this Section 12.6 (Publicity/Use of
Names). In such event, the Party seeking to make such disclosure will, to the extent and permitted under Applicable Law, prepare a draft confidential treatment request and proposed redacted version of this Agreement to request confidential treatment
for this Agreement, and the other Party agrees to promptly (and in any event, [***] days after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to allow the Party seeking
disclosure to file its request within the time lines prescribed by applicable SEC regulations. The Party seeking such disclosure shall exercise Commercially Reasonable Efforts to obtain confidential treatment of this Agreement from the SEC (or
equivalent foreign agency) as represented by the redacted version reviewed by the other Party. 
 (b) Further, each Party acknowledges that
the other Party may be legally required, or may be required by the listing rules of any exchange on which the other Party’s or its Affiliate’s securities are traded, to make public disclosures (including in filings with the SEC or other
agency) of certain material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by law or such listing rules, provided that the Party seeking such disclosure
shall provide the other Party with a copy of the proposed text of such disclosure sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment thereon. 

(c) If either Party desires to issue a press release or make a public announcement concerning the material terms of this Agreement or the
Development or Commercialization of the BioNTech Product under this Agreement, such as the achievement of Regulatory Approvals of the BioNTech Product, such Party shall provide the other Party with the proposed text of such announcement for prior
review and, except to the extent such press release or public announcement is permitted by subsection (a) or (b) above, approval by such other Party. 

(d) The Parties agree that after a public disclosure has been made or a press release or other public announcement has been issued in
compliance with subsection (a), (b) or (c) hereof, each Party may make subsequent public disclosures or issue press releases or other public announcements disclosing the same content without having to obtain the other Party’s prior
consent and approval. 

  
 45 

 12.7 Prior Confidentiality Agreement. As of the Effective Date, the terms of
this Article 12 (Confidentiality; Publication) shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) relating to the subject of this
Agreement, including the Operationally Enabling Agreement dated 23 April 2018. Any information disclosed pursuant to any such prior agreement shall be deemed Confidential Information for purposes of this Agreement. 

ARTICLE 13 
 TERM AND
TERMINATION 
 13.1 Term. Unless earlier terminated as permitted by this Agreement, the term of this Agreement will
commence upon the Effective Date and continue in full force and effect, until the later of (a) the expiration of the last Royalty Term for any BioNTech Product in the Territory; or (b) the date on which all
Co-Development Products have ceased being Developed or Commercialized by the Parties (the “Term”). Upon the expiration (but not early termination) of the Term, the licenses granted herein for
BioNTech Products and Co-Development Products shall continue in effect, as non-exclusive, fully paid-up, royalty-free,
transferable, perpetual and irrevocable. 
 13.2 Termination. 

(a) Termination by BioNTech for Convenience with respect to BioNTech Products. At any time, BioNTech may terminate this
Agreement with respect to one or more BioNTech Products, at its sole discretion and for any reason or no reason, by providing written notice of termination to Genevant, which notice includes an effective date of termination at least (i) ninety
(90) days after the date of the notice if the notice is given before the Regulatory Approval of the relevant BioNTech Product; or (ii) one hundred eighty (180) days after the date of the notice if the notice is given after the
Regulatory Approval of the relevant BioNTech Product. 
 (b) Termination for Cause. If either Party believes that the other is in
material breach of its obligations hereunder, then the non-breaching Party may deliver notice of such breach to the other Party. The allegedly breaching Party shall have ninety (90) days (or forty-five
(45) days in the case of any payment breach) to cure such breach from the receipt of the notice. If the allegedly breaching Party fails to cure that breach within the applicable period set forth above, then the Party originally delivering the
notice of breach may terminate this Agreement, entirely or in relation to the Products affected by such breach only at such Party’s discretion, on written notice of termination. Any right to terminate this Agreement under this
Section 13.2(b) (Termination for Cause) shall be stayed and the applicable cure period tolled in the event that, during such cure period, the Party alleged to have been in material breach shall have initiated dispute resolution in accordance
with Section 16.10 (Dispute Resolution) with respect to the alleged breach, which stay and tolling shall continue until such dispute has been resolved in accordance with Section 16.10 (Dispute Resolution). If a Party is determined to be in
material breach of this Agreement, the other Party may terminate this Agreement if the breaching Party fails to cure the breach within thirty (30) days after the conclusion of the dispute resolution procedure (and such termination shall then be
effective upon written notification from the notifying Party to the breaching Party). 
 (c) Termination for Patent Challenge. Except
to the extent the following is unenforceable under the laws of a particular jurisdiction, (i) Genevant may terminate this 

  
 46 

 
Agreement immediately upon written notice to BioNTech if BioNTech or its Affiliates or Sublicensees, individually or in association with any other person or entity, commences a legal action
challenging the validity, enforceability or scope of any Genevant Patents and does not dismiss or withdraw such legal action within thirty (30) days of receiving notice from Genevant; and (ii) BioNTech may terminate this Agreement
immediately upon written notice to Genevant if Genevant or its Affiliates or Sublicensees, individually or in association with any other person or entity, commences a legal action challenging the validity, enforceability or scope of any BioNTech
Patents and does not dismiss or withdraw such legal action within thirty (30) days of receiving notice from BioNTech. For purposes of this Section, “challenging” includes (i) filing a declaratory judgment action in which the
applicable Patent is alleged to be invalid or unenforceable, (ii) becoming party to an interference with the applicable Patent pursuant to 35 U.S.C. §135 or similar provisions under non-US law or
(iii) filing or commencing any reexamination, opposition, cancellation, nullity or similar proceedings against the applicable Patent, or petitioning for any form of administrative or judicial (or arbitration) review of the applicable Patent,
including post-grant review, inter partes review, or opposition proceedings. Notwithstanding the above, nothing in this clause will prevent a Party from challenging the validity, enforceability or scope of any Patent in response to a claim of
infringement made against it concerning that Patent. 
 (d) Termination for Bankruptcy. This Agreement may be terminated at any time
during the Term by either Party upon the other Party’s filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by
the other Party; provided, however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within
ninety (90) days after the filing thereof. 
 (e) Termination for Competitor Change of Control. This Agreement may be terminated
by either Party immediately upon written notice to the other Party if the other Party undergoes a Competitor Change of Control before the earlier of (i) three (3) years from the Effective Date or (ii) the other Party undergoing an Initial
Public Offering. 
 13.3 Effect of Termination for Convenience pursuant to Section 13.2(a). Upon
termination of this Agreement by BioNTech pursuant to Section 13.2(a) (Termination by BioNTech for Convenience), the following consequences shall apply and shall be effective as of the effective date of such termination: 

(a) BioNTech’s licenses under Section 2.1 (License for BioNTech Products) as well as either Party’s rights and obligations
under Article 4 (Development of BioNTech Products), Article 5 (Regulatory Activities for BioNTech Products), Article 6 (Manufacturing of BioNTech Products), Article 7 (Commercialization), and Article 8 (BioNTech Product Financial Provisions) shall
terminate for the BioNTech Product(s) which are the subject matter of the relevant termination. 
 (b) [***] following the termination of
this Agreement with respect to any BioNTech Product pursuant to Section 13.2(a) (Termination by BioNTech for Convenience), before granting any Third Party a license with respect to the BioNTech mRNA Payload included in the terminated BioNTech
Product, BioNTech will notify Genevant and give Genevant the opportunity to negotiate the terms of such a license with BioNTech before negotiating with any Third Party. If the Parties cannot reach agreement within [***] on the terms of a license,
then BioNTech may grant such a license to a Third Party, provided that the terms of such license granted to the Third Party are not more favorable than those offered to Genevant. 

  
 47 

 (c) For the avoidance of doubt, all other licenses granted to BioNTech under this Agreement
and either Party’s rights and obligations in relation to any other BioNTech Product or any Co-Development Product shall remain unaffected by such termination. 

13.4 Effect of Termination by BioNTech for Cause, Patent Challenge, Bankruptcy or Competitor Change of Control. Upon termination
of this Agreement by BioNTech pursuant to Section 13.2(b) (Termination for Cause), 13.2(c) (Termination for Patent Challenge), 13.2(d) (Termination for Bankruptcy) or 13.2(e) (Termination for Competitor Change of Control), the following
consequences shall apply and shall be effective as of the effective date of such termination: 
 (a) All rights and obligations of either
Party under this Agreement shall terminate unless otherwise specified in this Section 13.4 (Effect of Termination by BioNTech) or Section 13.7 (Survival). To the extent termination is limited to certain Products only, only the rights and
obligations of the Parties related to such Products shall terminate and all rights and obligations relating to all other Products shall survive such termination. 

(b) BioNTech shall (i) keep all licenses granted to BioNTech under this Agreement, (ii) have the sole right, but not the obligation,
to Develop, Manufacture and Commercialize any BioNTech Products in the BioNTech Field and Co-Development Products in the Co-Development Field, at its sole cost and
expense, and (iii) become the Lead Commercialization Party for all Co-Development Products in the Co-Development Field in the Territory. To the extent that any
royalties will be owed to [***] pursuant to the terms of the [***] Agreement for BioNTech’s continued exercise of any of the licenses granted to BioNTech under this Agreement, BioNTech will contact [***] and arrange to pay such royalties
directly to [***]. 
 (c) Genevant shall transfer to BioNTech or destroy, at BioNTech’s election, all Confidential Information relating
to its activities under this Agreement, including any copies thereof, and all materials, substances and compositions generated under this Agreement and shall provide reasonable technical assistance to BioNTech in connection with the understanding
and use of such Confidential Information, materials, substances and compositions at its own cost and expense, except that Genevant shall be permitted to retain electronic copies of Confidential Information that are created pursuant to automatic IT
backup or disaster recovery procedures (and any Confidential Information so retained will continue to be subject to Article 12(Confidentiality; Publication). 

(d) Upon request of BioNTech, Genevant shall comply with its obligations pursuant to Section 6.4 (Manufacturing Transfer) [***] BioNTech
under such Section. 
 (e) Genevant shall assign to BioNTech all Regulatory Filings and Regulatory Approvals for any BioNTech Product and Co-Development Product, and any Genevant Know-How contained in such Regulatory Filings and Regulatory Approvals shall be subject to the licenses granted Section 2.1
(License for BioNTech Products) and 2.2(a) (License Grant to BioNTech). 
 (f) Genevant shall disclose to BioNTech all Genevant Know-How and all Joint Inventions to the extent not already known to BioNTech, which may be necessary or reasonably 

  
 48 

 
useful for BioNTech to continue to Develop, Manufacture and Commercialize BioNTech Products in the BioNTech Field and/or Co-Development Products in the Co-Development Field. In addition, Genevant shall, at BioNTech’s request, provide reasonable technical assistance and transfer all Genevant Know-How and Joint Inventions
necessary to Manufacture BioNTech Products and Co-Development Products to BioNTech or its designee. 

(g) Genevant shall, at BioNTech’s request and election, use Commercially Reasonably Efforts to facilitate negotiations between BioNTech
and Genevant’s Third Party providers of clinical research, Manufacturing and/or Commercialization services. 
 (h) Genevant shall, and
hereby does, effective on such termination, assign to BioNTech all of Genevant’s and its Affiliates’ right, title and interest in and to any and all trademarks used by Genevant and its Affiliates in the Territory in connection with its
Development, Manufacture or Commercialization of Co-Development Products (excluding any such trademarks that include, in whole or part, any corporate name or logo of Genevant or its Affiliates), including all
goodwill therein, and Genevant shall promptly take such actions and execute such instruments, assignments and documents as may be necessary to effect, evidence, register and record such assignment. 

(i) All rights of Genevant to prosecute, maintain or enforce any Co-Owned Joint Patent pursuant to
Section 11.2 (Patent Prosecution and Maintenance) and 11.4 (Infringement by Third Parties) shall terminate, and all such rights shall solely vest in BioNTech. 

13.5 Effect of Termination by Genevant for Cause, Patent Challenge, Bankruptcy or Competitor Change of Control. Upon termination
of this Agreement by Genevant pursuant to Section 13.2(b) (Termination for Cause), 13.2(c) (Termination for Patent Challenge), 13.2(d) (Termination for Bankruptcy) or ) or 13.2(e) (Termination for Competitor Change of Control), the following
consequences shall apply and shall be effective as of the effective date of such termination: 
 (a) All rights and obligations of either
Party under this Agreement shall terminate unless otherwise specified in this Section 13.5 (Effect of Termination by Genevant) or Section 13.7 (Survival). To the extent termination is limited to certain Products only, only the rights and
obligations of the Parties related to such Products shall terminate and all rights and obligations relating to all other Products shall survive such termination. 

(b) Genevant shall (i) keep all licenses granted to Genevant under this Agreement, (ii) have the sole right, but not the obligation,
to Develop, Manufacture and Commercialize any Co-Development Products in the Co-Development Field, at its sole cost and expense, and (iii) become the Lead
Commercialization Party for all Co-Development Products in the Co-Development Field in the Territory. To the extent that any royalties will be owed by BioNTech to any
Third Party pursuant to the terms of any agreement concluded by BioNTech or its Affiliates with such Third Party for Genevant’s continued exercise of any of the licenses granted to Genevant under this Agreement, the Parties will work together
with the Third Party to arrange for the payment of such royalties directly from Genevant to such Third Party. 
 (c) Upon request of
Genevant, the Parties shall enter into good faith negotiations relating to the grant by BioNTech to Genevant of an exclusive, worldwide license, with the right to grant sublicenses through multiple tiers, under the BioNTech Technology and the Co-Owned Joint Patents, to research, Develop, make, have made, use, distribute, sell, offer for 

  
 49 

 
sale, have sold, import, export and otherwise Commercialize the BioNTech Product(s) which are the subject matter of the relevant termination in the BioNTech Field at commercial terms then to be
agreed.1 
 (d) BioNTech shall transfer to Genevant or destroy, at Genevant’s
election, all Confidential Information relating to its activities under this Agreement, including any copies thereof, and all materials, substances and compositions generated under this Agreement and shall provide reasonable technical assistance to
Genevant in connection with the understanding and use of such Confidential Information, materials, substances and compositions at its own cost and expense, except that BioNTech shall be permitted to retain electronic copies of Confidential
Information that are created pursuant to automatic IT backup or disaster recovery procedures (and any Confidential Information so retained will continue to be subject to Article 12 (Confidentiality; Publication). 

(e) BioNTech shall assign to Genevant all Regulatory Filings and Regulatory Approvals for any
Co-Development Product, and any BioNTech Know-How contained in such Regulatory Filings and Regulatory Approvals shall be subject to the licenses granted
Section 2.2(b) (License Grant to Genevant). 
 (f) BioNTech shall disclose to Genevant all BioNTech
Know-How and all Joint Inventions to the extent not already known to Genevant, which may be necessary or reasonably useful for Genevant to continue to Develop, Manufacture and Commercialize Co-Development Products in the Co-Development Field. In addition, BioNTech shall, at Genevant’s request, provide reasonable technical assistance and transfer all BioNTech
Know-How and Joint Inventions necessary to Manufacture Co-Development Products to Genevant or its designee. 

(g) BioNTech shall, at Genevant’s request and election, use Commercially Reasonably Efforts to facilitate negotiations between Genevant
and BioNTech’s Third Party providers of clinical research, Manufacturing and/or Commercialization services. 
 (h) BioNTech shall, and
hereby does, effective on such termination, assign to Genevant all of BioNTech’s and its Affiliates’ right, title and interest in and to any and all trademarks used by BioNTech and its Affiliates in the Territory in connection with its
Development, Manufacture or Commercialization of Co-Development Products (excluding any such trademarks that include, in whole or part, any corporate name or logo of BioNTech or its Affiliates), including all
goodwill therein, and BioNTech shall promptly take such actions and execute such instruments, assignments and documents as may be necessary to effect, evidence, register and record such assignment. 

(i) All rights of BioNTech to prosecute, maintain or enforce any Co-Owned Joint Patent pursuant to
Section 11.2 (Patent Prosecution and Maintenance) and 11.4 (Infringement by Third Parties) shall terminate, and all such rights shall solely vest in Genevant. 
  

 
 . 

  
 50 

 13.6 Opt-out in relation to Co-Development Product Development. 
 (a) Opt-out. At
any time after the filing of an IND (or equivalent foreign filing) of any Co-Development Product, either Party (“Opt-Out Party”) may elect to terminate
its participation in the Development of such Co-Development Products (“Opt-Out”) at its sole discretion and for any reason or no reason, by providing
written notice of termination to the other Party, which notice includes an effective date of the Opt-Out at least [***] after the date of the notice. 

(b) Effect of Termination. Upon any Opt-Out pursuant to Section 13.6(a) (Opt-out), the following consequences shall apply and shall be effective as of the effective date of such Opt-Out: 

(i) the Opt-Out Party’s license under Section 2.2 (License for Co-Development Products) shall terminate and the license granted to the other Party under Section 2.2 (License for Co-Development Products) shall become an exclusive
license (even as to the Opt-Out Party); 
 (ii) if BioNTech is the Opt-Out Party, BioNTech will continue to support GMP Manufacturing of Co-Development Products in accordance with Section 9.11 (Manufacturing Responsibilities); 

(iii) if Genevant is the Opt-Out Party, Genevant will continue to support GMP Manufacturing of
Co-Development Products in accordance with Section 9.11 (Manufacturing Responsibilities) until [***] to Co-Development Products; 

(iv) except as provided above, the other Party shall be solely responsible for all future Development, Manufacture and
Commercialization of such Co-Development Product in the Co-Development Field, at its sole cost and expense; 

(v) the Opt-Out Party shall assign to the other Party all Regulatory Filings and Regulatory
Approvals for such Co-Development Product, shall transfer control and responsibility for the global safety database to the other Party, and any Know-How contained in
such Regulatory Filings and Regulatory Approvals shall be subject to the license grants in 2.2 (License for Co-Development Products), as amended by Section 13.6(b)(i) (Effect of Termination - subsection
(i)) above; 
 (vi) if any clinical studies with respect to the Co-Development Product have
been initiated and are on-going as of the effective date of any Opt-Out (each, an “On-Going Clinical Study”),
the Opt-Out Party shall continue to fund its share of Development Costs with respect to such On-Going Clinical Study for [***]. In addition, if there are any On-Going Clinical Studies being conducted by or under authority of the Opt-Out Party or its Affiliates at the time of notice of the
Opt-Out, the Opt-Out Party agrees, as the other Party may request, to (A) promptly transition to the other Party or its designee some or all of such On-Going Clinical Studies and the activities related to or supporting such trials, (B) continue to conduct such On-Going Clinical Studies after the effective date of such
Opt-Out until they have been completed, or (C) terminate such On-Going Clinical Studies in a manner consistent with Applicable Laws; 

(vii) the Opt-Out Party shall disclose to the other Party all
Know-How and all Joint Inventions to the extent not already known to the other Party, which may be necessary 

  
 51 

 
or reasonably useful for the other Party to continue to Develop, Manufacture and Commercialize Co-Development Products in the Co-Development Field. In addition, shall, at the other Party’s request, provide reasonable technical assistance and transfer all Know-How and Joint Inventions necessary
to Manufacture Co-Development Products to the other Party or its designee; 
 (viii) the
other Party shall pay the Opt-Out Party the milestone and royalties set forth in Exhibit K (and the terms of Article 8 (BioNTech Product Financial Provisions) shall apply mutatis mutandis); 

(ix) the Opt-Out Party shall, at the other Party’s request and election, use Commercially
Reasonably Efforts to facilitate negotiations between the other Party and the Opt-Out Party’s Third Party providers of clinical research, Manufacturing and/or Commercialization services; 

(x) the Opt-Out Party shall, and hereby does, effective on such termination, assign to the
other Party all of its and its Affiliates’ right, title and interest in and to any and all trademarks used by it in the Territory in connection with its Development, Manufacture or Commercialization of
Co-Development Products (excluding any such trademarks that include, in whole or part, any corporate name or logo of the Opt-Out Party or its Affiliates), including all
goodwill therein, and the Opt-Out Party shall promptly take such actions and execute such instruments, assignments and documents as may be necessary to effect, evidence, register and record such assignment;
and 
 (xi) the other Party may choose to terminate its efforts with respect to the
Co-Development Products in its sole-discretion for any reason or no reason at any time after the Opt-Out Party elects to terminate. 

13.7 Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to
such expiration or termination, nor shall expiration or any termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement. In
addition, the provisions of Article 1 (Definitions), Sections 6.3(b) (Use of BioNTech Product Initial Manufacturing Know-How); 6.3(c) (Batch Records) 6.5 (Pre-existing
or Publicly Available Manufacturing Know-How); 8.6 (Late Payments); 8.7 (Financial Records and Audit; 8.8 (Audit Dispute) 11.1(a) (Ownership of Sole Inventions); 11.1(b) (Disclosure of Inventions), 11.1(d)
(Use of Joint Inventions); 11.2 (Patent Prosecution and Maintenance); 11.3 (Cooperation of the Parties); Article 12 (Confidentiality; Publication); Article 13 (Term and Termination); Article 15 (Indemnification; Liability) and Article 16 (General
Provisions) hereof shall survive the expiration or termination of this Agreement. 
 13.8 Termination Not Sole Remedy.
Termination is not the sole remedy under this Agreement and, whether or not the Agreement is terminated and notwithstanding anything contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise
herein. 

  
 52 

 ARTICLE 14 

REPRESENTATIONS AND WARRANTIES 

14.1 Representations and Warranties of Each Party. Each Party represents and warrants to each other Party as of the Effective
Date that: 
 (a) it has the full right, power and authority to enter into this Agreement, to perform its obligations hereunder; and 

(b) this Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, and does not
conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having
jurisdiction over it. 
 14.2 Representations and Warranties by Genevant. Genevant represents and warrants to BioNTech as of
the Effective Date that: 
 (a) it has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest
in Genevant Technology in a manner that is inconsistent with the licenses granted to BioNTech under Section 2.1 (Licenses for BioNTech) and Section 2.2(a) (License Grant to BioNTech) or its obligations under this Agreement; 

(b) Genevant has not received any notice from a Third Party that the Genevant LNP infringes any Patents of any Third Party or misappropriates
any other intellectual property of any Third Party and is not aware of any imminent or likely threat from a Third Party of such infringement or misappropriation; 

(c) Genevant has not as of the Effective Date, and will not during the Term, grant any right to any Third Party under the Genevant Technology
that would conflict with the rights granted to BioNTech hereunder; 
 (d) Genevant has no knowledge as of the Effective Date of any Third
Party that is infringing or misappropriating any of the Genevant Technology; 
 (e) no Claim or action has been brought or, to
Genevant’s knowledge, threatened in writing by any Third Party alleging that the Genevant Patents are invalid or unenforceable, and no Genevant Patent is the subject of any interference, opposition, cancellation or other similar proceeding
except as identified in Exhibit G; and 
 (f) the patents and patent applications listed on Exhibit G constitute
all existing Genevant Patents as of the Effective Date. 
 14.3 Representations and Warranties by BioNTech. BioNTech
represents and warrants to Genevant as of the Effective Date that: 
 (a) it has not previously assigned, transferred, conveyed or otherwise
encumbered its right, title and interest in the BioNTech mRNA Payloads, Co-Development mRNA Payloads, or BioNTech Technology in a manner that is inconsistent with the licenses granted to Genevant under
Section 2.2(b) (License Grant to Genevant) its obligations under this Agreement; 
 (b) BioNTech has not received any notice from a
Third Party that any BioNTech mRNA Payload or Co-Development mRNA Payloads infringes any Patents of any Third Party or misappropriates any other intellectual property of any Third Party and is not aware of any
imminent or likely threat from a Third Party of such infringement or misappropriation; 

  
 53 

 (c) BioNTech has not as of the Effective Date, and will not during the Term, grant any right
to any Third Party under the BioNTech Technology that would conflict with the rights granted to Genevant hereunder; 
 (d) BioNTech has no
knowledge as of the Effective Date of any Third Party that is infringing or misappropriating any of the BioNTech Technology; 
 (e) no Claim
or action has been brought or, to BioNTech’s knowledge, threatened in writing by any Third Party alleging that the BioNTech Patents are invalid or unenforceable, and no BioNTech Patent is the subject of any interference, opposition,
cancellation or other similar proceeding; and 
 (f) the patents and patent applications listed on Exhibit H
constitute all existing BioNTech Patents as of the Effective Date. 
 14.4 No Other Warranties. EXCEPT AS EXPRESSLY SET FORTH
IN THIS AGREEMENT, NEITHER PARTY MAKES, AND EACH PARTY EXPRESSLY DISCLAIMS, ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENTS, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. 

ARTICLE 15 

INDEMNIFICATION; LIABILITY 

15.1 Indemnification by Genevant. Genevant shall indemnify and hold BioNTech, its Affiliates and Sublicensees, and their
respective officers, directors, agents and employees (“BioNTech Indemnitees”) harmless from and against any Claims arising under or related to this Agreement against them to the extent arising or resulting from: 

(a) the gross negligence or willful misconduct of or violation of Applicable Laws by any of the Genevant Indemnitees; 

(b) the material breach of any of the covenants, warranties or representations made by Genevant to BioNTech under this Agreement; or 

(c) any material breach by Genevant of its obligations pursuant to this Agreement; 

except in each case, to the extent such Claims result from the material breach by BioNTech of any covenant, representation, warranty or other
agreement made by BioNTech in this Agreement or the negligence or willful misconduct of any BioNTech Indemnitee. Notwithstanding the above, Genevant will have no obligation to defend or indemnify BioNTech or its Affiliates for any claim brought by a
shareholder or a class of shareholders of BioNTech or its Affiliates including, but not limited to, securities fraud claims, shareholder direct claims, and shareholder derivative claims, expect to the extent resulting from the gross negligence or
willful misconduct on the part of Genevant or any Affiliate. 

  
 54 

 15.2 Indemnification by BioNTech. BioNTech shall indemnify and hold Genevant,
its Affiliates and Sublicensees, and their respective officers, directors, agents and employees (“Genevant Indemnitees”) harmless from and against any Claims arising under or related to this Agreement against them to the extent
arising or resulting from: 
 (a) the gross negligence or willful misconduct of or violation of Applicable Laws by any of the BioNTech
Indemnitees; 
 (b) the material breach of any of the covenants, warranties or representations made by BioNTech to Genevant under this
Agreement; or 
 (c) any material breach by BioNTech of its obligations pursuant to this Agreement; or 

(d) product recall, products’ liability, infringement claims, or similar claims based on the research, Development, Manufacture or
Commercialization of a BioNTech Product including any such claims made against [***] 
 except in each case, to the extent such Claims
result from the material breach by Genevant of any covenant, representation, warranty or other agreement made by Genevant in this Agreement or the negligence or willful misconduct of any Genevant Indemnitee. Notwithstanding the above, BioNTech will
have no obligation to defend or indemnify Genevant or its Affiliates for any claim brought by a shareholder or a class of shareholders of Genevant or its Affiliates including, but not limited to, securities fraud claims, shareholder direct claims,
and shareholder derivative claims, expect to the extent resulting from the gross negligence or willful misconduct on the part of BioNTech or any Affiliate. 

15.3 Indemnification Procedure. If either Party is seeking indemnification under Sections 15.1 (Indemnification by
Genevant) or 15.2 (Indemnification by BioNTech) (the “Indemnified Party”), it shall inform the other Party (the “Indemnifying Party”) of the Claim giving rise to the obligation to
indemnify pursuant to such section as soon as reasonably practicable after receiving notice of the Claim. The Indemnifying Party shall have the right to assume the defense of any such Claim for which it is obligated to indemnify the Indemnified
Party. The Indemnified Party shall cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified Party shall
have the right to participate, at its own expense and with counsel of its choice, in the defense of any Claim or suit that has been assumed by the Indemnifying Party. Neither Party shall have the obligation to indemnify the other Party in connection
with any settlement made without such Party’s written consent, which consent shall not be unreasonably withheld or delayed. If the Parties cannot agree as to the application of Section 15.1 (Indemnification by Genevant) or 15.2
(Indemnification by BioNTech) as to any Claim, pending resolution of the dispute pursuant to Section 16.10 (Dispute Resolution), the Parties may conduct separate defenses of such Claims, with each Party retaining the right to claim
indemnification from the other Party in accordance with Section 15.1 (Indemnification by Genevant) or 15.2 (Indemnification by BioNTech) upon resolution of the underlying Claim. 

15.4 Mitigation of Loss. Each Indemnified Party will take and will procure that its Affiliates take all such reasonable steps
and action as are reasonably necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Article 15 (Indemnification; Liability). Nothing in this Agreement shall or shall
be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it. 

  
 55 

 15.5 Special, Indirect and Other Losses. EXCEPT IN THE EVENT OF A PARTY’S
BREACH OF SECTION 2.6 (EXCLUSIVITY) OR Article 10 (CONFIDENTIALITY; PUBLICATION), NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR
ANY LICENSE GRANTED HEREUNDER; provided, however, that this Section 15.5 shall not be construed to limit either Party’s indemnification obligations under Section 15.1 (Indemnification by Genevant) or Section 15.2
(Indemnification by BioNTech), as applicable. 
 15.6 Conduct of Product Liability Claims. 

(a) Each of the Parties shall promptly notify the other in the event that any Third Party asserts or files any products liability claim or
other Claim relating to alleged defects in the Co-Development Product (whether design defects, Manufacturing defects or defects in sales or marketing) (“Third Party Products Liability Action”)
against such Party. In the event of a Third Party Products Liability Action against such a single Party, the unnamed Party shall have the right, in the unnamed Party’s sole discretion, to join or otherwise participate in such legal action with
legal counsel selected by the unnamed Party and reasonably acceptable to the named Party. The Party named in such Third Party Products Liability Action shall have the right to control the defense of the action, but shall notify and keep the unnamed
Party apprised in writing of such action and shall consider and take into account the unnamed Party’s reasonable interests and requests and suggestions regarding the defense of such action. In the event of a Third Party Products Liability
Action against both Parties, the Parties shall mutually agree upon which Party shall control the response to such Third Party Products Liability Action. 

(b) The non-controlling Party of a Third Party Products Liability Action shall reasonably cooperate
with the controlling Party in the preparation and formulation of a defense to such Third Party Products Liability Action, and in taking other steps reasonably necessary to respond to such Third Party Products Liability Action. The controlling Party
shall have the sole and exclusive right to select its counsel for the defense to such Third Party Products Liability Action. If required under Applicable Law in order for the controlling Party to maintain a suit in response to such Third Party
Products Liability Action, the non-controlling Party shall join as a party to the suit. The controlling Party shall assume and pay all of its own costs incurred in connection with any litigation or proceedings
related to such Third Party Products Liability Action, including the fees and expenses of the counsel selected by it, as well as the costs of the non-controlling Party associated with providing assistance
requested by the controlling Party or joining the suit if requested by the controlling Party or required to maintain the suit. The non-controlling Party shall also have the right to participate and be
represented in any such suit by its own counsel at its own expense. All Out-of-Pocket Costs and FTE Costs incurred in connection with any litigation or proceeding
related to such Third Party Products Liability Action shall be taken into account in determining Profit or Loss as, and to the extent, provided in Exhibit F. The controlling Party shall not settle or compromise any Third Party Products Liability
Action without the consent of the other Party, which consent shall not be unreasonably withheld. 
 15.7 Insurance. Each
Party, at its own expense, shall maintain product liability and other appropriate insurance (or self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term. Each
Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request. 

  
 56 

 ARTICLE 16 

GENERAL PROVISIONS 

16.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the United Kingdom without
reference to any United Kingdom rules of conflict of laws. 
 16.2 Assignment. Except as expressly provided hereunder, neither
this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that
either Party may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party’s consent (a) in connection with the transfer or sale of all or substantially all of the business or assets of
such Party to which this Agreement relates to a Third Party (except where such transfer or sale results in termination of the Agreement pursuant to Section 13.2(e) (Termination for Competitor Change of Control)), whether by merger,
consolidation, divesture, restructure, sale of stock, sale of assets or otherwise; provided that in the event of any such transaction (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g.,
in the context of a reverse triangular merger)), intellectual property rights of the acquiring party to such transaction (if other than one of the Parties to this Agreement) and its affiliates existing prior to the transaction shall not be included
in the technology licensed hereunder; or (b) to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and
observance of all such duties and obligations by such Affiliate. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a
Party appearing herein will be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Section 16.2
(Assignment) shall be null and void. 
 16.3 Entire Agreement; Modification. This Agreement is both a final expression of the
Parties’ agreement and a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all
matters contained herein. This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement. 

16.4 Relationship Between the Parties. The Parties’ relationship with one another, as established by this Agreement, is
solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the Parties. Neither Party is a legal representative of the other Party. Neither Party can assume or
create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. 

  
 57 

 16.5 Taxes 

(a) Taxes on Income. Except as otherwise set forth in this Section 16.5 (Taxes), each Party shall be solely responsible for the
payment of all Taxes imposed on such Party’s income arising directly or indirectly from the activities of the Parties under this Agreement. 

(b) Taxes of Co-Entrepreneurship. If and to the extent the Parties are considered to be
partners of a co-entrepreneurship for Tax purposes because of their collaboration governed by this Agreement and Taxes allocated to the co-entrepreneurship (e.g. German
trade tax, but excluding any Taxes imposed on or with respect to net income other than German trade tax) are owed by either of the Parties such Tax (as well as any related cost of reporting and preparation of relevant Tax returns) shall be
considered a cost item to be borne by the Parties in accordance with the Profit and Loss split set out in Section 10.4 and the principles set out in Exhibit C. The Parties shall cooperate in good faith to agree on a mutual tax filing position
for their collaboration governed by this Agreement in due course after the Effective Date. Each Party shall have the right to assign its contractual position under this Agreement to a wholly owned corporate subsidiary (“Blocker
Entity”) provided that the relevant Party (i) remains secondarily liable for any liabilities of the Blocker Entity under this Agreement and (ii) shall indemnify the other Party from any Taxes triggered by the
transfer of the contractual position to the Blocker Entity. 
 (c) Taxes as Development Costs. For the avoidance of doubt, any non-recoverable import taxes, export taxes, excise taxes, sales taxes, VAT, consumption taxes and comparable taxes and duties accruing in connection with any activity to be performed under the Co-Development Product Development Plan, including any Taxes described in Section 16.5(e) that accrue in connection with any activity to be performed under the
Co-Development Product Development Plan, shall qualify as Development Costs and considered a cost item to be borne by the Parties in accordance with the Profit and Loss split set out in Section 10.4. 

(d) Tax Cooperation. The Parties agree to use commercially reasonable efforts to cooperate with one another and use commercially
reasonable efforts to avoid or reduce, to the extent permitted by Applicable Laws, Tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by the paying Party to the receiving Party under this
Agreement (“Withholding Taxes”). If Withholding Taxes are imposed on any payment under this Agreement, the liability for such Withholding Taxes shall be the sole responsibility of the receiving Party, and the paying Party shall
(i) deduct or withhold such Withholding Taxes from the payment made to the receiving Party, (ii) timely pay such Withholding Taxes to the proper taxing authority, and (iii) send proof of payment to the receiving Party within thirty
(30) days following such payment. If and to the extent the paying Party failed to retain Withholding Taxes (e.g. because the Parties assumed that Withholding Taxes will not be imposed) or if Withholding Taxes are imposed on “deemed
payments” the receiving Party shall reimburse the paying Party for any Withholding Tax obligation vis-à-vis the tax authorities. Each Party shall comply with
(or provide the other Party with) any certification, identification or other reporting requirements that may be reasonably necessary in order for the paying Party to not withhold Withholding Taxes or to withhold Withholding Taxes at a reduced rate
under an applicable bilateral income tax treaty. Each Party shall provide the other with commercially reasonable assistance to enable the recovery, as permitted by Applicable Laws, of Withholding Taxes or similar obligations resulting from payments
made under this Agreement, such recovery to be for the benefit of the Party bearing the cost of such Withholding Taxes under this Section 16.5(d) (Tax Cooperation). Notwithstanding the foregoing, if as a result of any assignment or sublicense
by the paying Party, any change in the paying Party’s tax residency, any change in the entity that originates the payment, or any failure on the part of the paying Party to comply with Applicable Laws with respect to Withholding Taxes
(including filing or record retention requirements), Withholding Taxes are imposed that would not 

  
 58 

 
otherwise have been imposed (“Incremental Withholding Taxes”), then the paying Party shall be solely responsible for the amount of such Incremental Withholding Taxes and shall
increase the amounts payable to the receiving Party so that the receiving Party receives a sum equal to the sum which it would have received had there been no such imposition of Incremental Withholding Taxes. If a Party makes a payment in accordance
with the sentence above (gross-up) (“Tax Payment”) and 
  

	 	(i)	 a credit against, relief or remission for, or repayment of any Tax (“Tax Credit”) is
attributable to that Tax Payment and 

  

	 	(ii)	 the receiving Party determines in good faith that it has obtained and utilised that Tax Credit on an
affiliated group basis, 

 the receiving Party shall pay to the paying Party an amount equal to such Tax Credit, net of all out-of-pocket expenses (including Taxes) of such receiving Party and without interest (other than interest paid by the relevant taxing authority with respect to such Tax
Credit). Notwithstanding anything else in this Section 16.5(d), in no event will the receiving Party be required to pay any amount to paying Party pursuant to this Section 16.5(d) the payment of which would place the receiving Party in a
less favorable net after-Tax position than the receiving Party would have been in if the Tax giving rise to such Tax Credit had not been deducted, withheld or otherwise imposed and the applicable Tax Payment
had never been paid. This paragraph shall not be construed to require the receiving Party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the paying Party or any other Person. The
receiving Party shall use its commercially reasonable efforts to obtain and utilise that Tax Credit on an affiliated group basis. 
 (e)
Value Added Tax. All payments between the Parties under this Agreement are exclusive of applicable statutory value added tax (“VAT”), if any, which shall be listed separately on each invoice. If and to the extent any VAT will
become payable due to any supplies or services rendered under this Agreement and if and to the extent such VAT is to be paid by the Party providing the supply or service to the competent tax authorities, the receiving Party shall pay an amount equal
to such VAT to the providing Party upon receipt of a valid invoice allowing for the recovery of such VAT. The same shall apply mutatis mutandis for potential other transfer taxes such as stamp, sales, use or similar taxes (“Transfer
Tax”) imposed on any payments under this Agreement. In case there will be new Transfer Taxes introduced after the Effective Date, the Parties will agree on the burden of such Transfer Taxes in good faith. The Parties shall cooperate in good
faith to minimize and/or recover (such recovery to be for the benefit of the Party bearing the cost of such Transfer Tax) any Transfer Tax, as permitted by Applicable Laws. 

16.6 Non-Waiver. The failure of a Party to insist upon strict performance of any
provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any
waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party. 

16.7 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this
Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including embargoes, war,

  
 59 

 
acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or
acts, omissions or delays in acting by any governmental authority or unavailability of materials related to the Manufacture of Products. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably
practical, and shall promptly undertake and continue diligently all reasonable efforts necessary to cure such force majeure circumstances or to perform its obligations in spite of the ongoing circumstances. 

16.8 Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of
the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this
Agreement. 
 16.9 Notices. Any notice to be given under this Agreement must be in writing and delivered either (a) in
person, (b) by air mail (postage prepaid) requiring return receipt, (c) by overnight courier, or (d) by e-mail with delivery and return receipts requested and confirmation of delivery
thereafter, to the Party to be notified at its address(es) given below, or at any address such Party may designate by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes only upon receipt. 

 

			
	If to Genevant:	  	Genevant Science Inc.
		  	90 Broadway, Suite 204
		  	Cambridge MA 02142
		  	Attention: [***]

  

			
	With a copy to:	  	Roivant Sciences GmbH
		  	Viaduktstrasse 8
		  	4051 Basel, Switzerland
		  	Attention: [***]

  
 60 

			
	If to BioNTech:	  	BioNTech RNA Pharmaceuticals GmbH
		  	Goldgrube 13
		  	55131 Mainz
		  	Germany
		  	Attn.: [***]

 16.10 Dispute Resolution 

(a) The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related
to this Agreement or the breach thereof. Subject to Section 16.10(g) (Dispute Resolution - subsection (g)), in the event the Parties cannot resolve such dispute, controversy or claim within a period of thirty (30) days, then the matter
shall be referred to designated senior executives of the Parties for resolution. The initial designated senior executives shall be BioNTech’s Head Alliance Management . Each Party shall be entitled to name substitute senior executives upon
written notice to the other Party. 
 (b) Except as expressly set forth in Section 16.10(g) (Dispute Resolution - subsection (g)), if,
after going through this procedure, the Parties do not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim that is not an Excluded Claim (defined in Section 16.10(f) (Dispute Resolution - subsection
(f)) below) shall be finally resolved by binding arbitration according to the International Chamber of Commerce (ICC) Rules of Arbitration, as applicable on the date of commencement of the arbitration proceedings. Place of arbitration shall be
London, England. Exclusive language of the proceedings shall be English. In addition to the ICC Rules of Arbitration, the procedural law in force at the seat of arbitration shall apply. The arbitration shall be conducted by a panel of three
(3) neutral arbitrators who shall be attorneys and have (i) at least [***] of dispute resolution experience (which may include judicial experience) or (ii) at least [***] of legal or business experience in the biotechnology or
pharmaceutical industry, none of whom shall be a current or former employee or director, or a current stockholder, of either Party or any of their respective Affiliates or any Sublicensee: within thirty (30) days after initiation of
arbitration, each Party shall select one (1) person to act as arbitrator and the two (2) Party-selected arbitrators shall select a third (3rd) arbitrator within thirty (30) days of
their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third (3rd) arbitrator, the third (3rd)
arbitrator shall be appointed in accordance with the ICC Rules. In addressing any of the subjects within the scope of the Preliminary Conference, the arbitrators shall take into account both the desirability of making discovery efficient and
cost-effective and the needs of the Parties for an understanding of any legitimate issue raised in the arbitration. The award rendered by the arbitrators shall be final, binding and non-appealable, and
judgment may be entered upon it in any court of competent jurisdiction. 
 (c) Either Party may apply to the arbitrators for interim
injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. The arbitrators’ authority to award punitive or any other type of damages not measured by a Party’s compensatory

  
 61 

 
damages shall be subject to the limitation set forth in Section 15.5 (Special, Indirect and Other Losses). Each Party shall bear its own costs and expenses and attorneys’ fees and an
equal share of the arbitrators’ fees and any administrative fees of arbitration. 
 (d) Except to the extent necessary to confirm or
enforce an award or as may be required by law, neither Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of the other Party. In no event shall an arbitration be initiated
after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable statute of limitations of the United Kingdom. 

(e) The Parties agree that, in the event of a dispute over the nature or quality of performance under this Agreement, neither Party may
terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination. The Parties further agree that any payments made pursuant to this Agreement pending resolution of the dispute shall be refunded if an
arbitrator or court determines that such payments are not due. 
 (f) As used in this Section, the term “Excluded Claim”
means a dispute, controversy or claim that concerns (i) the construction, scope, validity, enforceability, inventorship or infringement of a patent, patent application, trademark or copyright; or (ii) any antitrust, anti-monopoly or
competition law or regulation, whether or not statutory. 
 (g) Nothing contained in this Agreement shall deny either Party the right to
seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing discussions
between the Parties or any ongoing arbitration proceeding. In addition, either Party may bring an action in any court of competent jurisdiction to resolve disputes pertaining to the validity, construction, scope, enforceability, infringement or
other violations of Patents or other intellectual property rights, and no such claim shall be subject to arbitration pursuant to subsections (b) and (c) of this Section 16.10 (Dispute Resolution). 

16.11 Performance by Affiliates. Each Party may discharge any obligations and exercise any rights hereunder through any of its
Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any
breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such
Party’s Affiliate. 
 16.12 Headings. The captions to the several Articles, Sections and subsections hereof are not a
part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. 

16.13 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review,
drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

16.14 Business Day Requirements. In the event that any notice or other action or omission is required to be taken by a Party
under this Agreement on a day that is not a Business Day then such notice or other action or omission shall be deemed to require to be taken on the next occurring Business Day. 

  
 62 

 16.15 English Language. This Agreement has been prepared in the English
language, and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement shall
be in the English language. 
 16.16 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 {REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK} 

  
 63 

 IN WITNESS WHEREOF, the Parties intending to be bound have caused this License and Co-Development Agreement to be executed by their duly authorized representatives. 
  

			
		  	

  

													
	 BIONTECH RNA PHARMACEUTICALS
GMBH
	 	GENEVANT SCIENCES GMBH
					
	By: [***]	 	            	 		 	By: [***]	 	 
		
	 Name: [***]
	 	Name: [***]
		
	 Title: [***]
	 	Title: [***]
					
	 Date:
	 	 July 4, 2018
	 		 	Date:	 	July 4, 2018

  
 64 

			
	Confidential	  	Execution Copy

  
 LIST OF
EXHIBITS 
  

			
	Exhibit A:	  	BioNTech mRNA Payloads
	Exhibit B:	  	Co-Development mRNA Payloads and Lead Commercialization Party
	Exhibit C:	  	Taxes of Co-Entrepreneurship
	Exhibit D:	  	Transfer Plan
	Exhibit E:	  	BioNTech Development Milestone Plan
	Exhibit F:	  	Procedure for Calculating Profit and Loss
	Exhibit G:	  	Genevant Patents
	Exhibit H:	  	BioNTech Patents
	Exhibit I:	  	BioNTech Products Collaboration Plan
	Exhibit J:	  	Co-Development Products Development Plan
	Exhibit K:	  	Opt-Out Financial Terms
	Exhibit L:	  	BioNTech Product Initial Manufacturing Know-How

			
	Confidential	  	Execution Copy

  

EXHIBIT A 

BIONTECH MRNA PAYLOADS 

[***] 

  
 A-1 

			
	Confidential	  	Execution Copy

  

EXHIBIT B 
 CO-DEVELOPMENT MRNA PAYLOADS AND LEAD COMMERCIALIZATION PARTY 
 [***] 

  
 B-1 

			
	Confidential	  	Execution Copy

  

EXHIBIT C 
 TAXES
OF CO-ENTREPRENEURSHIP 
  

			
	Burden-sharing trade tax in case of a co-entrepreneurship	  	Lastenverteilung Gewerbesteuer im Fall einer Mitunternehmerschaft
		
	 1.  If and to the extent the Parties are considered to be partners of a co-entrepreneurship for Tax purposes because of their collaboration governed by this Agreement and trade tax (including possible ancillary charges related thereto) with regard to this
co-entrepreneurship (Common Tax) accrues, this Common Tax shall be borne and, where required, compensated between the Parties (Tax Equalization) according to the following
provisions:
	  	 1.  Wenn und soweit die Parteien wegen ihrer Zusammenarbeit unter dieser Vereinbarung
als Mitunternehmer einer Mitunternehmerschaft anzusehen sind und Gewerbesteuer (einschließlich etwaiger damit zusammenhängender steuerlicher Nebenleistungen) betreffend dieser Mitunternehmerschaft (Gemeinsame Steuer)
geschuldet wird, soll diese Gemeinsame Steuer von den Parteien nach Maßgabe der folgenden Bestimmungen getragen und ggf. ausgeglichen (Steuerausgleich) werden:

		
	 2.  In principle, both Parties bear Common Taxes at a ratio of 50% | 50%.
	  	 2.  Die Parteien tragen eine Gemeinsame Steuer grundsätzlich im Verhältnis
50% | 50%.

		
	 3.  If and to the extent
	  	 3.  Wenn und soweit eine Gemeinsame Steuer

		
	 i.   attributions from special business balance sheets (assets, equity and
liabilities, special business income, special business expenses) or from (positive or negative) supplementary tax balance sheets of a Party or
	  	 i.   durch Zurechnungen aus Sonderbilanzen (Aktiva, Passiva,
Sonderbetriebseinnahmen, Sonderbetriebsaufwendungen) oder (positiven oder negativen) Ergänzungsbilanzen einer Partei oder

		
	 ii.  the transfer of the interest in the
co-entrepreneurship of a Party or the withdrawal of a Party from the co-entrepreneurship
	  	 ii.  durch Übertragung des Mitunternehmeranteils einer Partei oder durch das
Ausscheiden einer Partei aus der Mitunternehmerschaft

  
 C-1 

			
	Confidential	  	Execution Copy

  

			
	 cause either in this or (e.g. due to a bigger or smaller loss carry-forward) one of the following years an additional
Common Tax (Additional Tax Burden) or a reduced Common Tax (Reduced Tax Burden), the following shall apply: Additional Tax Burdens are, in derogation from No. 2 of this Exhibit, borne solely by the causative Party
and, where required, refunded to the other Party in accordance with this burden-sharing; Reduced Tax Burdens are, in derogation from No. 2 of this Exhibit, exclusively for the benefit of the causative Party and, where required, partly refunded
by the other Party to the causative Party in accordance with this burden-sharing; for the avoidance of doubt, the Parties clarify that a Tax Equalization shall also take place if a Common Tax is saved.

 
 If an Additional Tax Burden or a Reduced Tax Burden is caused by a
direct or indirect shareholder of a Party, this Additional Tax Burden or Reduced Tax Burden shall be deemed to have been caused by this Party for the purposes of this Exhibit.
	  	 in diesem oder (z.B. wegen eines erhöhten oder geminderten Verlustvortrags) einem der folgenden Jahre höher
ausfällt (Steuerliche Mehrbelastungen) oder niedriger ausfällt (Steuerliche Minderbelastungen), wird im Fall einer Steuerlichen Mehrbelastung diese Steuerliche Mehrbelastung abweichend von Ziffer 2 dieses
Exhibit ausschließlich von der verursachenden Partei getragen und ggf. entsprechend dieser Lastenverteilung der anderen Partei erstattet, und kommt im Fall einer Steuerlichen Minderbelastung diese Steuerliche Minderbelastung abweichend von
Ziffer 2 dieses Exhibit ausschließlich der verursachenden Partei zugute und hat die andere Partei der verursachenden Partei die Steuerliche Minderbelastung ggf. entsprechend dieser Lastenverteilung anteilig zu erstatten; die Parteien
stellen klar, dass auch im Fall einer ersparten Gemeinsamen Steuer ein Steuerausgleich stattfinden soll.
  

Werden Steuerliche Mehrbelastungen oder Steuerliche Minderbelastungen durch einen direkten oder indirekten Anteilseigner einer Partei
verursacht, gilt dies für Zwecke dieses Exhibit als durch die jeweilige Partei verursacht.

		
	 4.  Trade tax disadvantages which result from the fact that, due to the termination of
the co-entrepreneurship or a relevant transfer of a participation (section 10a sentence 10 German Trade Tax Act, section 8c German Corporate Income Tax Act), trade tax losses carried-forward may be forfeited,
shall not be compensated by the causative Party.
	  	 4.  Gewerbesteuerliche Nachteile, die dadurch entstehen, dass gewerbesteuerliche
Fehlbeträge wegen der Beendigung der Mitunternehmerschaft oder eines schädlichen Beteiligungserwerbs (§§ 10a S. 10 GewStG, 8c KStG) nicht mehr genutzt werden können, sind von der verursachenden Partei nicht
auszugleichen.

  
 C-2 

			
	Confidential	  	Execution Copy

  

			
		
	 5.  The amounts of the Tax Equalization according to this Exhibit are to be calculated
by way of an iterative calculation process which takes into account the respective additional or reduced income tax or corporate income tax of the Parties which results from the fact that, on the one hand, the Common Tax is not tax deductible,
while, on the other hand, the equalization payment is taxable by the receiving Party and possibly tax deductible by the paying Party.
	  	 5.  Bei der Berechnung des Steuerausgleichs nach diesem Exhibit ist im Rahmen eines
iterativen Rechenprozesses jeweils eine einkommen- bzw. körperschaftsteuerliche Mehr- bzw. Minderbelastung der Parteien zu berücksichtigen, die aus dem Umstand resultiert, dass einerseits die Gemeinsame Steuer einem steuerlichen
Abzugsverbot unterliegt, hingegen andererseits die Ausgleichszahlung bei der erstattungsberechtigten Partei steuerpflichtig und ggf. bei der erstattungspflichtigen Partei steuerlich abzugsfähig ist.

		
	 6.  To the extent the Tax Equalization has neither yet taken place nor can take place
in the course of the application of section 10.4 of the Agreement, the Party entitled to the compensation shall have a compensation claim against the other Party pursuant to this Exhibit. This claim shall become time-barred upon expiration of six
months after the relevant tax trade tax assessment has become formally and substantially binding. Additional Tax Burdens or Reduced Tax Burdens, which arise after the termination of the co-entrepreneurship,
are to be compensated (notwithstanding a possible termination of the Agreement) between the Parties as well.
	  	 6.  Soweit der Steuerausgleich einer Gemeinsamen Steuer nicht bereits im Rahmen von
Section 10.4 der Vereinbarung erfolgt ist oder erfolgen kann, hat die zum Ausgleich berechtigte Partei einen Ausgleichsanspruch gegen die andere Partei nach Maßgabe dieses Exhibit. Dieser Anspruch verjährt 6 Monate nach formeller und
materieller Bestandskraft des jeweiligen Gewerbesteuerbescheides. Steuerliche Mehr- oder Minderbelastungen, die erst nach Beendigung der Mitunternehmerschaft eintreten, sind zwischen den Parteien (auch nach Vertragsbeendigung) ebenfalls
auszugleichen.

		
	 7.  If and to the extent the Parties are considered to be partners of a co-entrepreneurship for Tax purposes because of their collaboration governed by this Agreement and there are, due to a
	  	 7.  Wenn und soweit die Parteien wegen ihrer Zusammenarbeit unter dieser Vereinbarung
als Mitunternehmer einer Mitunternehmerschaft anzusehen sind und es aufgrund von Abzugsverboten

  
 C-3 

			
	Confidential	  	Execution Copy

  

			
	        deduction prohibition (e.g. the German interest
barrier or royalty barrier), other special income tax effects (especially regarding corporate income tax and trade tax), which are caused by the respective other Party, an equalization shall take place between the Parties according to the principles
set out in this Exhibit.
	  	        (z.B. der deutschen Zins- und/oder Lizenzschranke) zu
anderen ertragsteuerlichen Sondereffekten (insbesondere betreffend Körperschaftsteuer und Gewerbesteuer) kommt, die durch die jeweils andere Partei verursacht sind, soll ein Aus-gleich zwischen den
Parteien entsprechend den in diesem Exhibit festgelegten Grundsätzen erfolgen.

		
	 8.  In the event of discrepancies between the German and the English version of this
Exhibit, the German version of this Exhibit shall prevail.
	  	 8.  Im Falle von Abweichungen zwischen der deutschen und der englischen Fassung dieses
Exhibit geht die deutsche Fassung vor.

  
 C-4 

			
	Confidential	  	Execution Copy

  

EXHIBIT D 

TRANSFER PLAN 
 The following activities
will be subject to a detailed 2-way transfer plan for know-how and materials between BioNTech and Genevant on an as-needed basis
to support the collaboration: 
  

	 	•	 	 Analytical Development 

 

	 	•	 	 Pharmaceutical Development 

 

	 	•	 	 Nonclinical 

Development of the detailed transfer plans will be initiated within [***] weeks of the Effective Date. 

  
 D-1 

			
	Confidential	  	Execution Copy

  

EXHIBIT E 

BIONTECH DEVELOPMENT MILESTONE PLAN 

[***] 

  
 E-1 

			
	Confidential	  	Execution Copy

  

EXHIBIT F 

PROCEDURE FOR CALCULATING PROFIT OR LOSS 

OF CO-DEVELOPMENT PRODUCTS 

Profit or Loss from Co-Development Products in the Territory shall be calculated in accordance with this Exhibit F.

 Calculation of Profit or Loss 
 Profit or Loss
shall be calculated for each Calendar Quarter by determining the Net Sales of Co-Development Products, adding any Other Income and subtracting the sum of the Allowable Expenses incurred during such Calendar
Quarter. Notwithstanding the foregoing, on a Calendar Year-to-date basis, Allowable Expenses shall not be included in such calculation if such expenses are in excess of
the amounts allocated for such Calendar Year-to-date period, in the budget for Commercialization approved by the JSC; provided, however, that Allowable Expenses in
excess of the Commercialization budget shall be included in the calculation of Profit or Loss in (i) if the JSC approves such excess Allowable Expenses (either before or after they are incurred), which approval shall not be unreasonably
withheld to the extent the Allowable Expenses in excess of the applicable budget were not within the reasonable control of the Party (or Party’s Affiliate) incurring such expense or (ii) to the extent such excess does not [***] in the
applicable Calendar Year-to-date period in accordance with the Commercialization budget for such Calendar Year. If any excess Allowable Expenses are excluded from
sharing by the Parties for a particular Calendar Year-to-date period pursuant to the foregoing sentence, such excess Allowable Expenses shall be carried forward to
subsequent Calendar Quarters (provided that such Calendar Quarters fall within the same Calendar Year) and, to the extent the total Allowable Expenses incurred by such Party and its Affiliates for the Calendar Year-to-date as of the end of such subsequent Calendar Quarter are less than [***] of the aggregate Allowable Expenses allocated to such Party under the commercialization budget for such Calendar Year-to-date period, such carried forward amounts shall be included in Allowable Expenses to be shared by the Parties for such Calendar Year-to-date period (i.e., so that the total Allowable Expenses incurred by such Party and its Affiliates that are shared pursuant to this paragraph do not exceed [***] of the Allowable Expenses
allocated to such Party under the commercialization budget, unless otherwise approved by the JSC). 
 Definitions 

The following definitions shall apply for purposes of calculating Profit or Loss in accordance this Exhibit F. 

 

	(1)	 “Allowable Expenses” means [***] 

  
 F-1 

			
	Confidential	  	Execution Copy

  
  

	(2)	 “Blocking Third Party Patent Costs” means [***] 

 

	(3)	 “Distribution Costs” means [***] 

 

	(4)	 [***] 

  

	(5)	 [***] 

  

	(6)	 “Health Care Reform Fees” [***] 

 

	(7)	 “Marketing Expenses” means [***] 

 

	(8)	 “Medical Affairs Expenses” [***] 

 

	(9)	 “Other Commercialization Costs” [***] 

 

	(10)	 [***] 

  

	(11)	 [***] 

  

	(12)	 [***] 

  

	(13)	 [***] 

  

	(14)	 “Selling Costs” means [***] 

  
 F-2 

			
	Confidential	  	Execution Copy

  
 (15)
“Total Sales Representative Costs” means [***] 
 (16) “Trademark Costs” [***] 

Reconciliations 
 The JSC will coordinate to
resolve any differences in or disputes regarding the calculation of Profit or Loss, or any component thereof. 

  
 F-3 

			
	Confidential	  	Execution Copy

  

EXHIBIT G 
 GENEVANT
PATENT 
 Patents 
  

	 	I.	 [***] 

[***] 

  
 G-1 

			
	Confidential	  	Execution Copy

  

CSN5 

  
 G-2 

			
	Confidential	  	Execution Copy

  

[***] 

  
 G-3 

			
	Confidential	  	Execution Copy

  

[***] 

  
 G-4 

			
	Confidential	  	Execution Copy

  

[***] 

  
 G-5 

			
	Confidential	  	Execution Copy

  

[***] 

  
 G-6 

			
	Confidential	  	Execution Copy

  

[***] 

  
 G-7 

			
	Confidential	  	Execution Copy

  

II [***] 

  
 G-8 

			
	Confidential	  	Execution Copy

  

[***] 

  
 G-9 

			
	Confidential	  	Execution Copy

  

1:57 SNALP 
 [***] 

  
 G-10 

			
	Confidential	  	Execution Copy

  

7:54 SNALP 
 [***] 

  
 G-11 

			
	Confidential	  	Execution Copy

  

SNALP structure 
 [***] 

  
 G-12 

			
	Confidential	  	Execution Copy

  

ApoB C2K SNALP 
 [***] 

  
 G-13 

			
	Confidential	  	Execution Copy

  
 II. NOVEL
LIPID CASES DLinDMA/DLenDA 
 [***] 

  
 G-14 

			
	Confidential	  	Execution Copy

  
 IV.
MODIFIED siRNA CASES Chem mod 
 [***] 

  
 G-15 

			
	Confidential	  	Execution Copy

  
 V.
MISCELLANEOUS CASES 
 Combination therapy w/NA & conventional drugs 

[***] 

  
 G-16 

			
	Confidential	  	Execution Copy

  

Combination therapy w/NA & radiotherapy 

[***] 

  
 G-17 

			
	Confidential	  	Execution Copy

  

Lipid-mediated GDEPT 
 [***] 

  
 G-18 

			
	Confidential	  	Execution Copy

  

Use of temperature to control lipoplex size 

[***] 

  
 G-19 

			
	Confidential	  	Execution Copy

  

08155 Matters 
 [***] 

  
 G-20 

			
	Confidential	  	Execution Copy

  

EXHIBIT H 

BIONTECH PATENTS 

  
 H-1 

			
	Confidential	  	Execution Copy

  

EXHIBIT I 

BIONTECH PRODUCTS COLLABORATION PLAN 

Consists of the following PDF files attached: 
  

	 	•	 	 [***]. 

  
 I-1 

			
	Confidential	  	Execution Copy

  

EXHIBIT J 

CO-DEVELOPMENT PRODUCTS DEVELOPMENT
PLAN 
 Consists of the following PDF files attached: 
  

	 	•	 	 [***]. 

  
 J-1 

			
	Confidential	  	Execution Copy

  

EXHIBIT K 

OPT-OUT FINANCIAL TERMS 

[***] Milestones 
 Within [***] days after the
first achievement of each milestone event below for the Co-Development Product that is the subject of the Opt-Out, the other Party shall notify the Opt-Out Party of the achievement of such milestone event and shall remit payment to the Opt-Out Party within [***] days of its receipt of the
Opt-Out Party’s invoice for such payment 
 [***] 

Commercial Milestones 
 Within [***] days after the
end of the Calendar Quarter in which aggregate annual Net Sales of the Co-Development Product that is the subject of the Opt-Out by or on behalf of the other Party or
any of its Affiliates or Sublicensees in the Co-Development Field in the Territory first reach any threshold indicated in the milestone events listed below, the other Party shall notify the Opt-Out Party of the achievement of such milestone event and shall remit payment to the Opt-Out Party within [***] days of its receipt of the
Opt-Out Party’s invoice for such payment. 
 [***] 

  
 K-1 

			
	Confidential	  	Execution Copy

  
 Royalty
Payments 
 During the Royalty Term (as applied mutatis mutandis for the Co-Development Product and
provided that only Valid Claims of Patents Controlled by the Opt-Out Party shall be taken into account for evaluating the time period under Section (b) (Royalty Term)) for the
Co-Development Product, the other Party shall pay to the Opt-Out Party non-refundable,
non-creditable royalty at the rates below on aggregate annual Net Sales of the Co-Development Product in the Co-Development Field
in the Territory in each Calendar Year. 

  
 K-2 

			
	Confidential	  	Execution Copy

  

 EXHIBIT L 

BIONTECH PRODUCT INITIAL MANUFACTURING KNOW-HOW 
 As required for Regulatory Approvals for clinical trials: 

[***] 

  
 L-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]